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CCATCTTATGGGCGG (SEQ ID N0:3) 
FIG. 3 






































ACGGTCC (SEQ ID N0:6) 
FIG.6 





































































(SEQ ID NO: 10) 
FIG. 10 













































ACTCCACACTACCGCTGTTGCCTACCCTCCCGCTCTCCCTTCCCCTA(SEQ ID N0:13) 
FIG. 13 







































(SEQ ID N0:16) 
FIG. 16 













































TCTCTGATGTTCTTGAGATCAAAGAC(SEQ ID N0:19) 
FIG. 19 





































AACC(SEQ ID NO:21) 
FIG. 21 












































AGGCCTACCCGGGGA(SEQ ID NO:24) 
FIG. 24 














































TATGAGGGGGGAGGGGGGGCGGGAGGCT(SEQ ID N0:27) 
FIG. 27 



































TGTTGCCTCAT(SEQ ID N0:29) 
FIG. 29 
































TGCCTTAACCCG (SEQ ID NO: 31) 
FIG. 31 





































TTGCTCAA(SEQ ID N0:33) 
FIG. 33 
CIJVlsolate 155 156 
i 
Ondemeport GAG TCA 
AV964110(EW) GAT ACA 
'; Af112189IAM-2) GA"T ACA 
a: A"Y!l62112(AR) GA"T ACA 
9041474 GAT ACA 
8120857 CAA ACC 
9041303 GAT /t,CA 
~ 8031346 GAT ACA 
'5 7091D32 GAT ACA 
i 7091030 GAT ACA 
C 7111080 GAT ACA .. 
., 
08011277A GAT ACA a. 
0 8080941 GM ACA ~ 08011277C GAT ACA 
7101508 TAT ACA 
8010939 GAT ACA 
7091031 GAT ACA 
09020504-3(08-7 589) GAT ACA 
8060351 GAT ACA 
.... 8021509 GAT ACT 
c !l050216 GA( ACA ~ 8050180 GAT ACA ~ 
E 7100609 GGC ~ q: 8080696 GCC a:c, 
9011024 GAT TCC 
8030777 GAT M:r.• 






157 158 15t 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG A"TC 
ATT GGG ATC 
CTT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
CTT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATG GGG ATC 
ATT GGG ATC 
ATT GGG ATC 
ATT GGG TAG 
ATT GGG ATC 
Cl'G GGG GCA 
'ATT GGC ATC 
ATT GGG ATC 
am 11116 atd 






























































165 l&t 170 171 in 173 174 175 176 
TCG CCT ATC CTT TTA TCA GCC erA lCT 
TCG CCC ATC CTC erG TCA GCA ere "TCT 
TCG CCT ATC CTT TTA "TCA GCA ere -rec 
TTG CCC ATC CTT TTA TCA GCA ere -rec 
TCG CCC A"TC CTC erG "TCA GCA CTC lCT 
TCG CCC ATC CTC CTG TCC CCA CTC -rer 
TCG CCC ATC CTC CTG TCA GCA ere lCT 
TCG CCA ATC CTC CTG TCA GCA CTC TCT 
TCG CCC ATC CTC CTG TCA GCA ere lCT 
TCG CCC ATC ere CTG TCA GCA ere TCT 
TCG CCC ATC CTC CTG TCA GCA ere Ter 
TCG CCC ATC CTC CTG TCA GCA ere Ter 
TCG CCC ATC CTC CTG TCA GCA ere TCT 
TCG CCC ATC CTC CTG TCA GCA CTC TCT 
TCG CCC ATC CTC CAG TCA GCA CTC lCT 
TCG CCC ATC CTC CTG TCA GCA ere Ter 
TCG CCC ATC CTC erG TCA GCA CTC TCT 
TCG cer ATC CTT TTA TCA GCA ere TCC 
KG CCT ATC CTT TTA TCA GCA CCC TCC 
TCG CCC ATC CTT TTA TCA GCA ere TCC 
TCG CCC ATC CTT TTA TCA GCA ere TCC 
TCG CCC ATC CTT TTA TCA GCA ere -rec 
TCG CCC ATC CTT TTA TCA GCA ere TCC 
TCG CCC ATC ere TTA TCA GCA ere TCC 
TCG CCC ATC CTC TTA TCA GCA CTC TCC 
TCG CCC ATC CTT TTA TCA GCA CTC TCC 
TTG CCC ATC CTT TTA TCA GCA CTC TCC 
qT cccP cttl C1IL ttaS accA aaL tttS 
tqiS a:tP ttcl ttal tccS gcaA acL tccS 
tlll ccaP ctal caaQ «aP a:cP 
si;-~3'-IA 
177 us 17t llO us 
GGG GGC AGA AGT CCA 







GGG GGC AGA GGT CCA 
GGG GGC AGA GGT CCA 




GGG GGC AGA GGT CCA 
GGG GGC AGA GGT CCA 
GGG GGC AGA GGT CCA 
GGG GGC NiA GGT CCA 




GGG GGC AGA GGT CCA 
GGG GGC AGA (.GT CCA 
GGG GGC NiA GGT CCA 
GGA GGC AGA GGT CCA 




GGA GGC ACA GGT "TCA 
GGA GGT MiA GGT CCA 
GGA GGC AGA GGT CCA 
CGA GGC AGA GGT CCA 









apR 0 ~ 




































































































CDV boliite H1 192 193 HS 197 191 l99 201 203 205 2116 :zog 2:111 212 
Onderstep0<'1 GCT ACT ACT GTA .lAA GTT TTC CTA GTC TTA TCC CTG ATC AGA fl AY91i4110(EW) GCT GCT l<C GTA AGA GTT TTC CTA GTG TTG TCC TCG ATC AGA 
" j AF1121119(AM-2) GCT ACT ACT GTA It.GA GTT TTC CTA GTA TTG TCC TCG ATC AGA A V9621121ARI GCT ACT ACT GTT .lAA TCT TTC CTA GTA TTA TCC TCG ATC AGA 
9041474 GCT GCT ACC GTA AGA GTT T1C CTG GTG TTG TCC TCG ATC AG.A 
8120AS7 GCT GCT MX GTA AGA GIT TTC CTA GTG TTG TCC TCG MX AGA 
!l04]303 GCT GCT ACX: GTA AGA GTT m: CTG GTG TTG TCC TCG ATC AGA 
.. 8031346 GCT GCT ACC GTA AGA GTT TTC CTA GTG TTG TCC TCG ATC AG.A j 7091032 GCT GCT Acx: GTA AGA GTT TTC CTA GTG TTG TCC TCG ACC AGA 
j 7091030 GCT GCT ACC GTA AGA GTT m: CTA GTG TTG TCC TCG ATC AGA 
C: 7111080 GCT GCT ACC GTA AGA GTT T1C CTA GTG TTG Tex: TCG ATC It.GA .. 
.. 080l1277A GCT GCT ACX: GTA AGA GTT TTC CTA GTG TTG Tex: TCG ATC It.GA Q 
l! BIB0941 GCT GCT ACX: GTA AGA GTT TTC CTA GTG TTG TCC TCG ACC AGA ,. 
... 08011277C GCT GCT ACC GTA AGA GTT TTC CTA GTG TTG TCC TCG ATC It.GA 
7101508 GCT GCT ACC GTA It.GA GTT TIC CTA GTG TTG TCC TCG ATC AGA 
8010939 GCT GCT ACC GTA AGA GTT TTC CTA GTG TTG TCC TCG ATC It.GA 
7091031 GCT GCT A(C GTA AGA GTT TTC CTA GTG TTG TCC 1CG ATC AGA 
09020S04-3(08-75891 GCT ACT ACT GTA AGA GTC TIC CTA GTA TTG TCC TCG ATC AGA 
N 8060351 GCT ACT ACT GTA AGA GTC T1C CTA GTA TTG TCC TCG ATC AG.A 
c 1021509 GCT ACT ATC GTA MG ATT TTC CTA GTA TTA TCT 1CG ATC AG.A 
.!:! 9050216 CCT ACT ACT GTA AGA GTC T1C CTA GTA TTG TIX TCG ATC AGA ~ 
E 8050180 GCT ACT ACT GTA AGA GTC T1C CTA GTA TTG TIX 1CG GTC NJA 
< 8030777 GCT ACT ATC GTA AAG ATT m: CTA GTA TTA TCT 1CG ATC AGA 
II0806ti GCT ACT ATC CTA MG ATT TCC CTA GTA TTA TCT TCG ATC CGA 
An:tic 7llOO!IB GCT ACT ACT GTT AG.A TCT TTC CTA GTA TTA Tex: TCG ATC AG.l 
ICIT actl gt.av aaaK gt.tV t1cF dal p:V ti"'- tccS ct&l atcl 11a11 
-caA IICCT gt.IV agal gt.cV «c5 ctcl ctcll ttg\. tctS tcaS ilCCT cpll 
atCl ctol MCK tCIS fla<I stcY 
attl 
~.~341?:, 
JU 2:ul ns 220 2ll :us 
ACX: TCA GAG CTG GCT GAC 
.lAA TCA GAG CTA GCT AA( 
ACA TCA GAG CTA GCT GAC 
ACA TCA GAG CTG TCT GAC 
.lAA TCA GAG CTA GCT AA( 
AAA TCA GAG CTA GCT /UC 
AAA TCA GAG CTA GCT AAC 
.lAA TCA GAG CTA GCT AA( 
.lAA TCA GAG CTA GCT AAC 
.lAA TCA GAG CTA GCT AAC 
AAA TCA GAG CTA GCT /UC 
.lAA TCA GAG CTA GCT AAC 
.lAA TCA GAG CTA GCT AAC 
.lAA TCA GAG CTA GCT AAC 
.lAA TCA GAG CTA GCT AAC 
.lAA TCA GAG CTA GCT AAC 
.lAA TCA GAG CTA GCT AAC 
ACA TCT GAA CTA GCT GAC 
ACA TCT GM CTA GCT GAC 
ACA TCA GAG CTA GCT GAC 
ACA TCT GAA CTA GCT CAC 
ACA TCT GM CTA GCT GAC 
ACA TCA GAG CTA GCT GAC 
ACA TCA GAG CTA GCT TAC 
ACA TCT GAG CTG TCT GAC 
OUT laS 
""'- ct&l ICtA coco 
accT tl:tS pal: c:tal tctS ucN 
uaK ca<H 
226 zza ll!I n, 
GGC TAT GGC TAI 
GGA TAT GGT TAl 
GGA TAT GGT TAl 
GGA TAT GGT TAl 
GGA TAT GGT TAl 
GG.l CAT GGT T.l1 
GGA TAT GGT TA1 
GGA TAT GGT TAl 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA1 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA' 
GGA TAT GGT TA 
GGA TAT GGT TA 
GGA TAT GGT TA'. 
GGA TAT GGT TA1 
GGT TAT GGT TA 
~ tatY ucG 0 





































































CDV Isolate 236 237 231 239 241 242 245 246 247 252 255 258 
Ondersteport ccr GAT GAT ATA NiA GAG ACT CAA GAG GAA TTC AGG 
. 
l! A'1'364llO(EW) CCA GAT TAT ATT GAG GAG ACA CAA MG GAG TTC CGG 
i Afll2189(AM-2) CAT GAT TAT ATT GGG GGG ACG CAA MG GAG TTC CGG 
"' 
A V962112(ARI ccr GAT TAT ATT GGG GAG M:G CAA AAG GAG TTC N;G 
9041474 ccr GAT TAT ATT GAG GAG ACA CAA AAG GAG TTC CGG 
8120857 ccr Gl'.T TAT ATT GAG GAG ACA CAA MG GAG TTC CGG 
9041303 ccr GAT TAT ATT GAG GAG ACA CAA AAG GAG TIC CGG 
;s 8031346 ccr GAT TAT ATT GAG GAG ACA CAA AAG GAG TIC CGG 7091032 ccr GAT TAT ATT GAG GAG ACA CAA MG GAG TIC CGG I 7091030 ccr GAT TAT ATT GAG GAG ACA CAA AAG GAG TIC CGG 
C 7111080 ccr GAT TAT ATT GAG GAG ACA CAA AAG GNi TIC CGG 
I oao112nA ccr GAT TAT ATT GAG GAG ACA CAA MG GAG TIC CGG 80110941 ccr GAT TAT ATT GAG GAG ACA CAA AAG GAG TIC CGG 
.;: 
08011277C ccr GAT TAT ATT GAG GAG ACA CAA AAG GAG TIC CGG 
7101508 ccr GAT TAT ATT GNi GNi ACA CAA MG GAG TIC CGG 
8010939 ccr GAT TAT ATT GAG GAG ACA CAA MG GAG TIC CGG 
7091031 CCT GAT TAT ATT GAG GAG ACA CAA MG GAG TTC CGG 
09020504-3(08-75a9) CCT GAT TAT ATT GGG GAG ACG CCG MG GAG TTC CGG 
1. 8060351 CCT GAT TAT ATT GGG GAG ACG CAA AAG GAG TTC CGG 8021509 CCT GAT TAT ATT GGG GAG ACG CAA MG GAG TTC NO ~ 9050216 CCC GAT TAT ATT GGG GAG NX CAA AAG GAG TCC CGG 
e 8050180 ccr GAT TAT ATT GGG GAG ACG CAA MG GAG TTC CGG 
... 8030n7 CCT GAT TAT ATT GGG GAG ACG CAA MG GAG TTC CGG 
&080696 CCC GAC TAT ATT GGG GAG ND ND ND NO ND NO 
Atttk 7110098 CCT GAT TAT ATT GGG GAG ACG CAA MG GAG TTC CGG 
cctP ptD 0 ataM agaR P&I! .actT CHO. 0 0 ttcf 0 
ccaP pdl mt ff agG acaT cqP u:cS 
catH 0 ggG aqT 
ca:P 
!Jt~34C 
261 262 267 269 27J 275 277 
AAT GAC CAA ACC GTA CCG AAT 
AAT GAC CAG ACC GTC CCA MT 
AAT GAC CAG Aa: GTC CCG AAT 
AAT GAC CAG Aa: ATC co; MT 
AAT GAC CAG Aa: GTC CCA MT 
AAC MC CAG ACf GTC CCA AAT 
AAT GAC CAG Aa: GTC CCA AAT 
AAT GAC CAG Act GTC CCA AAT 
AAT GAC CAG ACT GTC CCA MT 
AAT GAC CAG AOC GTC CCA AAT 
AAT GAC CAG AOC GTC CCA AAT 
AAT GAC CAG Act GTC CCA AAT 
AAT AAC CAG ACT GTC CCA AAT 
AAT GAC CAG Aa: GTC CCA AAT 
MT GAC CAG NX GTC CCA AAT 
MT GAC CAG NX GTC CCA AAT 
MT GAC CAG ACC GTC CCA MT 
AAC MC CAG ACC GTC CCG GAT 
AAC MC CAG ACC GTC CCA GAT 
ND ND ND ND ND ND ND 
AAC MC CAG ACC GTC CCG GAT 
AAC AAC CAG ACC. GTC ca; GAT 
AAT GAC CAG ACC GTC CCA AAT 
ND NO ND ND ND ND ND 
AAT GAC CAG NX ATC CCG AAT 
aatN pd) 0 accT pV cqP 
-aacN aacN actT ct<11 a:aP ptD 
.Jld 
278 2llO 282 
TCC GCC GTA 
,cc GCT GTA 
1CC GCC GTA 
TCT M:C GTA 
,cc GCT GTA 
TCC GCT GCA 
TCC GCT GTA 
TCC Ger GTA 
TCC GCT GTA 
TCC GCT GTA 
,cc GCT GTA 
TCC GCT GTA 
,cc GCT GTA 
TCC GCT GTA 
TCC GCT GTA 
TCC GCT GTA 
TCC GCT GTA 
TCC GCT GTA 
TCC GCC GTA 
ND ND ND 
,cc GCC GTA 
TCC GCC GTA 
TCC GCC GTA 
ND ND ND 
1CT NX GTA 
tccS &«A ataV 
































































































CDVlsolate 294 295 296 298 301 302 303 309 311 314 31S 317 319 
Onders!eport TCC TTG TGT GAA Acr GTA TTA AGT TCA GGT ATT GTA ICA ~ AY964111l{EW) TCC GTG TGT GGT ACC GTG TTG AAT TCG AGT ATC GCA ACG !! AF112189{AM•2) TCC TTG TGT GAT ACC GTA TTG GAT TCA GGT ATT GTG ACG 
-i Al'9621121ARl TCC TTG TGT GAT Acr GTA TTA AAT TCA GGT ATT GTA ACG « 
9041474 TCC TTG TGT GGT AC.C GTG TCA AAT TCG A6T ATC GCA ACG 
81208S7 TCC TCG CGT GGT N:.C GTG CTG CCT TCG A6T ATC GCA ACG 
9041303 TCC TTG TGT GGT ACC GTG TCA AAT TCG AGT ATC GCA ACG 
~ 8031346 TCC TTG TGT GGT ACC GTG TTG AAT TCG AGT ATC GCA ACG 
Ji 7091032 TCC TTG TGT GGT ACC GTG TTG AAT TCG AGT ATC GCA N:.G §; 7091030 TCC TTG TGT GGT ACC GTG TTG AAT TCG AGT ATC GCA ACG 
li nuoao TCC TTG TGT GGT AC.C GTG TTG AAT TCG AGT ATC GCA ACG 
.. 08011277A TCC TTG TGT GGT N:.C GTG TTG AAT TCG AAT ATC GTA ACG a. 
e 8080941 TCC TTG TGT GGT ACC GTG TTG AAT TCG AGT ATC GCA ACG 
.;l 08011277( TCC TTG TGT GGT ACC GTG TTG AAT TCG AAT ATC GTA ACG 
7101508 TCC TTG TGT GGT ACC GTG TTG AAT TCG AAT ATC GTA ACG 
8010939 TCC TTG TGT GGT ACC GTG TTG AAT TCG AAT ATC GTA ACG 
7091031 TCC TTG TGT GGT ACC GTG TTG AAT TCG NO ATC 6CG ACG 
09020504-3(08-7S89) TCC TTA TGT GAT ACC GTA TTG AAT TCA GGT ATT GTG ACG 
"' 
80603S1 TCC TTG TGT GAT ACC ATA TTG AAT TCA GGT ATT GTG ACG 
c 80Zl~ "'D NO ... o NO NO NO NO "'o NO ... o NO NO NO .. 
.g 9050216 ND NO NO NO NO NO "'0 NO NO ND NO NO NO ., 
8050180 TCC TTG TGT GAT ACC GTA TTG AAT TCA GGT ATT GTA ACG ~ 8030777 1tT TTG TGT GAT ACC GTA TTG MT TCA GGT GTT GTA ACG 
8080696 NO ND NO NO ND NO ND ND ND ND NO NO NO 
A~ 7110098 TCC TTG TGT GAT Acr GTA lTA AAT TCA GGT ATT GTG ACG 
ta:5 nsL qtC IHf ilCtT gtaV tuol •115 tQS gtG an1 gtaV 0 
tctS AV cirtR gtG accT 11111" ttgl aatN tqS il8tS •td gcaA 
ttal p!O 1cas ptO atG lltV n:,I 
cctl' aatN 
511<.-vt-t, s L{ 0 
321 322 323 324 327 330 331 
GGG ATA TTT TGG ccr CK. ATT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG CCT CAA GTT 
GGA ATC TTT GGG CCT CAA GlC 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGC NO NO NO 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG ,er CAA GTT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG TCT CAA GTT 
GGA ATA TTT GGG NO "'0 "'D 
GGA ATA TTT GGG ccr CGA GTT 
GGA ATA TTT GGG CCT CAA GTT 
NO NO NO GGG NO NO NO 
NO NO NO GGG NO NO NO 
GGA ATA TTT GGG CCT CAA GTT 
GGA ATA TTC GGG TCT CAA GTT 
NO NO NO NO ND ND NO 
GGA ATC TTT GGG CCT CAA GTC 
0 atal 0 0 act!' cacti attl 
atd tctS caaQ &ttV 
actT cpR gtcll 
332 333 337 
GAG GAA GTC 
GAA GAG GTT 
GAA GAG GTT 
GAA GAG GTC 
GAA GAG GTT 
NO NO NO 
GAA GAG GTT 
GAA GAG GTT 
GAA GAG GTT 
GAA GAG GTT 
GAA GAG GTT 
GAA GAG GTT 
GAA GAG GTT 
GAA GAG GTT 
GAA GA6 GTT 
GAA GAG GTT 
... o ND ... o 
GAA GAG GTT 
GAA GAG GTT 
NO NO NO 
NO NO ND 
GAA GAG GTT 
GAA GAG GTC 
NO NO ND 
GAA GA6 GTC 




































































lsalata 342 343 347 
-
349 352 353 354 356 351 365 366 367 3711 
Ondersteport ATG GAG ATA A.CA AAC GGT TTT ATA GAT All GCC CTG GCC AAA ll AY964110(eW) GTA GAA ATA A.CA AAT GGG TTC ATA GAT ATA GCA TTG GTC AAA C 
!! AF1l2189(AM.2l GTA GAA ATA ACA AAT GGG TTC ATA GAT ATA GCA TTG GTA AAA 
-i A'19621UIARI GTC GAA ATA ACA AAT GGT llC ATA GAT GTA GCA TTG GTC AAC 
"' 9041474 GTA GAA ATA A.CA AAT GGG llC ATA GAT ATA GCA TTG GTC AAA 
8120857 NO NO NO ND NO ND ND NO NO ND ND NO ND ND 
9041303 GTA GAA ATA ACA AAT GGG llC ATA GAT ATA GCA TTG GTC AAA 
., 8031.346 GTA GM ATA ACA AAT GGG TTC ATA GAT ATA GCA llG GTC AAA 
l!i 70,1032 GTA GAA ATA ACA AAT GGG TTC ATA GAT ATA GCA TTG GTC AAA ~ 
~ 70,10]0 GTA GAA ATA ACA AAT GGG llC ATA GAT ATA GCA llG GTC AAA 
C 7U1080 GTA GAA ATA ACA AAT GGG llC ATA GAT ATA GCA TTG GTC AAA .. 
8. 08011277A GTA GAA ATA ACA AAT GGG TTC ATA GAr ATA GCA TTG GTC AAA 
e 8080941 GTA GAA ATA ACA AAT GGG TTC ATA GAT ATA GCA llG GTC AAA :, 
LU 08011277C GTA GAA ATA ACA AAT GGG TTC ATA GAT ATA GCA llG GTC AAA 
7101508 GTA GM ATA A.CA AAT GGG llC ATA GAT ATA GCA llG GTC AAA 
8010939 GTA GAA ATA ACA AAT GGG llC ATA GAT ATA GCA llG GTC AAA 
7091031 NO ND NO ND ND ND ND ND ND ND ND ND ND ND 
09020504-3f08-7S19l GTA GAA ATG GCA AAT GGG llC ATC GAT ATA GCA TTG GlC AAA 
N 80603S1 GTA GAA ATA GCA AAT GGG llC ATC GAT ATA GCA TTG GTC AAA I: 
:, 8021509 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
i 9050216 ND ND NO ND ND ND ND ND ND ND ND ND ND ND e 8050180 GTA GAA ATA GCA AAT GGG llC ATC GAT ATA GCA llG GlC AAA 
-< 
8030777 GCA GAA ATA A.CA AAT GGG TTC ATA GAC ATA GCA TTG GTT AAA 
Arctic 7110098 GTC GAA ATA ACA AAT GGT 
--
llC ATA GAT GTA GCA llG GTC AAC 
atgM 0 atal acaT 0 atG 0 Ital 0 attl 0 8 accA aaaK 
gtaV •ICM gcaA qgG atd 
-
gt<V HCN 
gtcV graV gtaV 
gttV 
11~3'1 E.. 
371 372 373 375 37& 380 
CAA GAA GAA AAA GGT TCA 
iCAG GAA GAG AAA AAT TCG 
CAA GAG GAA AAA AAT TCG 
CTA GAG GAA GAA AAT TCG 
~ GAA GAG AAA AAT TCG 
ND ND ND ND ND ND 
PG GM GAG AAA MT TCG 
CAG GAA GAG AAA AAT TCG 
PG GAA GAG AAA AAT TCG 
PG GAA GAG AAA AAT TCG 
CAG GAA GAG AAA AAA TCG 
iCAG GAA GAG AAA AAT TCG 
PG GAA GAG AAA AAT TCG 
CAG GAA GAG AAA MT TCG 
CAG GAA GAG AAA All TCG 
CAG GAA GAG AAA MT TCG 
ND ND ND ND ND ND 
CAA GAG GAA AAA AAT TCG 
CAA GAG GAA AAA AAT TCG 
ND ND ND ND ND NO 
ND ND ND N) ND ND 
CAA GAG GAA AAA AAT TCG 
CAA GAG GAA GCA AAT TCG 
CTA GAG GAA GAA MT TCG 
~ao. pa£ paE ccaA 0 0 





ACC CCC AAC 
TCC CCT AAC 
TCC CCT AAC 
rec CCT MT 
TCC CCT AAC 
NO ND ND 
TCC CCT AAC 
TCC CCT AAC 
rec CCT AAC 
rec CCT AAC 
TCC CCT AAC 
TCC CCT AAC 
TCC CCT MC 
TCC CCT AAC 
TCC CCT AAC 
TCC CCT AAC 
NO ND ND 
TCC CCT AAC 
TCC CCT AAC 
ND ND NO 
ND ND ND 
TCC CCT AAC 
TCC CCT MT 






























































































COVlsolate 398 401 410 411 412 414 415 416 417 418 
l'! 
Ondersteport TTC AGA ACA TTA CCT GAT GCA AGT GTT GAC 
C AY964110(EW) lTC GGA ACA TTA CCT GAT CCA AGC ACT GAC 
I!! Af112189(AM-2) TTT GGA ACA TTA CCT GAT CCA AGC ATT GAC 
.!! 
QI AY962112(AR) TTT GGA ACG TTA CAT GAT GCA AGC ATT GAC a: 
9041474 TTC GGA ACA TTA CCT GAT CCA AGC ACT GAC 
8120857 TTC NO NO NO NO NO NO NO NO NO 
9041303 lTC GGA ACA TTA CCT GAT CCA AGC ACT GAC 
~ 8031346 TTC GGA GAC ATT CCT GAT CCA AGC ACT GAC 
=a 7091032 TTC GGA ACA TTT CCT GAT CCA AGC ACT GM 
1 7091030 TTC GGA ACA TTA CCT GAT CCA AGC ACT GAC 
C 7111080 ND NO NO NO NO NO NO NO NO NO .. 
& 080112nA TTC GGA ACA TTA CCT GAT CCA AGC ACT GAC 
0 8080941 ACT CCT ... TTT GGA TTA GAT CCA AGC ACT GAC ::, 
w 08011277C TTC GGA ACA TTA CCT GAT CCA AGC ACT GAC 
7101508 TTC GGA ACA TTA CCT GAT CCA AGC ACT GAC 
8010939 TTC GGA ACA TTA CCT GAT CCA AGC ACT GAC 
7091031 TTC NO NO NO ND NO NO NO NO NO 
09020504-3(08-7589) TTT GGA ACA TTA CCT GAT CCA AGC ATT GAC 
N 8060351 TTT GGA ACA TTA CCT GAT CCA AGC ATT GAC c 
~ 8021509 NO NO NO NO NO NO NO NO NO NO 
1i 9050216 NO NO ND NO ND ND ND NO ND ND 
E 8050180 TTT GGA ACA TTA CCT GAT CCA AGC ATT GAC c( 
80307n TTT GGA ACA TTA CCT CAT CCA AGC ATT GAC 
Arctic 7110098 TTT GGA ACG TTA CAT GAT CCA AGC ATT GAC 
tttP 0 acaT ttal cctP gatD 0 0 gttV gacD 
ttcP acgT tttF catH catH actT gaaE 
gacO attl 
~,~34F 
419 420 422 423 
CTT CAA MC CTA 
CTT CAA AAC CTA 
CTT CAA AAC ere 
CGT CAA AAC CTA 
CTT CAA AAC CTA 
NO ND ND NO 
CTT CAA AAC CTA 
CTT CAA TAC CTA 
CTT CAA AAC CTA 
CTT CAA MC CTA 
NO ND NO NO 
CCT CAA MC CTA 
CTT CAA AAC NO 
CTT CAA AAC CTA 
CTT CAA AAC CTA 
CTT CAA AAC CTA 
NO NO NO NO 
CTT CK. AAC ATC 
CTT CAG AAC ATC 
NO NO NO NO 
ND ND ND ND 
CTC CAG MC ATC 
CTC CAA AAC CTA 
CTT CAA AAC CTA 
cttl caaQ aac:N ctal 
cgtR cacH tllCY Cid. 
ctcl cagQ atd 
424 425 427 
TCG TTC TAC 
TCG TTT TAC 
TCG TTT TAC 
TCA TTT TAC 
TCG TTT TAC 
NO ND NO 
TCG TTT TAC 
TCG TTT TAC 
TCG TTT TAC 
TCG TTT TAC 
NO NO NO 
TCG TTT TAC 
NO NO NO 
TCG TTT TAC 
TCG TTT TAC 
TCG TTT TAC 
NO NO TAC 
TCA TTT TAC 
TCA TTT TAC 
NO NO TAC 
NO ND TAC 
TCA TTT TAT 
TCA TTT TAC 
TCA TTT TAC 
trgS ~ WC 
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ttga (SEQ ID NO: 42) 
Fig. 37 




























TTGA (SEQ ID NO: 43) 
Figure 38 





















TNSTTSVENLVRMRFSCNRSRP (SEQ ID NO: 45) 
Fig. 40 
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IMMUNOGENIC COMPOSITIONS, 
VACCINES AND DIAGNOSTICS BASED ON 
CANINE DISTEMPER VIRUSES 
CIRCULATING IN NORTH AMERICAN DOGS 
2 
Unfortunately, CDV vaccines currently in use have not 
been updated for about 60 years (Woma et al., 2010. Phylo-
genetic analysis of the hemagglutinin gene of the current 
wild-type canine distemper viruses from South Africa:Lin-
5 eage Africa.Vet. Microbial. doi:10.1016/jvet-
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
mic .2009.11.013) and have not kept pace with these changes. 
The use of these outdated vaccines is the likely cause of recent 
outbreaks of CDV infection, since these vaccines may not 
provide protection against infection with newly emerging This application claims benefit of U.S. provisional patent 
application 61/148,791, filed Jan. 30, 2009, the complete 
contents of which is hereby incorporated by reference. 
BACKGROUND OF THE INVENTION 
10 lineages of CDV. Moreover, PCR sequencing has revealed 
that the vaccine isolate used in one commercial vaccine was 
misidentified (Demeter et al., 2009: Controversial results of 
the genetic analysis of a canine distemper vaccine strain. Vet. 
Micro biol. Published Online), further complicating the prob-
1. Field of the Invention 
The invention generally relates to newly identified isolates 
15 !em of determining how to best detect, monitor, and prevent 
CDV infection and transmission. 
of canine distemper virus (CDV). In particular, the invention 
provides improved CDV immunogenic compositions, vac-
cines and diagnostics that contain or take into account these 
newly discovered isolates, and describes a systematic proto-
col for selecting, based on genetic makeup, broad spectrum 
isolates for use in immunogenic compositions, vaccines and 
diagnostics. 
Clearly, epidemiological studies to investigate the rise in 
CDV clinical cases are warranted, as is the development of 
new immunological and vaccine compositions and diagnostic 
20 methods that take into account emerging isolates of CDV. 
2. Background of the Invention 
Canine distemper virus (CDV) is a single-stranded RNA 25 
Morbillivirus that affects dogs of all ages. CDV causes a 
multi-systemic infection that may involve the ocular, respi-
ratory, gastrointestinal, integument and nervous systems, and 
is usually rapidly fatal. While the disease is a devastating 
problem for dogs, other species are also susceptible to the 30 
virus, for example, raccoons, foxes, coyotes, wolves, various 
fur-producing animals, and large non-domestic cats such as 
lions, leopards, cheetahs, and tigers. In the past, vaccines have 
proven to be effective in reducing the incidence of CDV 
infection. However, there appears to be a resurgence of the 35 
incidence ofCDV, even in fully vaccinated animals. 
The hemagglutinin (H) protein of CDV is a viral surface 
protein that is involved in host cell-virus binding, and muta-
tions in the protein affect host cell-virus interactions. H pro-
tein is considered to be a virulence factor for CDV. The H 40 
protein displays significant ( e.g. about 10%) variation in 
amino acid sequence among CDV isolates, and phylogenetic 
analysis of this variation serves as the basis for the division of 
viral isolates into seven lineages: American-I, American-2, 
Arctic-like, Asia-I, Asia-2, Europe, and European wildlife 45 
(McCarthy,A. J., M.A. Shaw, and S. J. Goodman. 2007. Proc. 
Biol. Sci. 274:3165-3174). Antibodies to H protein provide 
protection against infection, and are thus the likely basis for 
vaccine efficacy. However, antibodies do not necessarily 
cross-react between lineages. Hence, vaccines based on a 50 
particular isolate may or may not provide the vaccine recipi-
ent with protection against infection with other isolates. This 
is particularly problematic given 1) the high rate of mutation 
exhibited by RNA viruses such as CDV and 2) the increase in 
the global transport of dogs from one country to another, 55 
which fosters the introduction of new lineages into territories 
where they were previously unknown. Further, for dogs vac-
cinated with a particular CDV isolate, exposure to a geneti-
cally distant CDV may lead to sequestration of the incoming 
CDV virus in immunologically privileged sites ( e.g. brain, 60 
ganglion, spinal cord, central, autonomic nervous systems, 
nasal plenum and bladder epithelium), allowing the propaga-
tion and spread of the genetically distant CDV without detec-
tion, since neurological symptoms may be overlooked by 
veterinary practitioners due to lack of sensitivity of the diag- 65 
nostic tests and expense of long term treatment of a neuro-
logical patient. 
SUMMARY OF THE INVENTION 
In one aspect, the present invention provides newly iden-
tified isolates of canine distemper virus (CDV). Accordingly, 
the present invention further provides updated immunogenic 
compositions and vaccine compositions. The vaccine com-
positions of the present invention are designed to provide 
broad-spectrum protection against emerging forms of CDV. 
In addition, the present invention provides updated diagnostic 
methods and kits for detecting CDV infection. The diagnostic 
methods and kits provide the ability to detect the newly 
evolved forms of the virus. The compositions and diagnostic 
methods and kits of the present invention are based, at least in 
part, on the discovery of previously unknown CDV variants, 
and take into account the emergence of mutant forms of the 
virus for which prior vaccine formulations and diagnostics 
are inadequate. 
In a further aspect, the present invention provides a system-
atic method for selecting an antigen, e.g., a pathogenic isolate 
or portion thereof, that correspond to the genetic makeup of a 
broad spectrum of the source of the antigen, e.g. pathogen 
isolates or portion thereof, for use in such compositions and 
diagnostics. 
The present invention further provides an isolated canine 
distemper virus (CDV) of European wildlife (EW) lineage 
comprising the characteristics ofCDV 9041474B CDV-EW 
(ATCC Deposit No. PTA-10596). In another embodiment, 
the invention provides an attenuated strain ofCDV isolated in 
cell cultures in which CDV strain CDV 9041474B CDV-EW 
(ATCC Deposit No. PTA-10596), or a progeny strain thereof, 
has been propagated. In a particular embodiment of this type, 
the attenuated strain of CDV may be plaque-purified. In yet 
another embodiment, the invention provides an immunogenic 
composition or vaccine, comprising the isolated CDV com-
prising the characteristics of CDV 9041474B CDV-EW 
(ATCC Deposit No. PTA-10596), or progeny thereof. 
In still another embodiment, the invention provides an 
isolated canine distemper virus (CDV) of American-2 (AM-
2) lineage having the characteristics ofCDV 08021509 CDV-
AM-2 (ATCC Deposit No. PTA-10597). In yet another 
embodiment, the invention provides an attenuated strain of 
CDV isolated in cell cultures in which CDV strain CDV 
08021509 CDV-AM-2 (ATCC Deposit No. PTA-10597), ora 
progeny strain thereof, has been propagated. In a particular 
embodiment of this type, the attenuated strainofCDV may be 
plaque-purified. In a further embodiment, the invention pro-
US 8,647,637 B2 
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vides an innnunogenic composition or vaccine comprising 
the isolated CDV having the characteristics of CDV 
08021509 CDV-AM-2 (ATCC Deposit No. PTA-10597), or 
progeny thereof. 
The present invention also provides methods of eliciting an 
immune response to canine distemper virus in a subject in 
need thereof. One such method comprises administering to 
the subject an innnunogenic composition or vaccine compris-
ing an isolated CDV comprising the characteristics of CDV 
9041474B CDV-EW (ATCC Deposit No. PTA-10596), or 
progeny thereof. In another such embodiment, the method 
comprises administering to said subject the innnunogenic 
composition or vaccine comprising the isolated CDV having 
the characteristics of CDV 08021509 CDV-AM-2 (ATCC 
Deposit No. PTA-10597), or progeny thereof. 
The present invention also provides diagnostic kits. One 
such embodiment comprises oligonucleotide primers specific 
for amplifying a nucleotide sequence as set forth in SEQ ID 
NO: 42. In another embodiment, the diagnostic kit compris-
ing oligonucleotide primers specific for amplifying a nucle-
otide sequence as set forth in SEQ ID NO: 43. Those of skill 
in the art will recognize that such primers are based on the 
nucleotide sequence of a nucleotide sequence of interest that 
is to be amplified (e.g. a sequence that is targeted). In some 
embodiments, primers are homologous to or complementary 
to unique sequences of the target sequence. 
The present invention further provides the recombinant 
and/or isolated nucleic acid molecules of the present inven-
tion. One such nucleic acid encodes the amino acid sequence 
of SEQ ID NO: 44, and/or the nucleic acid complement 
thereof. In another such embodiment, the nucleic acid mol-
ecule comprises the nucleotide sequence of SEQ ID NO: 42, 
and/or the complement thereof. In still another such embodi-
ment, the isolated nucleic acid molecule comprises a nucle-
otide sequence that has greater than 99 .5% identity to that of 
SEQ ID NO: 42, and/or to the complement thereof. 
In still another embodiment, the recombinant and/or iso-
lated nucleic acid molecule encodes the amino acid sequence 
of SEQ ID NO: 45, and/or the nucleic acid complement 
thereof. In yet another embodiment, the nucleic acid mol-
ecule comprises the nucleotide sequence of SEQ ID NO: 43, 
and/or the complement thereof. In still another such embodi-
ment, the isolated nucleic acid molecule comprises a nucle-
otide sequence that has greater than 95% identity to that of 
SEQ ID NO: 43, and/or to the complement thereof. 
The present invention further provides expression vectors 
that can comprise any of the isolated nucleic acid molecules 
of the present invention. In one such embodiment the expres-
sion vector comprises the isolated nucleic acid molecule 
encoding the amino acid sequence of SEQ ID NO: 44, and/or 
the complement thereof. In yet another embodiment, the 
invention provides an expression vector that comprises an 
isolated nucleic acid molecule encoding the amino acid 
sequence of SEQ ID NO: 45, or the complement thereof. 
4 
proteins and chimeric proteins of the present invention. In one 
such embodiment the polypeptide comprises the amino acid 
sequence of SEQ ID NO: 44. In another such embodiment 
that polypeptide is encoded by the nucleotide sequence of 
5 SEQ ID NO: 42. 
In a further embodiment, the present invention provides 
innnunogenic compositions and vaccines comprising CDV 
virions that encode a hemagglutinin protein. In related 
embodiments, the hemagglutinin can be partially encoded by 
10 a nucleic acid that comprises a nucleotide sequence as set 
forth in SEQ ID NOS: 1-33. In still other related embodi-
ments, the present invention provides methods of eliciting an 
innnune response to canine distemper virus in a subject in 
need thereof by administering to the subject one or more of 
15 such innnunogenic compositions or vaccines. 
The present invention further provides a method of select-
ing one or more isolates ofa pathogen for use in innnunogenic 
compositions, wherein the isolate( s) utilize(s) one or more of 
a most frequently used codon to encode a selected innnuno-
20 genie protein, polypeptide or peptide of interest. One such 
method comprises the steps of 1) determining, for each isolate 
in a plurality of pathogen isolates, a nucleotide sequence 
encoding said selected innnunogenic protein, polypeptide or 
peptide of interest; 2) for nucleotide sequences obtained in 
25 the determining step, obtaining codon usage data for one or 
more amino acid residues of interest in said innnunogenic 
protein, polypeptide or peptide of interest, whereby data for 
frequency of codon usage is obtained; 3) identifying, from 
said data for frequency of codon usage, a most frequently 
30 used codon for each of said amino acid residues of interest in 
the innnunogenic protein, polypeptide or peptide of interest; 
and 4) selecting, from among the plurality of pathogen iso-
lates, one or more isolates that utilize(s) one or more of the 
most frequently used codons to encode the protein, polypep-
35 tide or peptide of interest. In one embodiment of the inven-
tion, the pathogen is a canine distemper virus. 
In yet another embodiment, the invention provides a 
method of selecting one or more nucleotide sequences for a 
nucleic acid (which may be from an isolate of a pathogen) for 
40 use in innnunogenic compositions. The nucleic acid utilizes 
one or more of a most frequently used codon to encode a 
selected innnunogenic protein, polypeptide or peptide of 
interest. The method comprises the steps of 1) determining 
( e.g. from a plurality of pathogen isolates) a plurality of 
45 nucleotide sequences which encode the selected innnuno-
genic protein, polypeptide or peptide of interest; 2) for nucle-
otide sequences obtained in the determining step, obtaining 
codon usage data for one or more amino acid residues of 
interest in said immunogenic protein, polypeptide or peptide 
50 of interest, whereby data for frequency of codon usage is 
obtained; 3) identifying, from the data for frequency of codon 
usage, a most frequently used codon for each of the amino 
acid residues of interest in the innnunogenic protein, 
polypeptide or peptide of interest; and 4) selecting, from 
55 among the plurality of nucleotide sequences, the nucleotide 
sequence( s) that utilize( s) one or more of the most frequently 
used codons to encode the protein, polypeptide or peptide of 
The present invention further provides innnunogenic compo-
sitions and vaccines that can comprise any of the expression 
vectors of the present invention. In one such embodiment the 
immunogenic composition or vaccine comprises an expres-
sion vector that comprises the isolated nucleic acid molecule 
encoding the amino acid sequence of SEQ ID NO: 44, and/or 60 
the complement thereof. In another embodiment the innnu-
nogenic composition or vaccine comprises an expression vec-
interest. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG.1. Isolate 07091030 (SEQ ID NO: 1, nucleotides (nt) 
438-1302 ofH gene ofCDV). This isolate is from a dog with 
a history of seizures and exhibiting neutrophils with multiple, 
65 intra-cytoplasmic inclusions. This CDV isolate formed large, 
multi-nucleated, syncytia in a Vero cell line expressing canine 
signaling lymphocyte-activation molecule (Vero+SLAM). 
tor that comprises the isolated nucleic acid molecule encod-
ing the amino acid sequence of SEQ ID NO: 43, and/or the 
complement thereof. 
The present invention further provides all of the isolated 
and/or recombinant proteins, polypeptides, peptides, fusion 
US 8,647,637 B2 
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Based on the H protein sequence, this is a European wild life 
lineage isolate. This CDV isolate may be particularly useful, 
for example, as a challenge virus. 
FIG. 2. Isolate 07091031 (SEQ ID NO: 2, nt 440-1494 ofH 
gene). 
FIG. 3. Isolate07091032 (SEQ IDNO: 3, nt440-1225 ofH 
gene). 
6 
FIG. 28. Isolate 09011024 (SEQ ID NO: 28, nt 578-1613 of 
H gene). 
FIG. 29. Isolate 09020504-3 (SEQ ID NO: 29, nt 418-1549 
ofH gene). 
FIG. 30. Isolate 09041289 (SEQ ID NO: 30, nt 889-1646 of 
H gene). 
FIG. 31. Isolate 09041303 (SEQ ID NO: 31, nt394-1526 of 
H gene). 
FIG. 32. Isolate09041474A (SEQ ID NO: 32, nt 410-1539 
of H gene). Fully vaccinated dogs (two vaccinations with 
commercial Ondersteport CDV vaccine) in a large shelter in 
Tennessee developed upper respiratory tract disease, high 
fevers, green nasal discharge, cough, and eventually neuro-
logical symptoms, e.g. twitching. About 20 out of 55 dogs 
FIG. 4. Isolate07101508 (SEQ IDNO: 4, nt427-1335 ofH 
gene). This isolate has high identity with European wildlife 
(EW) genetic lineage but is from a dog from Southern Cali- 10 
fornia with a history ofOndersteport vaccination. This isolate 
produces large syncytia in Vero+SLAM cells. The isolate has 
high identity with CDV from the lesser panda and Danish 
mink but is not closely related to the Ondersteport vaccine 
isolate. 15 died, including the 4 month old female from which isolates 
09041474A and 09041474B (see FIG. 37) were obtained. FIG. 5. Isolate07100609 (SEQ ID NO: 5, nt 833-1213 ofN 
gene). The sequence of the nucleocapsid encoding genes of 
this CDV-like virus from a marine mammal (seal), matches 
canine isolate 164071 from the US (EU716337). 
FIG. 6. Isolate07110098 (SEQ ID NO: 6, nt439-1286 ofH 20 
gene). 
FIG. 7. Isolate07111080 (SEQ ID NO: 7, nt 630-1501 ofH 
gene). 
FIG. 33. Isolate 09040826 (SEQ ID NO: 33, nt418-1546 of 
H gene). 
FIGS. 34A-F. Codon table showing canine distemper virus 
hemagglutinin (H) codon sequences from field isolates 
aligned with CDV-H vaccine and reference strain codon 
sequences using Bio Edit program. Sequences: 
Ondersteport=CDV vaccine sequence; AY96411 0=reference 
European wildlife (EW) strain); AF112189=reference FIG. 8. Isolate08010939 (SEQ IDNO: 8, nt443-1343 ofH 
gene). 
FIG. 9. Isolate08011277A (SEQ ID NO: 9, nt423-1556 of 
H gene). 
25 American-2 (AM-2) strain;AY962112=referenceArctic (Ar) 
strain. Differences in codons are shaded. 
FIG.10. Isolate 08011277B (SEQ ID NO: 10, nt 1530-410 
ofH gene). 
FIG.11. Isolate 08011277C (SEQ ID NO: 11, nt 433-1230 30 
ofH gene). 
FIG. 12. Isolate 08011277D (SEQ ID NO: 12, nt 833-1578 
of nucleocapsid gene). The H gene of this isolate could not be 
amplified. Lack of amplification indicates genetic variation 
(and hence, lack of homology) in the primer binding 35 
sequences. The nucleocapsid gene sequence matches that of a 
CDV isolate. 
FIG.13. Isolate08011671 (SEQ IDNO: 13, nt422-1589 of 
H gene). 
FIG.14. Isolate 08021509 (SEQ ID NO: 14, nt 441-686 of 40 
H gene). 
FIG.15. Isolate08030074 (SEQ IDNO: 15, nt447-1282 of 
H gene). 
FIG. 35. Phylogenetic tree showing genetic relatedness of 
the many recent United States CDV isolates in the United 
States and GenBank reference sequences (underlined). The 
phylogenetic tree was constructed using MEGA4.1 program 
(available free of charge at the website located at megasoft-
ware.net; Tamura K, Dudley J, Nei M & Kumar S (2007) 
MEGA4: Molecular Evolutionary Genetics Analysis 
(MEGA) software version 4.0. Molecular Biology and Evo-
lution 24: 1596-1599). 
FIG. 36. Blood film showing erythrocyte inclusions of 
CDV from a CDV infected dog (OADDL:07091030). CDV 
inclusions (arrows) are visible within a neutrophil and a lym-
phocyte. (Aqueous Romanowsky stain; bar=l0 microns). 
FIG. 37. Complete sequence ofH gene from 09041474B 
(SEQ ID NO: 42), including stop codons. 
FIG. 38. Complete sequence of H gene from 08021509 
(SEQ ID NO: 43), including stop codons. 
FIG.16. Isolate08030776 (SEQ IDNO: 16, nt422-1541 of 
H gene). 
FIG. 39. Complete amino acid sequence ofH protein from 
45 09041474B (SEQ ID NO: 44). 
FIG.17. Isolate08030777 (SEQ IDNO: 17, nt411-1537 of 
H gene). 
FIG.18. Isolate08031346 (SEQ IDNO: 18, nt436-1059 of 
H gene). 
FIG. 40. Complete amino acid sequence ofH protein from 
08021509 (SEQ ID NO: 45). 
DETAILED DESCRIPTION 
FIG.19. Isolate08040383 (SEQ IDNO: 19, nt 1486-620of 50 
H gene). The present invention provides compositions that elicit an 
immunogenic response to CDV, vaccine compositions 
designed to provide protection against CDV infection, and 
CDV diagnostics. The compositions contain newly discov-
FIG. 20. Isolate 08050180A (SEQ ID NO: 20, nt 418-1552 
ofH gene). 
FIG. 21. Isolate08060351 (SEQ IDNO: 21, nt412-1536 of 
H gene). 
FIG. 22. Isolate08060352 (SEQ IDNO: 22, nt408-1553 of 
H gene). 
FIG. 23. Isolate 08080696 (SEQ ID NO: 23, nt 423-726 of 
H gene). 
55 ered CDV variants. The new variants reflect the evolutionary 
trends of CDV, and provide an indication of the predominant 
CDV strains currently circulating in the United States. The 
variants were, in part, isolated from dogs that had already 
FIG. 24. Isolate08080941 (SEQ IDNO: 24, nt387-1522 of 60 
H gene). 
been vaccinated for CDV, but which nevertheless contracted 
CDV and became ill, i.e. the dogs were the victims of vaccine 
failure. In order to stop or curtail the spread of CDV and to 
FIG. 25. Isolate08081112 (SEQ IDNO: 25, nt41 l-1207 of 
H gene). 
FIG. 26. Isolate08120827 (SEQ IDNO: 26, nt413-1535 of 
H gene). 
FIG. 27. Isolate08120857 (SEQ IDNO: 27, nt724-1522 of 
H gene). 
prevent vaccine failure, one or more of these new variants 
should be incorporated into new vaccine protocols. The 
invention also provides new diagnostic methods for detecting 
65 the new CDV isolates, and for differentiating between canine 
distemper caused by vaccine administration and canine dis-
temper caused by an emerging virus which was not included 
US 8,647,637 B2 
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in the vaccine, and against which the vaccine did not provide 
protection. In addition, the invention provides a method of 
analyzing RNA virus field isolates and emerging pathogens in 
order to determine which isolates are likely to be useful for 
inclusion in broad-spectrum immunogenic and vaccine com-
positions. 
8 
various protozoan pathogens such as Malaria, Trypanosoma, 
Toxoplasma, Entamoeba, Giardia, and Cryptosporidia spe-
cies, etc. Those of skill in the art will recognize that a "rep-
resentative number" of isolates of a pathogen may vary, but 
5 will generally be in the range of at least 20-25, usually at least 
30-35, and may be any number of isolates (or sequences) 
without limit, depending on the availability of biological 
samples, the availability of resources that can be directed to 
Several of the new isolates belong to the European wildlife 
CDV lineage; others belong to the American-2 (AM-2) and 
Arctic genetic lineages. 34 CDV viruses have been isolated, 
propagated in cell culture and the H genes of the viruses have 10 
been partially or fully sequenced. These viruses were from 
various states in the US ( e.g. Oklahoma, Florida, Georgia, 
California, Missouri, Texas, Kansas and Tennessee). FIGS. 
1-33 show partial sequences of cDNA complementary to the 
the effort, etc. 
A "population of interest" will generally be a population of 
individuals that are susceptible to a pathogen of interest, and 
may include individuals that exhibit disease symptoms when 
infected with the virus, or may be "carriers" who harbor the 
virus with few or no symptoms, but which are nevertheless 
H gene from the isolates; FIGS. 37 and 38 show the complete 
H gene sequence for isolates 09041474B and 08021509, 
respectively, including stop sequences (TGA for both); and 
FIGS. 39 and 40 show the corresponding amino acid 
sequences of the H protein from isolates 09041474B and 
08021509, respectively. In the amino acid sequences, the 
amino acid as position 5 in the sequence from 09041474B is 
glutamine, and amino acid at position 5 in the sequence from 
08021509 is arginine. 
The present invention also provides recombinant and/or 
isolated nucleic acids that encode any of the H-proteins of the 
present invention, but which do not include the signal 
sequence (the first 12 amino acid residues at the amino ter-
minus of the H protein) and/ or the stop codon and/or comprise 
an alternative signal sequence and/or an alternative stop 
codon. Expression vectors comprising such nucleic acids are 
also included in the present invention, as are the expressed 
recombinant polypeptides (including isolated recombinant 
polypeptides) that these nucleic acids encode. 
FIGS. 34A-F show CDV hemagglutinin (H) sequences 
from several of the field isolates aligned with CDV-H vaccine 
sequences and reference strains. An analysis of this data 
served as the basis for the development of the Relative Pre-
ferred Codon Usage (RPCU) method/ concept of analysis and 
selection of broad spectrum pathogen isolates for use in vac-
cines. The method is based on the newly recognized patterns 
ofRPCU in pathogens, as disclosed herein. While the method 
15 infected with the pathogen. 
A geographical area or region of interest may be, for 
example, a region or area bounded by geographical and/or 
legal boundaries, for example, a country, continent, state, 
county, etc.; or regions separated by geographical barriers 
20 such as bodies of water (rivers, lakes, oceans, etc.), mountain 
ranges, deserts, etc.; or regions/areas with a common climate 
or weather pattern, e.g. similar average temperature or rain-
fall, presence or absence of snow and ice, etc. 
At least one protein, polypeptide or peptide of interest 
25 common to all isolates is selected for detailed gene sequence 
analysis. Generally, such a protein, polypeptide or peptide of 
interest is one that is known to be immunogenic. By immu-
nogenic, it is meant that the protein, polypeptide or peptide 
elicits an immune response (e.g. the production of antibodies) 
30 in a host when the protein, polypeptide or peptide if present in 
the host ( e.g. when a pathogen comprising the protein, 
polypeptide or peptide infects a host). Major immunogens 
can be determined by any of several methods known to those 
of skill in the art, including by Western blot analysis of serum 
35 from a convalescent patient that has recovered and is pro-
tected from further infection with the pathogen. Those of skill 
in the art will recognize that one or more than one such 
proteins, polypeptides or peptides may be analyzed using 
RPCU, but at least one is selected. Otherwise, more can be 
40 systematically selected for analysis but the one that is pre-
dominant based on, for example, Western blot analysis can be 
a good starting point. An unknown immunogenic protein can 
be sequenced by MALDI-TOFF. This helps to design the 
is widely applicable to many pathogenic organisms ( dis-
cussed in detail below), herein, an exemplary use for the 
analysis ofRNA virus isolates is described.As used herein, an 
"isolate" ( e.g. which may be a pathogen, such as, for example 45 
an RNA virus) has been substantially isolated and purified 
from a biological sample, and may have been subjected to 
passage and/or propagation in a suitable cell culture. Alter-
natively, the isolate may have been obtained from a pure 
culture, e.g. from anATCC deposit. 
primers to amplify the sequences. 
After selection of a suitable protein, polypeptide or pep-
tide, the nucleotide sequence encoding the protein, polypep-
tide or peptide is determined using techniques that are well 
established, e.g. polymerase chain reaction (PCR) sequenc-
ing, etc. Alternatively, the sequences that are compared using 
50 this method may be obtained directly from biological samples 
without isolation of the virus, or they may be known 
sequences obtained from a database (e.g. GenBank or others). 
In order to practice the method of RPCU, a representative 
number of isolates of interest are isolated from biological 
samples of animal subjects (including humans) obtained in 
one or more populations of interest. The isolates can be 
obtained within a given geographical region or area of inter-
est, and/or from animal subjects suspected of harboring the 
pathogen. Suitable biological samples are those with the 
highest concentrations of the virus collected during the acute 
stage of pathogen infection, and include various tissue 
samples, bodily fluids or excreted substances (phlegm, saliva, 
blood, urine, stool, swabs [ a generic term for many types of 
samples], etc.). Examples of suitable pathogens ( e.g. emerg-
ing pathogens), which can be analyzed by RPCU include but 
are not limited to: various viruses such as RNA viruses, 
single-stranded DNA viruses, influenza viruses, HIV virus, 
etc.: various bacterial pathogens such as Mycobacteria, Yers-
inia, Rickettsia and Bartonella species; various fungi; and 
The nucleotide sequences are then subjected to analysis to 
identify triplet codons and to align the codons in the correct 
55 translation (reading) frame. Sequence analysis may be con-
ducted with any of the many nucleotide analysis programs, 
including but not limited to CLUSTAL W analysis using 
BioEdit software, the Multiple Sequence Alignment Program 
(MAP) provided by the Baylor School of Medicine, etc. Usu-
60 ally, the sequences that are analyzed are cDNA sequences, 
although the method is not limited to the use of cDNA, e.g. 
DNA, RNA, etc. may also be analyzed. Optionally, the cor-
responding sequence from one or more reference sequences 
( e.g. RNA virus reference strains) is included in the analysis. 
65 Generally, a reference strain will represent, for example, a 
pathogen type ( e.g. a virus lineage) which was previously 
dominant ( e.g. present at a high frequency) in the population 
US 8,647,637 B2 
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and/or region under consideration. Such a reference strain 
may be, for example, an RNA virus that has been used in a 
vaccine against infection with the RNA virus. The preferred 
candidates for reference sequences are those which display 
the highest levels of homology and identity with both nucle-
otide and protein sequences of the pathogens (e.g. emerging 
pathogens), when analyzed using, for example, BLASTn and 
BLASTp programs. The level of homology and/or identity 
will be at least about 90% or 95%, or even at least about 99% 
or greater. 
The triplet codons specifying the amino acids from the 
isolates ( and, optionally, of one or more reference sequences) 
are aligned in frame in a format that may be readily compared, 
including but not limited to in tabular form, for example, in an 
Excel table. Those of skill in the art are well aware that the 
triplet code is redundant, and that more than one codon can 
encode the same amino acid. For each position corresponding 
to an amino acid residue in the protein, polypeptide or peptide 
of interest, the identity of the three nucleotides encoding the 
residue from each isolate is noted and compared across all 
isolates. For example, in a hypothetical protein of interest, if 
position 50 is a leucine, possible codons for this residue 
include tta and ttg. The actual codon at position 50 of all 
isolates is noted and compared to the codon present at all 
other isolates. From this comparison, the Relative Preferred 
Codon Usage (RPCU) can be determined. For example, if 
75% of the isolates use "tta" to encode the Leu residue and 
25% of the isolates use "ttg", then the RPCU value of tta is 
75% and that ofttg is only 25%. Thus, tta is the preferred (i.e. 
the most frequently occurring or used) codon at that residue. 
In this manner, the most frequently used or preferred codon 
for each residue of interest of the sequence of interest is 
determined. The analysis may be carried out for all residues of 
a sequence, or for only a subset of residues, e.g. residues that 
are known to be involved in crucial pathogen activities or 
which are known to be part of an epitope or antigenic region, 
or which associated with virulence, etc. 
The goal of the RPCU method is to identify isolates with 
nucleotide sequences which possess a high percentage of 
preferred codons for use in broad-spectrum vaccine prepara-
tions. This can be accomplished by any of several means. For 
example, a theoretical "ideal" sequence comprising only the 
most preferred codons can be determined and the actual 
sequences of the isolates can be compared to the theoretical 
sequence. The level of homology between each isolate and 
the ideal sequence is calculated. The isolate that displays the 
highest level (e.g. amount, percentage, etc.) of homology to 
the ideal sequence will be the isolate that utilizes the highest 
numberof preferred codons. This isolate is the best "fit" to the 
ideal, and is selected as a vaccine component. Alternatively, 
an ideal sequence may not be determined but codon usage at 
each position is tabulated or calculated as described above, 
and a comparison is made among sequences by other methods 
that will occur to those of skill in the art, e.g. by simple visual 
inspection, to identify a sequence from an isolate that utilizes 
a very high level, or the highest level, number of preferred 
codons. 
Without being bound by theory, this selection is consistent 
with the understanding that when a mutation occurs in the 
three-nucleotide sequence that encodes a residue, that muta-
tion is likely to be perpetuated or to become widespread only 
if pathogens (e.g. RNA viruses) containing the mutation have 
some selective advantage over pathogens which do not con-
tain the mutation. For example, some codons are translated 
more rapidly or with greater accuracy than others, and patho-
gens with such mutations may reproduce and infect new hosts 
more successfully than non-mutant pathogens. Therefore, 
10 
these codons are eventually present more frequently in a 
population of pathogens due to natural selection. An isolate 
with a high percentage of frequently used codons likely pos-
sesses the cumulative advantages associated with the codons, 
5 and is likely to display the favorable characteristics of 
afforded by the codons, and thus, when included in a vaccine 
preparation, is likely to provide broad-spectrum protection. 
RPCU takes into consideration the internal protein epitopes 
of pathogens (such as viruses) that interact with the genomic 
10 nucleic acids (Pepin KM, J Domsic, and R McKenna. 2008. 
Genomic evolution in a virus under specific selection for host 
recognition. Infection, genetics, and evolution: 825-834). 
RPCU impacts biological functions of RNA viruses such 
as CDV. The codons (triplet of nucleotides) are the most basic 
15 biological unit because they encode amino acids, which form 
the functional units of protein, including epitopes (e.g. about 
6-7 amino-acids) and antigenic regions, or sequence motifs, 
which are directly involved in eliciting a host immune 
response to antigenic proteins, such as the H protein of CDV. 
20 Thus, the selection of CDV isolates based on RPCU reflects a 
phenotype/function of the virus, such as gene expression, 
H-protein expression and titers of the virus. Codon usage can 
also affect the breadth of protein expression and hence influ-
ence the tissues in which the virus or a protein is expressed. In 
25 a preliminary analysis, a gel-based PCR analysis ofH protein 
expression by CDV showed that most American-2 isolates 
had uniformly lower (about 8-10 fold lower) H-gene PCR 
product expression, compared to most EW isolates. This 
result likely reflects the robust and biologically favorable 
30 H-gene codon composition in most EW CDV isolates, which 
leads to a higher frequency of EW CDV isolates in canine 
populations. An application of this method to CDV RNA 
viruses is presented in Example 4 below. 
Those of skill in the art will recognize that computer imple-
35 mented software (a computer program) may be developed to 
implement the RPCU method. Such software includes or 
encodes instructions for causing a computer to carry out the 
RPCU method, and may include, for example, means for 
entering sequences and other relevant data (e.g. name of 
40 isolate, codon alignment features, etc.), means for displaying 
entered data, means for representing the results of the analysis 
( e.g. a display on a screen, or a printout ["hard copy"] of the 
results in a suitable form, e.g. as a sequence, as one or more 
numerical indicators (such as "sequence #4" or "#4" as the 
45 best result), in graphical form, tabular form, etc.). Means for 
statistical analyses may also be included in the computer 
program, and the analysis may provide gradations of results, 
i.e. the program may rank the candidate sequences in terms of 
those that are likely to be the most suitable to those that are the 
50 least likely, and/or may simply provide one or more highest 
ranking (most suitable) sequences. The computer program 
may include instructions for carrying out an algorithm that is 
used to carry out the analysis. 
The RPFU method is thus a method of selecting and/or 
55 obtaining an isolate of a pathogen for use in immunogenic 
compositions and vaccines. Such an isolate can be selected or 
otherwise obtained (e.g., through modification by standard 
genetic engineering techniques), which has preferred codons 
that encode a protein, polypeptide or peptide (usually an 
60 immunogen) of interest. 
The RPFU method may include steps of: obtaining a plu-
rality of isolates of the pathogen ( e.g. an RNA virus) from 
biological samples from a plurality of different animals 
infected with the pathogen; selecting an immunogenic pro-
65 tein, polypeptide or peptide of interest associated with the 
RNA virus; determining a nucleotide sequence encoding the 
immunogenic protein, polypeptide or peptide of interest for 
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sequence was not isolated. In contrast, the H gene sequence 
from 09041474B as described herein was obtained from an 
isolated CDV that had been grown and propagated in cell 
culture. The two sequences also differ in codon usage. For 
09041474B, the codon at position 187 is CGA, the codon at 
position 201 is CTG, the codon at position 236 is CCT and the 
codon at position 303 is TCA. In further contrast to 
AY964110, in the 09041474B sequence, the codon at position 
303 encodes serine rather than leucine (see FIGS. 34A-F). 
each isolate of the plurality ofisolates; identifying, in each of 
the nucleotide sequences encoding the immunogenic protein, 
polypeptide or peptide of interest, codons encoding amino 
acid residues of interest in the immunogenic protein, 
polypeptide or peptide of interest; determining, by comparing 5 
the nucleotide sequences encoding the immunogenic protein, 
polypeptide or peptide of interest, frequency of codon usage 
data for each of the amino acid residues of interest in the 
immunogenic protein, polypeptide or peptide of interest; 
from said frequency of codon usage data, identifying a most 
frequently used codon for each of the amino acid residues of 
interest in the immunogenic protein, polypeptide or peptide 
10 Isolate 09041474B displays robust growth in cell culture and 
it is possible that serine at position 303 confers advantages 
with respect to eliciting an immune response in subjects to 
whom virions with this sequence are administered. A deposit 
of the 09041474B CDV isolate, labeled 09041474B CDV-
of interest; and selecting, from among the plurality of isolates 
of the pathogen, an isolate that utilizes one or more of the 
most frequently used codons to encode the protein, polypep-
tide or peptide of interest. In some RNA viruses, quasi-popu-
lations of the immunogen may be analyzed by RPCU soft-
ware. 
15 EW (whole, live viruses at a low passage of2-3) was made at 
the American Type Culture Collection (ATCC) in Manassas, 
Va., with deposition #PTA-10596, deposit date Jan. 21, 2010. 
A second CDV isolate of interest, 08021509 (American-2, 
labeled 08021509 CDV-AM-2) was also deposited atATCC FIG. 35 shows a phylogenetic tree of the genetic related-
ness of the isolates, based on the sequence of the H gene. In 
the tree, a very close related population of CDV isolates has 
emerged, a "predominant CDV population" that belongs to 
the European wild-life lineage. These European wild-life 
viruses can be checked by challenge with other minor CDV 
viruses of two other lineages, Arctic and American, i.e. the 25 
"minor CDV population". One or more broadly reactive, 
predominant isolates that are protective against both the 
European-Wildlife and one or the other ( or both) of Arctic and 
American-2 lineage viruses can be used to make a CDV 
immunogenic composition for use as a vaccine that is effec- 30 
tive against all CDV lineages currently circulating in the 
United States, or other suitable locations. In other words, the 
immunogenic compositions should elicit an immune reaction 
20 with deposition #PTA-10597, deposit date Jan. 21, 2010. 
( e.g. antibody production) against European wild-life lineage 
viruses and against one or both of Arctic and American-2 35 
lineage viruses. Vaccines of the invention should be protec-
tive against European wild-life lineage viruses and against 
one or both of Arctic and American-2 lineage viruses. The 
CDV used in such an immunogenic composition or vaccine 
contains nucleic acid sequences encoding antigens ( antigenic 40 
regions, antigenic determinants, etc.) previously found only 
in and believed to be characteristic of European wild-life 
viruses, together with antigens previously found only in and 
believed to be characteristic of Arctic or American lineage 
viruses, or preferably both Arctic and American-2 lineage 45 
viruses. 
One example of such a virus is isolate 09041474B, the 
complete hemagglutinin gene sequence of which is set forth 
Both deposits were of whole viruses. The invention includes 
viruses that have the characteristics of the isolates that were 
deposited, for example: nucleotide sequences as disclosed 
herein; virulence and propagation attributes; attributes of syn-
cytia (e.g. size, shape, number, appearance ([e.g. clearly 
demarcated, fuzzy, etc.), number of nuclei in the syncytia, 
etc.; among others. 
In some embodiments of the invention, a multivalent CDV 
immunogenic composition and/or vaccine (e.g. European 
wildlife andAmerican-2) will be employed. These two CDV 
lineages can be combined in a single preparation or adminis-
tered separately as two separate dosages, for example, if they 
interfere with induction of CDV immunity. 
The present invention provides all of the isolates disclosed 
herein, as well as vaccines and immunogenic compositions 
made from the isolates, and/or from antigenic portions of the 
isolates as described herein, e.g. nucleic acids comprising the 
nucleotide sequences as set forth in SEQ ID NOS: 1-33 and 
42-43 and/or the proteins, polypeptides, or peptides encoded 
therefrom. The vaccines of the invention may be formulated 
in any suitable manner, including but not limited to using the 
whole virus (e.g. killed or attenuated, as described in detail 
below). In this embodiment, any of the novel CD viruses 
disclosed herein may be used to prepare a vaccine. Generally, 
such viruses may be identified by isolating the virus from 
tissue samples from dogs with symptoms of CDV infection, 
especially dogs that have been previously vaccinated against 
CDV, and sequencing and comparing the viral genome to 
known sequences (i.e. compared to CDVs isolated prior to the 
50 present invention, especially to CDV isolates that are cur-
rently used in vaccines). In particular, such new virus isolates 
may have an H gene sequence that contains a region that is 
identical to or homologous to that of isolate 09041474B (an 
in SEQ ID NO: 42. Several criteria were used for selection of 
this CDV isolate as a vaccine candidate. First, a panel of 
current CDV isolates was developed. (Historically, only a few 
isolates have been available based on published reports. 
Moreover, the reports to investigate the issue of CDV vaccine 
failure have been few.) Second, hemagglutinin sequencing 
and CDV genotyping were performed. Global nucleotide 55 
analysis using BALSTn, CLUSTAL-W, and phylogenetic 
analysis allowed clustering and characterization of CDV iso-
lates in lineages, and 090414 7 4B was determined to be ofEW 
lineage. Then, codon usage tables (shown in FIGS. 34A-F) 
were used to select CDV vaccine isolate 09041474B accord-
ing to the Relative Preferred Codon Usage (RPCU) analysis 
method described above. 
The H gene sequence from isolate 09041474B (complete 
sequence, FIG. 37), differs from reference EW sequence 
(AY964110 in FIGS. 34A-F) in several respects. Firstly, the 
nucleotide sequence for the H gene of AY964110 was 
obtained using a tissue sample, i.e. a CDV virus with this 
exemplary isolate). 
Generally, such viruses will have an H gene ( or portion 
thereof) that is at least about 75%, preferably about 80%, 
more preferably about 85%, most preferably about 90%, or 
even 95, 96, 97, 98, 99, or 100% homologous (and/or identi-
cal) to the nucleic acid sequences disclosed herein, or 
60 complements thereof. In one particular embodiment of the 
present invention, the CDV isolate comprises an H-gene with 
a nucleotide sequence, comprising greater than 99% homol-
ogy (and/or identity) with SEQ ID NO: 42 (i.e., that ofisolate 
09041474B). In a related embodiment, the CDV isolate com-
65 prises an H-gene with a nucleotide sequence comprising 
greater than 99.5% homology (and/or identity) with that of 
SEQ ID NO: 42 (i.e., that of isolate 09041474B) 
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comprising about 1 M salt, preferably 6xSSC or any other 
solution having a comparable ionic strength, and washing at 
65° C. in a solution comprising about 0.1 M salt, or less, 
preferably 0.2xSSC or any other solution having a compa-
In yet another embodiment, the CDV isolate comprises an 
H-gene comprising a nucleotide sequence with greater than 
95% homology (and/or identity) with SEQ ID NO: 43 (i.e., 
that of isolate 08021509). In a related embodiment, the CDV 
isolate comprises an H-gene comprising a nucleotide 
sequence with greater than 99% homology (and/or identity) 
with that of SEQ ID NO: 43 (i.e., that of isolate 08021509) 
5 rable ionic strength. These conditions allow the detection of 
sequences having about 90% or more sequence identity. 
Nucleic acids encompassed by the present invention, e.g. 
those with nucleotide sequences set forth in SEQ ID NOS: 
1-33 and42-43 (and variants thereofas described herein) may 
Alternatively, such viruses may encode H proteins contain-
ing amino acid sequences that are at least about 75%, prefer-
ably about 80%, more preferably about 85%, most preferably 
about 90%, or even 95, 96, 97, 98, 99, or 100% identical to the 
amino acid sequence encoded by the nucleic acid sequence 
disclosed herein. Those of skill in the art are familiar with 
methods to calculate% homology or% identity. Such variant 
viruses may have H gene coding sequences that differ from 
those disclosed herein because of natural variations among 
isolates, or due to changes that are introduced deliberately 
e.g. by genetic engineering techniques. In other words, the 
viruses may be recombinant. 
10 be obtained in various ways. For example, they may be 
obtained from natural sources such as from a viral isolate; 
alternatively, they may be produced synthetically. Those of 
skill in the art will understand that the capability exists in the 
art to synthetically produce very large sequences, e.g. entire 
15 viral or bacterial genomes ( e.g. Myca plasma), and the present 
invention encompasses sequences of any origin or manufac-
ture that comprise the sequences disclosed herein, as well as 
the proteins, polypeptides and/or peptides expressed from the 
In other embodiments, only antigenic portions of the 20 
viruses described herein are present in the immunogenic or 
vaccine compositions of the invention. Such compositions 
may be formulated using, for example, nucleic acids encod-
ing antigenic peptides or proteins as presented in SEQ ID 
NOS: 1-33 and 42-43, or antigenic epitopes or regions of 25 
peptides or proteins, from those sequences. For example, the 
vaccine preparations of the invention may comprise nucleic 
acid sequences that include the sequences set forth herein, 
complements thereof, and/or proteins, polypeptides or pep-
tides encoded by such sequences. In addition, vaccines with 30 
certain variations of such sequences are also encompassed. 
While the sequences represent cDNA, the invention also 
includes corresponding ssRNA, ssDNA, double-strand ( ds) 
DNA, dsRNA, complementary DNA, and RNA of any form 
(e.g. mRNA, RNA/DNA hybrids, etc.) that is based on, 35 
derived from or that complements these sequences. Such 
sequences may be either sense or antisense sequences. Fur-
ther, sequences which display at least about 90% homology, 
or even about 95, 96, 97, 98 or 99% or greater homology to 
nucleic acid sequences of the CDVs disclosed herein, are also 40 
contemplated for use in the vaccines. Such sequences may 
differ, for example, by containing alternate codons that 
encode the same amino acid at one or more positions in order 
to maximize expression. In addition, portions of these 
sequences which encode epitopes or antigenic regions of e.g. 45 
the H protein are also contemplated, as are sequences which 
display 70%, or even more preferably about 80, 90, or 95% or 
even greater identity ( e.g. 96, 97, 98 or 99% identity) to such 
amino acid sequences. Generally, about 6-8 amino acids con-
stitute an epitope. Such sequences may vary, for example, by 50 
containing conservative or non-conservative amino acid sub-
stitutions, or deletions ( especially amino or carboxy terminal 
deletions), or various insertions, etc., so long as the resulting 
protein/peptide is antigenic as described herein. Such anti-
genic regions are preferably at least about 10 amino acids in 55 
length, but may be much longer, e.g. encompassing an entire 
protein such as the H protein. 
Further, nucleic acid sequences which hybridize to 
sequences disclosed herein ( or to portions of those 
sequences) under stringent conditions ( especially conditions 60 
of high stringency) are also contemplated. Stringent condi-
tions refer to hybridization conditions which allow a nucleic 
acid sequence to hybridize to a particular sequence. In gen-
eral, high stringent conditions refer to the hybridization con-
ditions which allow a nucleic acid sequence of at least 50 65 
nucleotides and preferably about 200 or more nucleotides to 
hybridize to a particular sequence at about 65° C. in a solution 
sequences. 
The invention also provides recombinant constructs such 
as recombinant viruses, vectors, and expression vectors 
which express the proteins/polypeptides/peptides described 
herein (i.e. the amino acid sequences encoded by the nucleic 
acid sequence set forth in SEQ ID NOS: 1-33 and 42-43, or 
variants thereof). Such constructs include those which have 
been produced, for example, by cloning one or more of the 
sequences disclosed herein into a vector or host (e.g. plas-
mids, cosmids, viral vectors such as adenoviral and poxyiral 
vectors, or bacterial vectors, etc.). 
In one embodiment, the construct is an expression vector 
that includes the previously noted nucleic acids and/or frag-
ments thereof. Recombinant expression vectors used in this 
invention are typically self-replicating DNA or RNA con-
structs comprising nucleic acids encoding a CDV hemaglu-
tinnin of the present invention and/or an antigenic fragment 
thereof, usually operably linked to suitable genetic control 
elements that are capable of regulating expression of the 
nucleic acids in compatible host cells. Genetic control ele-
ments may include a prokaryotic promoter system or a 
eukaryotic promoter expression control system, and typically 
include a transcriptional promoter, an optional operator to 
control the onset of transcription, transcription enhancers to 
elevate the level of mRNA expression, a sequence that 
encodes a suitable ribosome binding site, and a sequence that 
terminates transcription and translation. Expression vectors 
may also contain an origin of replication that allows the 
vector to replicate independently of the host cell. Recombi-
nant expression vectors may be constructed by any of several 
means known to those of skill in the art. For example, genetic 
engineering techniques are known by which sequences of 
interest are removed e.g. from an isolate of origin such as a 
virus and ligated into a suitable expression vector. Alterna-
tively, portions of an expression vector or an entire expression 
vector may be made synthetically; or a combination ofliga-
tion and synthesis protocols may be employed. 
In addition, other useful elements may be included in the 
constructs described herein. For example, the constructs may 
encode various sequences such as histidine tags or other tags 
that are used to facilitate protein isolation, such as glu-
tathione-S transferse (GST), and maltose binding protein; 
various linker or spacer sequences; various adjuvants and 
sequences that increase the antigenicity of the protein ( e.g. 
haptens); sequences which introduce a desired/convenient 
restriction enzyme cleavage site or which encode a desired 
protease cleavage site; sequences encoding fluorescent or 
other detectable labels, or tagging or marking sequences ( e.g. 
Green Fluorescent Protein (GFP), or portions thereof); vari-
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ous sequences that direct the location, export or processing of 
the encoded protein (e.g. leader sequences); heterologous 
signal sequences (i.e. signal sequences not normally associ-
ated with CDV H protein in nature); etc. Other possibilities 
will occur to those of skill in the art and are also intended to 
be encompassed by the present invention. When such 
sequences are included in the constructs, if they are contigu-
ous with the viral sequences described herein, the entire cod-
ing sequence may be translated as a fusion or chimeric pro-
tein/polypeptide/peptide, and may or may not ( depending on 
the sequence) be susceptible to post-translational modifica-
tion. The expressed recombinant proteins/polypeptides/pep-
tides of the present invention and their corresponding fusion 
or chimeric proteins/polypeptides/peptides are also provided 
16 
addition, expression of the H gene could be accomplished in 
bacterial, yeast or parasite recombinant systems. In a pre-
ferred embodiment, the virus is a live, attenuated (modified) 
high titer CDV, and the nucleic acid is ssRNA. In addition, 
5 other forms of the vaccine are also contemplated. For 
example, "empty" virion particle vaccines (without nucleic 
acid) are also contemplated, as are vaccines comprising anti-
genic virion or other CDV proteins that are not assembled into 
a capsid. In addition, the vaccines of the invention may be 
10 multivalent and include multiple viruses. Alternatively, a 
single virus genetically engineered to contain nucleic acids 
encoding proteins from two or more of the novel CDV s can be 
constructed by recombinant technology by exchanging cod-
ing regions, as is known by those of skill in the art. 
by the present invention. In particular embodiments such 15 
recombinant proteins/polypeptides/peptides and their corre-
sponding fusion or chimeric proteins/polypeptides/peptides 
are also isolated. 
The CDV that is used in the compositions described herein 
is generally attenuated and safe, i.e. produces no or few symp-
toms of disease when administered to a suitable host animal. 
A CDV vaccine should not elicit antibody production in cere-
brospinal fluid of a host. However, administration of the In addition, the present invention provides host cells that 
comprise such expression vectors. The host cell is optionally 
a prokaryote or a eukaryote host cell. Expression of nucleic 
acids encoding a CDV hemaglutinnin of the present invention 
can be carried out by conventional methods in either prokary-
otic or eukaryotic cells. 
The vaccines and immunogenic compositions of the inven-
tion may comprise any of the sources of the sequences 
described herein, e.g. a virus isolate, an attenuated virus, a 
recombinant construct, etc. Several methods of making vac-
cines suitable for vaccination against CDV are known in the 
art. See, for example, U.S. Pat. Nos. 4,193,990 and 4,193,991 
to Appel et al., U.S. Pat. No. 4,303,645 to Carmichael et al., 
U.S. Pat. No. 4,971,793 to Wood et al.; U.S. Pat. No. 5,882, 
652 to Valdes et al., and U.S. Pat. Nos. 5,885,585 and 5,814, 
510 to Parrish et al., each of which offers variations of suitable 
vaccine-formulating strategies. The complete contents of 
each of these patents are hereby incorporated by reference. 
Generally, to manufacture a vaccine, a viral or other vector 
containing genetic sequences of the invention ( either natu-
rally, or due to genetic engineering) is employed. Examples of 
such viral vectors include viruses and virions ( e.g. CDV) that 
are "killed", inactivated or otherwise attenuated so as to not 
cause severe disease symptoms in the animal to which it is 
administered, together with a suitable physiological carrier. 
The CDV virus can be inactivated (rendered unable to repli-
cate) using chemicals such as formalin, binary ethylene 
amine, beta propriolactone, by using ganima irradiation or 
heat, or by other methods known in the art. Attenuation may 
be carried out, e.g. by repeated passage of the viral isolate in 
suitable host cells, and subsequent isolation of the resulting 
clonal isolate. In some embodiments, the attenuated virus 
retains the ability to replicate within the host, although this is 
not strictly necessary. Preferably, no disease symptoms will 
occur as a result of administration. However, those of skill in 
the art will recognize that many effective vaccine composi-
tions cause some discomfort or relatively minor distress upon 
or after administration. However, the benefits of being pro-
tected against full-blown disease far outweigh this possibility. 
The attenuated virus may be a virus that naturally contains the 
nucleic acid sequence(s) of the invention (e.g. a CDV), or the 
virus may be recombinant in that the nucleic acid sequence is 
inserted into the virus by genetic engineering. In the case of 
recombinant vaccines, the nucleic acid sequences may be 
incorporated into viruses other than CDV to form heterotypic 
recombinant vaccines. Examples of such viruses include but 
are not limited to various herpesviruses, adenoviruses, pox-
viruses, non-pathogenic "orphan viruses", enteric viruses 
such as enterovirus, and others well known in the art. In 
20 attenuated CDV still results in an immune response ( e.g. a 
protective immune response) to CDV immunogens such as 
the H protein. The most frequently used method for produc-
ing an attenuated live-virus vaccine is to serially passage the 
virus in cell culture. For example, the virus may be passaged 
25 in a primary canine cell culture or canine cell line that does 
not harbor an oncogene, although other cell lines may also be 
used (e.g. chick embryo or fibroblast, VERO-SLAM cells, 
baby hamster kidney cell lines, as well as other hamster cell 
lines (Sultan S, NT Lan, T Ueda, RYamaguchi, K Maeda, and 
30 K Kai. 2009. Propagation of Asian isolates of canine distem-
per virus (CDV) in hamster cell lines. Acta Veterinaria Scan-
dinavica 51:38 doi: 10.1186/1751-0147-51-38), etc. Typi-
cally, for the first passage, a cell culture is infected with the 
selected inoculum of CDV. After obtaining clear evidence of 
35 virus replication (for example, virus-induced cytopathic 
effects [CPE] in the infected cells), an aliquot of the cell 
culture medium, or infected cells, or both, of the first passage 
are used to infect a second cell culture. The process is 
repeated until one or more mutations in the viral genome 
40 cause sufficient attenuation so that the virus can be safely 
used as a vaccine. The number of passages may vary some-
what e.g. at least about 20 and usually about 50 passages are 
used, but as many as e.g. 150 passages may be used. By then, 
the virus is sufficiently attenuated (i.e., reduced in virulence 
45 or diseases-producing ability) to be used in a vaccine formu-
lation. The degree of attenuation is usually determined 
empirically by exposing the natural host to progressively 
greater passage levels of the virus. 
It is also possible to attenuate the CDV viruses by repeat 
50 passages at decreasing incubation temperatures with or with-
out mutagenic chemicals. Normally, CDV viruses are propa-
gated at 3 7° C. However, over e.g. 50 passages at successively 
decreasing incubation temperatures for example, clonal 
strains of the virus are produced which no longer have the 
55 ability to replicate at core body temperature (3 7° C.) or above. 
Such viruses retain the ability to multiply in areas of the body 
that typically exhibit lower temperature, e.g. the nasal cavity, 
but do not replicate at the core body temperature. For 
example, in one embodiment, a cold-adapted, temperature 
60 CDV propagates in tissue culture cells at temperatures from 
about 26° C. to about 34° C., but does not do so at a non-
permissive temperature of about 37° C. (US patent applica-
tion 2006121521, Dowling and Younger, the complete con-
tents of which is hereby incorporated by reference). These 
65 viruses are therefore completely safe for use in CDV vaccines 
for animals, including wildlife and highly susceptible species 
such as large cats, mink and ferrets. 
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The invention provides methods ofimmunizing or prevent-
ing the symptoms ofCDV infection in a subject (e.g. a mam-
mal) in need thereof by administering to the subject a com-
position of the invention. Generally, the CDV vaccines are 
5 administered in an amount sufficient to provide active immu-
nity in puppies and/or adult dogs. Preferably, the immune 
response is protective against future exposure to CDV, i.e. 
administration of the composition prevents the symptoms of 
disease associated with CDV infection, when compared to 
Other suitable vaccine components, e.g. pharmacologi-
cally acceptable carriers, are well-known to those of skill in 
the art, as is the preparation of such compositions for use as 
vaccines. Typically, such compositions are prepared either as 
liquid solutions or suspensions, however solid forms such as 
tablets, pills, powders and the like are also contemplated. 
Solid forms suitable for solution in, or suspension in, liquids 
prior to administration may also be prepared. The preparation 
may also be emulsified. The active ingredients may be mixed 
with excipients which are pharmaceutically acceptable and 
compatible with the active ingredients. Suitable excipients 
are, for example, water, saline, dextrose, glycerol, and the 
like, or combinations thereof. In addition, the composition 
may contain minor amounts of auxiliary substances such as 
wetting or emulsifying agents, pH buffering agents, and the 15 
like. If it is desired to administer an oral form of the compo-
sition, various thickeners, flavorings, diluents, emulsifiers, 
dispersing aids or binders and the like may be added. The 
composition of the present invention may contain any such 
additional ingredients so as to provide the composition in a 20 
form suitable for administration. The final amount of the 
10 non-vaccinated controls. However, much benefit may also 
accrue if the immune response simply lessens or decreases 
the severity of disease symptoms, even if all symptoms are not 
eliminated. 
In a preferred embodiment of the invention, the animals 
that are vaccinated using the vaccines of the invention are 
domestic dogs, including both adult dogs and puppies. How-
ever, the vaccination of other potential CDV hosts is also 
contemplated. Other potential hosts include other canids such 
as wild canids (e.g. wolves, wild dog species, etc.), larger 
species of cats (whether domesticated or wild), mink, red 
panda, foxes, lion and tigers, ferrets, rabbits, goats, etc. as 
well as other carnivores in general. Ferrets are highly suscep-
tible to CDV. Thus a highly attenuated, modified live virus 
vaccine or recombinant CDV vaccine can be used. According 
translatable nucleic acid in the formulations may vary. How-
ever, in general, the amount will be from about 1-99%. The 
compositions may further comprise an adjuvant, suitable 
examples of which include but are not limited to Seppic, Qui! 
A, Alhydrogel, oil-in-water emulsions, aluminum phosphate, 
carbopol, Emulsigen, and the like. 
25 to the American Ferret Association, MD, three CDV vaccines 
can be administered to healthy kits at 8, 11, and 14 weeks of 
age. While the vaccines will of course be used in domestic 
animals, wild or partially domesticated animals may also 
benefit from such vaccination, e.g. animals in zoos or pro-
The immunogenic/vaccine preparations of the present 
invention may be administered by any of many suitable 
means which are well known to those of skill in the art, 
including but not limited to by injection, orally, intranasally, 
intratracheal, by ingestion of a food product containing the 
antigen, by intramuscular, subcutaneous, intravenous, trans-
dermal, and intradermal routes, by eyedrops, or with a nebu-
lizer or a needle-free instrument, etc. However, in a preferred 
embodiment, the mode of administration is by injection. In 
addition, the compositions may be administered alone or in 
combination with other medicaments or immunogenic com-
positions, e.g. as part of a multi-component vaccine. In par-
ticular, the immunogenic CDV could be combined with 40 
rabies virus, Borrelia burgdorferi, Ehrlichia canis, canine 
parvovirus, canine adenovirus, canine parainfluenza virus, 
canine coronavirus, Babesia canis, Anaplasma phagocyto-
philium, Giardia species, Leishmania species, Leptospira 
species or any combination thereof. etc. Further, administra-
tion may be a single event, or multiple booster doses ( of the 
same or a different strain) may be administered at various 
timed intervals to augment the immune response. In addition, 
administration may be prophylactic, i.e. before exposure to 
the virus has occurred, or is suspected to have occurred, or 
after the fact, i.e. after a known or suspected exposure, or 
therapeutically, e.g. after the occurrence of disease symptoms 
associated with viral infection. 
30 tected areas, parks, in research facilities, etc. Wildlife can in 
particular be vaccinated with killed CDV vaccine because 
they are more susceptible to modified live virus vaccines, e.g. 
by use of edible bait which contains vaccine components. Any 
animal that can host the CDV variants, whether or not the 
35 virus causes disease symptoms in the host, may benefit by 
being vaccinated by the vaccine preparations provided herein. 
Vaccination of animals that are asymptomatic upon infection 
by the virus (i.e. silent carriers) would be beneficial in order to 
curtail the spread of the virus to more susceptible populations. 
The invention also provides antibodies that bind specifi-
cally or selectively to antigenic determinants or antigenic 
regions of the CDV disclosed herein. In some embodiments, 
the antibodies are neutralizing antibodies that can neutralize 
the virus and thus prevent infection. Such differential anti-
45 bodies may be polyclonal or monoclonal, although mono-
clonal antibodies are generally preferred. The antibodies may 
be of canine origin. Monoclonal antibodies will be prepared 
by injecting the viruses (e.g. killed viruses, proteins, or 
nucleic acids encoding the proteins) in mice or another suit-
50 able host such as rabbit or canine host. After 3 boosters, the 
spleens will be harvested and fused with myeloma cells. The 
monoclonal antibodies producing clones will be screened by 
ELISA, HA-HI, and indirect fluorescent antibody test. The 
clones that react with the viruses described herein, or with The invention also provides various types of recombinant 
vectors and/or expression vectors that contain and express the 
nucleic acid sequences disclosed herein ( or portions thereof 
that encode antigenic peptides and/or polypeptides). 
Examples of such vectors and expression systems include but 
are not limited to: various bacterial ( e.g. Escherichia coli) or 
probiotic-based (e.g. Lactobacillus) expression vectors; 60 
adenoviral vectors, baculovirus, Pichia, and other yeast 
expression systems; pox vectors such as raccoon pox vectors; 
etc. Such recombinant vectors and expression systems may 
also be utilized in vaccine preparations. Alternatively, they 
may be employed for other purposes such as for laboratory 65 
manipulation of the sequences, or for research or diagnostic 
purposes. 
55 proteins isolated from the same, will be saved for develop-
ment of CDV diagnostic assays. Polyclonal antibodies may 
be prepared by injecting one or more peptides that span amino 
acid codons that are preferred antigenic targets e.g. the H 
protein, into rabbits. 
The invention also provides diagnostic methods and kits 
for the detection of the CDV variants described herein. Such 
kits include, for example, oligonucleotideprimers specific for 
amplifying (e.g. by polymerase chain reaction, PCR) the 
nucleic acid sequences disclosed herein. Alternatively, such 
kits may include antibodies (e.g. monoclonal or polyclonal) 
that bind selectively or specifically to unique antigenic deter-
minants displayed by the novel CDV variants. The kits are 
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useful in monitoring the CDV status of, for example, any 
animal that is susceptible to CDV, especially canines. The kits 
are especially useful to monitor the CDV status of puppies 
and dogs that are exported or transported from one jurisdic-
tion to another. In one embodiment, the diagnostic tests and 5 
methods of the invention are used to detect the presence of 
CDV in dogs (or other animals) that have been fully vacci-
nated but have nevertheless developed symptoms of CDV 
infection. Using the methods of the invention, it is possible to 
determine the genotype of the etiological agent of disease, 10 
and to ascertain whether the disease symptoms are caused by 
the vaccine strain, or by superinfection with a genetic variant 
that was not neutralized by vaccination, i.e. the vaccine did 
not provide protection against the genetic variant. 
Pullman, Wash.), the sections were incubated for 30 min at 
37° C. After the unbound antibody conjugates were washed, 
the sections were counterstained with Evans blue for 15 min. 
After being mounted in buffered glycerol (pH 9.4), the sec-
tions were examined by fluorescent microscopy. Positive 
cells showed apple-green fluorescence in the cytoplasm and 
negative cells were brick-red. 
For isolation, the tissues from CDV-infected samples were 
finely chopped, freeze-thawed twice to release the virus, and 
centrifuged at 8,000xg. The clear supernatant was filtered 
though a 0.22 µm syringe filter. The Vero cell line was derived 
from the kidney of a normal, adult African green monkey 
(Ceropithecus) in Japan. The recombinant cell line was 
derived by transfection of the Vero cells with canine signaling 
lymphocyte activation molecule (SLAM, also known as 
CDl 50) as described before by Seki et al. (Seki, F., N. Ono, R. 
The invention is further illustrated in the following 15 
Examples, which should not be construed so as to limit the 
invention in any way. Yamaguchi, and Y. Yanagi. 2003. Efficient isolation of wild 
strains of canine distemper virus in Vero cells expressing 
canine SLAM (CD 150) and their adaptability to marmoset EXAMPLES 
Example 1 
Preliminary Studies of Seven CDV Isolates 
Canine distemper virus (CDV) is a highly contagious virus 
that causes multi-systemic disease in dogs. Seven cases of 
CDV in dogs from the USA were received. These CDV iso-
lates formed large, multi-nucleated, syncytia in a Vero cell 
line expressing canine signaling lymphocyte-activation mol-
ecule (SLAM) (described below). Based on the hemaggluti-
nin gene sequences, the CDV isolates from 3 states (CA, MO, 
and OK) formed two CDV genetic groups: Group I (major, 
6/7) consisted of CDV isolates closely related to the European 
wildlife lineage ofCDV. The group II (minor, 1/7) was geneti-
cally related to the Arctic-like lineage ofCDV. However, both 
the CDV groups were genetically different from the current 
vaccine strains that belong to American-I lineage of the old 
(1930-1950) CDV isolates. 
In this study, an evolutionary and genetic analysis of 7 
CDV isolates from the United States was performed using the 
H gene sequences. The biological effects of the 1-1 gene 
sequence variation were investigated using an in vitro cell 
culture system. Ante-mortem samples included ocular swabs, 
nasal swabs, and peripheral blood anti coagulated with EDTA. 
The swabs were received in 1 to 2 ml of cold normal saline 
sent on ice by overnight delivery within 24 h of collection. 
Urine samples were not tested. Post-mortem samples were 
from tonsils, brains, bladders, and lungs (Kubo, T., Y. 
Kagawa, H. Taniyama, and A. Hasegawa. 2007. Distribution 
of inclusion bodies in tissues from 100 dogs infected with 
canine distemper virus. J. Vet. Med. Sci. 69:527-529). 
Approximately 2 to 5 g of each tissue was received in tubes 
sent on ice by overnight delivery for virological examination. 
The specimens were obtained from seven suspected cases of 
CD from three states in the United States (Oklahoma, four; 
Missouri, one; and California, two). 
For direct fluorescent antibody testing, tissues were sec-
tioned at 8-µm thickness and fixed with an acetone (75%)-
methanol (25%) mixture at room temperature. Veterinary 
Medical Research and Development (VMRD), Pullman, 
Wash., USA supplied pretitrated, lot-to-lot certified conju-
gates for veterinary diagnostic applications. As part of quality 
control/quality assurance, the conjugates were tested before 
use on negative and known positive CDV controls. After 
addition of ready-to-use, prediluted, fluorescein isothicyan-
ate-labeled, anti-CDV monoclonal antibody (VMRD, Pull-
man, Wash.) or polyclonal antibody conjugates (VMRD, 
20 B95a cells. J. Viral. 77:9943-9950). The inoculums (about 1 
ml per 25-cm2 flask) were incubated for 1 hat 37° C. with 
rocking every 20 minutes. After inoculation on a recombinant 
Vero cell line expressing canine SLAM, about 3.5 ml of 
Dulbecco's modified of Eagle's medium (Cellgro, Hendron, 
25 Va.) with 5% fetal calf serum was added. The cells were 
examined daily for cytopathic effects (multinucleated-syncy-
tium formation) (Seki, supra). Vero cells expressing canine 
SLAM have been found to be useful for the primary isolation 
ofCDV (Lan, N. T., R. Yamaguchi, K. Uchida, S. Sugano, and 
30 S. Tateyama. 2005. Growth profiles ofrecent canine distem-
per isolates on Vero cells expressing canine signaling lym-
phocyte activation molecule (SLAM). J. Comp. Path. 133 :77-
81 ). 
For total RNA extraction (host and viral RN As) from speci-
35 mens, QIAmp viral RNA extraction kits were used (Qiagen 
Inc., CA). The quality and quantity of the RNA were checked 
by A260/A280 using a Nonodrop spectrophotometer (Nano-
drop Technologies, CA). 
For detection of CDV RNA, reverse transcriptase (RT)-
40 PCR based on the nucleocapsid (N) gene was targeted (Kim, 
Y. H., K. W. Cho, H. Y. Youn, H. S. Yoo, and H. R. Han. 2001. 
Detection of canine distemper virus (CDV) through one step 
RT-PCR combined with nested PCR. J. Vet. Sci. 2:59-63). 
This protocol provides high sensitivity due to the nested 
45 amplification of the target gene, high copy number of the N 
gene, and the conserved sequence of the N-gene among CDV 
isolates. Briefly, the first-round product was amplified by the 
forward primer (Primer 1 :5'-ATTTGGGATTGCTTAGGA-
3', SEQ ID NO: 34) and reverse primer (Primer 2: 
50 5'-GGCGCTCATCTTGGACAT-3', SEQ ID NO: 35). The 
protocol was reverse transcription at 45° C. for 1 hour, 95° C. 
for 3 min; 30 cycles of PCR with denaturation at 94 ° C. for 30 
s, annealing at 54 ° C. for 30 s, and an extension at 72° C. for 
1 min; and a final extension at 72° C. for 7 min, with the 
55 reaction mixture held at 4° C. The small-portion (1-microli-
ter) product of the first reaction was subjected to a second 
round of amplification using primer 3 (5'-GT-
TAGCTAGTTTCATCCT-3', SEQ ID NO: 36) and primer 4 
(5'-GGTCCTCTGTTGTCTTGG-3', SEQ ID NO: 37). The 
60 protocol for the second round was denaturation at 95° C. for 
3 min; 30 cycles of denaturation at 94° C. for 30 s and 
annealing at 54 ° C. for 30 s; with an extension at 72° C. for 1 
min. The final extension was performed at 72° C. for 7 min, 
and the reaction mixture was held at 4 ° C. before electro-
65 phoresis. The size of the second-round amplicon was 419 
base-pairs, verified by including molecular size standards in 
agarose gel analysis. 
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For CDV genotyping, the H gene was used as the target 
(Martella, V., G. Elia, M. S. Lucente, N. Decaro, E. Lorusso, 
K. Banyai, M. Blixenkrone-Moller, N. T. Lan, R. Yamaguchi, 
22 
phocytes, consistent with CDV inclusions (FIG. 36). The 
presence of CDV inclusions was confirmed by the direct 
fluorescent-antibody test in both cases. 
Six of the seven CDV positive samples were successfully 
5 isolated in the Vero cell line with canine SLAM/CD 150. The 
F. Cirone, L. E. Carmichael, and C. Buonavoglia. 2007. 
Canine distemper virus (CDV) by hemi-nested multiplex 
PCR provides a rapid approach for investigation of CDV 
outbreaks. Vet. Microbial. 122:32-42). The forward primer 
(primer 204+, nucleotides 388 to 409, 5'-GAATTCGACT-
TCCGCGATCTCC-3', SEQ ID NO: 38) and reverse primer 
(primer 232b-, nucleotides 1543 to 1519, 5'-TAGGCAA- 10 
CACCACTAATTTRGACTC-3', SEQ ID NO: 39) yield an 
amplicon of 1160 base-pairs. The H-gene RT-PCR protocol 
was RT at 50° C. for 30 min and 94 ° C. for 2 min. The PCR 
protocol was 35 cycles of94° C. for 1 min, 50° C. for 1 min, 
and 72° C. for 3 min and a final extension at 72° C. for 10 min, 
with the reaction mixture held at 4 ° C. The positive and 
negative CDV controls were included in each run of both 
detection (N gene) and genotyping (H gene) RT-PCR proto-
cols. For phylogenetic analysis of the H gene sequences, the 
amplicons were sequenced at the Oklahoma Medical 
Research Foundation, Oklahoma City, Okla. The sequences 
were subjected to Basic Local Alignment Search Tool for 
Nucleotides (BLASTN) analysis (Altschul, S. F., T. L. Mad-
den, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. 
Lipman. 1997. Gapped BLAST and PSI-BLAST: a new gen-
eration of protein database search programs. Nuc. Acid Res. 
25:3389-3402) and compared to GenBank H gene sequences 
for CDV isolates from different species and geographic areas 
around the world. The percentage identities of the H gene 
sequences were recorded. Further, the H gene sequences were 
OADDL State 
cytopathic effects of CDV isolates were characterized by 
multinucleated syncytia that formed 1 to 2 days after inocu-
lation. The presence of CDV was further detected by RT-PCR 
for the hemagglutinin gene. One CDV sample (OADDL 
07061535) was tested only by RT-PCR and sequencing of the 
H gene; there was insufficient sample for virus isolation. 
Based on RT-PCR for the H gene followed by sequencing, 
the level of identity among the CDV isolates (OK-1, OK-2, 
OK-3, OK-4, CA-1 and CA-2; major group I) was highest 
15 with a canine CDV isolate 19876 from Missouri, that is 
genetically most related to a Danish mink CDV isolate 
(Pardo, I. D.R., G. C. Johnson, and S. B. Kleiboeker. 2005. 
Phylogenetic characterization of canine distemper viruses 
detected in naturally infected dogs in North America. J. Clin. 
20 Microbial. 43:5009-5017). Thus, it was the predominant 
CDV variant (six of seven isolates) in this study. These six 
CDV isolates belonged to the European wildlife lineage of 
CDV isolates. However, one isolate (MO-1; minor group II) 
was found that was most genetically similar to the canine 
25 CDV isolate 21260 from Missouri (Pardo, supra) that is 
closely related to a lesser-panda CDV isolate. This CDV 
isolate belongs to the Arctic-like lineage ofCDV isolates. The 
information on the 2007 OADDL CDV isolates is summa-
rized in Table 1, and partial nucleotide sequences of the H 
gene of these isolates are provided in FIGS. 1-7 
TABLE 1 




to Current Homology 
No.I of Vaccination Age Vaccine to MO Virus CDV 
Designation Origin Status1 (weeks) Breed Virus2 198763 Isolation Lineage5 
07061535 OK-1 12 Mixed 89 98 nd6 EW 
07091030 OK-1 NV 44 Siberian 89 98 yes EW 
husky 
07091031 OK-1 NV na na 89 99 yes EW 
07091032 OK-1 NV na na 84 96 yes EW 
07101508 CA-1 V 10 American 89 98 yes EW 
bulldog 
07110098 MO-1 V 10 Weimaraner 89 90 yes A 
07111080 CA-2 V 1364 Border collie 97 96 yes EW 
1 I - vaccination incomplete; NV = not vaccinated; V = vaccinated 
2 All isolates had less than 90% identity with the current vaccine isolates (Ondersteport, Lederle and Convac) 
3 All isolates had less than 90% identity with the USA MO 19876 CDV isolate except M0-1, which belongs to the Arctic lineage 
4Animal recovered completely after supportive therapy 
5EW = European wildlife; A= Arctic 
6nd = not done. 
55 
subjected to phylogenetic analysis and sequence comparison 
with H gene sequences of the vaccine CDV isolates (Onder-
steport, Convac, Lederle, and Snyder Hill CDV isolates) 
deposited in GenBank. Alignments of the top 100 matches 
with known sequences were used to perform phylogenetic 60 
analysis by neighbor-joining using Jnkes-Cantor method 
(NCBI, MD). 
Peripheral blood films from two of the CD case samples 
(OADDL 07091030 and OADDL 07091031) were stained 
with an aqueous Romanowsky stain and examined by light 65 
microscopy. Both blood films revealed numerous eosino-
philic structures within the cytoplasm ofneutrophils and lym-
The hemagglutinin glycoprotein varies approximately 
10% among the CDV isolates and envelope protein H deter-
mines the cytopathology and tropism of the virus (von 
Messling, V. G. Zimmer, G. Herder, L. Haas, and R. Cattaneo. 
2001. In a preliminary analysis, the OADDL CDV isolates 
were compared with all the H sequences in the GenBank and 
it was found that CDV isolates cluster in geographically dis-
tinct lineages. For example, all the Argentina CDV isolates 
formed one distinct cluster. The South American CDV iso-
lates were not included in the recent analysis of CDV isolates 
based on geography and H gene phylogeny (McCarthy, 
supra). However, they form a distinct SouthAmerican cluster. 
US 8,647,637 B2 
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In recent papers, the terms genotype, cluster, and lineage have 
been used interchangeably by different investigators, but the 
results on CDV phylogeny were similar in all the studies 
(Martella, V., F. Cirone, G. Elia, E. Lorusso, N. Decaro, M. 
Campolo, C. Desario, M. S. Lucente, A. L. Bellacicco, M. 
Blixenkrone-Moller, L. E. Carmichael, and C. Buonavoglia. 
2006. Heterogeneity within the hemagglutinin genes of 
canine distemper virus (CDV) strains in Italy. Vet. Micro biol. 
116:301-309; McCarthy, supra; Mochizuki. M., M. Hash-
imoto, S. Hagiwara, Y. Yoshida, and S. Ishiguro. 1999. Geno-
types of canine distemper virus determined by analysis of the 
hemagglutinin genes ofrecent isolates from dogs in Japan. J. 
Clin. Microbial. 37:2936-2942), including this analysis, 
because all the investigators used the GenBank accession 
sequences. A member of a particular genotype of CDV has 
been proposed to have a more than 95% identity in the nucle-
otides of the H gene sequences (Mochizuki, supra) and, thus, 
the intragenotypic variation is less than 5% (Martella, supra). 
24 
The CDV isolate CA-1 (OADDL 07101508) was obtained 
from a tissue pool from a 10-week-old male vaccinated 
American bull dog from California that died of CD. Three out 
of 4 littermates died of CD with respiratory signs, hyperkera-
5 to sis, and seizures. Of the three dead littermates, the necropsy 
report was available for one littermate. Its lungs were firm and 
congested on necropsy. The necropsy results of one of the 
four littermates were completely normal. The H gene 
sequence was 98% identical to a canine origin CDV isolate 
10 19876 (GenBank accession number AY964110.1 ). The CDV 
isolate was 94% identical to the Hungarian CDV isolate, the 
lesser panda isolate (AF! 78039.1), and CDV strain A75/17 
(AF164967). The CDV H gene sequence was 93% identical 
to CDV isolate 01-2641 (AY.526496.1). The H gene of this 
15 CDV isolate lacked the Pst I site present in all vaccine CDV 
isolates (Demeter, Z., B. Lakatos, E. A. Palade, T. Kozma, P. 
Forgach, and M. Rusvai. 2007. Genetic diversity of Hungar-
ian canine distemper virus strains. Vet. Microbial. 122:258-
269). 
The CDV isolate MO-1 (OADDL 07110098) was obtained 
from nasal and conjunctiva! swabs of a 10-week-old, CDV 
vaccinated Weimaraner dog that had clinical signs compat-
ible with CD. The dog developed 'chewing-gum' seizures, 
thickened footpads, coughing, nasal discharge, and con-
The CDV isolate OK-1 (OADDL 07061535) was obtained 
from a 3-month-old, female, mixed breed, vaccinated dog 20 
from Oklahoma with history of conjunctivitis, nasal dis-
charge and weight loss. The dog had not finished the complete 
course of vaccination, and had a history ofroaming and eating 
garbage. This CDV isolate had maximum identity (98%) with 
CDV isolate 19876 (GenBank accession number 
AY964110.1 ). Based on the H gene analysis, CDV isolate 
19876 belongs to the European wildlife lineage ofCDV iso-
lates along with OK-1. 
25 gested lungs. The swabs were collected before euthanasia, 
and CDV was isolated in cell culture. The CDV isolate H gene 
had maximum identity (98%) with CDV isolates 21261 and 
18133 from Missouri, and 97% identity with CDV isolates 
from Italy ( 48/05 and 179/94) and Hungary (H06Bp10S, H06 The CDV isolate OK-2 (OADDL 07091030) was obtained 
from a tissue pool of an 11-month-old unvaccinated Siberian 
husky from Oklahoma. On necropsy, the conjunctiva! and 
tracheal epithelium contained intracytoplasmic, eosinophilic 
inclusions surrounded by clear halos. In the tonsils, there 
were marked lymphoid depletion and numerous inclusion 
bodies in the epithelium. This isolate had maximum identity 
(98%) with CDV isolate 1987 6 ( canine origin, Missouri), and 
94% identity with CDV isolates from Hungary (GenBank 
accession number EF095750.1), a Danish mink (Z47759.1), 
and a lesser panda (AF178039.1), CDV strain A75/17 
(AF164967.1), and morbillivirus from a German ferret iso-
late (X84999.1). The CDV isolate A75/17 from the United 
States is regarded as a virulent protype of field CDV isolates 
(Simon-Martinez, supra). The level of identity of the H gene 
with the vaccine isolates (Convac, Lederle, and Ondersteport) 
was 89%. 
The CDV isolate OK-3 (OADDL 07091031) was obtained 
from a dog in a shelter in Oklahoma. A blood tube was 
obtained but no other history was available on this case. 
Inclusions consistent with CDV were observed in leukocytes 
on a peripheral blood film and further confirmed by direct 
fluorescent-antibody test. The blood sample was positive for 
CDV by virus isolation. The H gene was sequenced and had 
99% identity with CDV canine isolate 19876 (GenBank 
accession number AY964110.1 ), and 95% identity with CDV 
isolates from Hungary (EF095750.1), a Danish mink 
(Z47759.1), and a lesser panda (AF178039.1), CDV virus 
strainA75/17; CDV isolate 01-2641 and a German ferret 
morbillivirus strain (X84999 .1 ). 
30 Bp8F, HOS Bp7F, HOS Bp6F, and HOS BpBp5F). The H gene 
sequence of this CDV isolate had 95% identity with a CDV 
isolate from a Greenlandic dog and only 90% identity with 
CDV 19876. It had 89% identity with the vaccine CDV iso-
lates and 70% identity with the phocine distemper virus H 
35 gene. Moreover, this CDV isolate lacks the Pst I restriction 
site present in all vaccine CDV isolates (Demeter, supra). 
Based on phylogenetic analysis this isolate belongs to the 
Arctic-like lineage of the CDV isolates. 
The CDV isolate CA-2 (OADDL 07111080) was obtained 
40 from a combination of nasal, pharyngeal, tonsil, and conjunc-
tiva! swabs of a 32-month-oldneuteredmale, vaccinated Bor-
der collie with a history of vomiting, diarrhea and lymphope-
nia. The H gene sequence had maximum identity (96%) with 
CDV isolate 19876. This isolate had 93% identity with the 
45 Hungarian CDV isolate, the lesser Panda CDV isolate, and 
the Danish mink CDV isolate; 92% identity with CDV strain 
A 7 5/ 17 ( GenBank accession number AF 164 967 .1); and 92% 
identity with the German ferret CDV isolate. Based on phy-
logenetic analysis, this CDV isolate clusters with CDV iso-
50 !ates of the European wildlife lineage. This dog recovered 
after treatment and has been clinically healthy for the last 3 
months. The survival of this dog after a natural exposure to a 
CDV isolate of European wildlife lineage is probably due to 
resistance based on age, genetic resistance, and immunity 
55 after complete vaccination with a commercial CDV vaccine. 
This dog had a CDV titer of 1: 16 by CDV serum neutraliza-
tion 3 months after recovery from CDV infection. 
The CDV isolate OK-4 (OADDL 07091032) was obtained 
from a tissue pool (bladder and lungs) from a dog adopted 60 
from an animal shelter in Oklahoma. This CDV isolate had 
maximum identity (96%) with CDV isolate 19876 (GenBank 
accession number AY.964110.1). In descending order, it had 
93% identity with CDV isolates from Hungary 
(EF095750.1), a lesser panda (AF178039.1), and a Danish 65 
mink (Z4 77 59 .1 ); 84% identity with the vaccine isolates; and 
70% identity with the phocine distemper virus. 
Five out of six OADDL 2007 CDV isolates were found to 
produce multinucleated, syncytia in a Vero cell line express-
ing the canine SLAM receptor. It has been proposed that 
syncytial size is a correlate of the degree of virulence of the 
CDV isolates (Cosby, S. L., C. Lyons, S. P. Fitzgerald, S. J. 
Martin, S. Pressdee, I. V. Allen. 1981. J. Gen. Viral. 52:345-
353) because it correlates with the ability of the CDV to 
spread from cell-to-cell. The aggressive spread in cell culture, 
the ability to produce large numbers of inclusions in canine 
lymphocytes that naturally express SLAM/CD150, and the 
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ability to produce fatal infections in vaccinated dogs indicate 
that these canine isolates of European wildlife lineage are 
virulent for dogs. 
26 
sample inoculation 18-24 hours after inoculation (Fast-grow-
ing CDV isolates). In some CDV isolates, the margins of the 
syncytia were well defined with almost circular margins. In 
other CDV isolates, the margins of the syncytia were not that This Example shows that the EW lineage is emerging as the 
predominant CDV isolate in the US. 
Example 2 
Additional CDV Isolates 
5 clearly demarcated. These "fuzzy" CPE CDV isolates tended 
to spread rapidly with daughter syncytia next to the mother 
syncytium. In other CDV isolates, daughter syncytia 
appeared far away indicating another colony (colonies) of 
virus growth. In short, CDV isolates showed variable cytopa-
Using the methods described in Example 1, additional 
CDV isolates were identified and are listed in Table 2. 
10 tho logy. CDV isolates from USA differ in the speed (Fast and 
Slow), spread (Large and Small), size, shape (Round and 
Irregular) of the syncytia formation and invasiveness of the 
TABLE2 
OADDL Canine Distemper Virus (CDV) Isolates 
OADDLNo./ State of Clinical Vaccination Age CDV 
Designation Origin 1 Sign2 CPE3 Status4 (weeks) Breed Lineage5 
8010939 OK R,N na na 20 Miniature EW 
Schnauzer 
08011277-A OK R + na 12 Small breed EW 
08011277-B OK R + na 12 Small breed EW 
08011277-C OK R + na 12 Small breed EW 
8011671 GA R na V 10 Mix EW 
8021509 FL R,N + V 12 Mix AM-2 
8030674 CA R,N na V 8 Golden EW 
Retriever Mix 
8030776 OK R,N + V 16 Mix EW 
8030777 FL N + V 12 Mix AM-2 
8031346 CA na na V 12 Pitbull EW 
8040383 MO R +!- na 6 Weimaraner AR 
8050180A OK R na na 14 PitbullMix AM-2 
8060351 MO R,N na V 9 Shih Tzu AM-2 
8060352 MO R na V 8 Welsh Terrier AM-2 
8080696 FL R + V 24 Mix EW 
8080941 OK N + na 12 Rat Terrier EW 
8081112 MO N +!- V 11 Irish Terrier AM-2 
8120827 OK N + na 0.3 Dachshund EW 
8120857 OK N + na 5 Yorkshire EW 
Terrier 
9011024 na N + V 156 Akita Mix EW 
09020504-3 KS na + na na na AM-2 
(08-75891) 
09020504-2 KS na na na na na AM-2 
(56928) 
09020504 KS na + na na Leopard AM-2 
(58829B) 
9041303 na R +!- V 24 Cattle Dog EW 
Mix 
09041474A TN R + V 16 Border Collie EW 
Mix 
0904147B TN R + V 16 Border Collie EW 
Mix 
1State of origin; na = not available 
2Clinical Signs: R = Respiratory (coughing, ocular and nasal discharge, sneezing); N = nervous (tremors, twitching, 
urination change, exterior rigidity) 
3CPE = Cytopathic Effect: + = positive; - = negative; +/- = suspect; na = not available 
4Vaccination Status: V = vaccinated; NV= not vaccinated; na = not available 
5CDV lineage: EW = European wildlife; Arn-2 = Arnerican-2 
Example 3 host cells by CDV isolates. These biological properties may 
Continuing Investigations of Emerging CDV 
Isolates: Differences in Cytopathology (CPE) 
Among Recent USA Canine Distemper Viruses 
55 have bearing on the protection offered by the current vac-
cines. For example, codon usage of critical viral genes can 
affect the replication efficiency of CDV, as discussed in 
Example 11. 
The results obtained in Examples 1 and 2 prompted a 60 
continued effort to isolate and characterize additional CDV 
isolates from the USA. Studies were carried out as described 
for Example 1. CDV samples were inoculated in Vero+ 
SLAM cell line. Most CDV isolates produced large syncytia 
with large number of nuclei. A smaller number ofCDV iso- 65 
!ates produced smaller sized syncytia with few cell nuclei. In 
several CDV isolates, multiple syncytia appeared after virus 
Example 4 
Comparative Genetic Analysis of CDV Isolate 
Sequences: Relative Preferred Codon Usage (RPCU) 
Ten hemagglutinin residues (29, 178, 180, 225, 386, 412, 
475, 530, 549, and 603) are known to be under positive 
selection among CDV lineages (McCarthy, supra). The 
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hemagglutinin (H) gene of the isolates were sequenced or 
partially sequenced and the resulting sequences are shown in 
FIGS. 1 to 33. The partial H-gene sequenced (about nucle-
otide 534-1236 hemagglutinin gene fragment) from the wild 
type CDV isolates were aligned with reference CDV 
sequences from GenBank using CLUSTAL W provided with 
Bio-edit program). Of note, a viral isolate containing the 
reference sequence for the EW strain has never been isolated, 
propagated in cell lines, or characterized. The reference EW 
sequence was obtained by sequencing carried out on tissue 
extracts. 
The results of the RPCU analysis, depicted in FIGS. 34A-
F, showed the following: 
At residue 180, the codon is AGT in Ondersteport-like 
vaccines such as Galaxy, Proguard, Continuum, and Van-
guard. However, this codon is GGT in European wildlife 
(EW), and in all wild type CDV isolates. This codon can be 
useful in designing a Taqman RT-PCR to distinguish the 
Ondersteport-like vaccines from wild type CDV isolates cir-
culating in the USA. 
At residue 225, the codon is GAC encoding aspartic acid 
(D) in all vaccines. However, it is AAC in American-2 CDV 
and in raccoon distemper virus (RDV) 09050216 it is CAC 
( encoding histidine, H). 
At residue 386, the codon is ACC (threonine, T) in all 
Ondersteport-like vaccines (all except the Pfizer vaccine). 
However, it is TAC in EW, AM-2 and AR lineage CDV wild 
type viruses and in the Pfizer vaccine. This codon is thus 
useful in developing a differential Taqman RT-PCR for dis-
tinguishing most of the commercial CDV vaccines and wild 
type CDV isolates. 
At residue 412, the codon is CCT, which encodes praline 
(P) in vaccines and wild type CDV viruses. However, in 
isolate 07110098 it is CAT ( encoding histidine, H) as is also 
the case for the Arctic-lineage of CDV. 
Relative Preferred Codon Usage (RPCU) has been devel-
oped from analysis of the codon usage comparisons. One goal 
of an RPCU analysis is to identify RNA viral isolates ( e.g. 
CDV isolates) suitable for making a broad-spectrum vaccine 
capable of providing protection against most isolates circu-
lating in a particular geographic area ( e.g. the United States). 
RFCU also allows evaluation of the genetic distance of iso-
lates that are outside an area of interest based on codon usage. 
RPCU is based in part on the observation that, in addition to 
amino acid residues, codons themselves are under evolution-
ary selection pressure (Gustavo et al., Lost in Translation: 
Codon Usage and HIV-1 Evolution, AIDS Reviews 2004; 
6:54-60). 
28 
codons in the Table (i.e. is an outlier) were also noted by an 
"O" at the bottom of the colunm) e.g. residue positions 180 
and 186. Some residue positions were identical in all CDV 
isolates. These identical residue positions are not shown in the 
5 codon usage Table because they did not affect the selection of 
the CDV vaccine isolate. 
To identify the relatively preferred codon at each residue, 
the entire Table was examined residue by residue, i.e. column 
by colunm. For example, in the colunm representing codons 
10 
at residue position 185, either CCA orTCA is used to encode 
the amino acid at this position. However, CCA is the preferred 
codon compared to TCA, since CCA is present in the majority 
of isolates. Similarly, preferred codons were determined at 
each of the residue positions. For some residues, the least 
preferred codons were also identified. As can be seen, most of 
15 the least preferred codons occur in American-2 and Arctic 
isolates. This pattern of relative preferred codon usage could 
be one of the major reasons for the biological advantage of 
EW over AM-2 and AR CDV isolates. Canine distemper virus 
is labile in the environment but highly contagious, similar to 
20 the measles virus. A CDV isolate in a geographical area that 
has a replication advantage due to more biologically fit codon 
usage and higher replication titers and shedding ( e.g. in nasal 
secretions and other portals of delivery in a dog population) 
has the ability to spread to and affect even vaccinated dogs. 
25 Thus, codon usage is the minimum functional unit of viru-
lence factors (such as H protein of CDV) with effects on 
epidemiological, biological and disease outcomes in host 
populations. 
As noted above, a major goal of the present RPCU analysis 
30 is to identify one or more CDV isolates for use in a broad-
spectrum CDV vaccine development. Preferably, a vaccine 
preparation containing or based on such CDV isolates would 
provide protection against infection by most CDV isolates 
currently circulating in the US, or at least lessen deleterious 
35 symptoms associated with such infection. EW isolate 
09041474B was identified as using a preferred codon at most 
residue positions (e.g. at positions 185, 192, 193, 203, 205, 
etc.) and was thus selected for further vaccine development. 
The approach of RPCU was developed in part because the 
40 residues that are critical for the immunogenicity of the CDV 
H protein have not been determined. RPCU analysis provides 
a method to identify robust CDV vaccine candidates in the 
absence of detailed knowledge of the antigenic characteris-
tics ofH protein residues. RPCU can be used to analyze and 
45 select vaccine candidates from among isolates of other types 
of RNA viruses as well, and will be useful in cases where the 
newly emerged virus has not been well studied but an emer-
gency vaccination is called for to stop a growing outbreak. 
Further, the new variant AM-2 isolates described herein 
50 have higher isolate specific codon usage (as determined by 
RPCU) and, while this makes them less suitable for a broadly 
reactive CDV vaccine, these genetically unique isolates will 
make excellent challenge viruses to check the efficacy of the 
improved CDV vaccines. RPCU is consistent with self-opti-
To develop and implement RPCU analysis, a codon usage 
Table depicted in FIGS. 34A-F was created in which each 
entry presents the three nucleotides of a single triplet codon. 
The codon usage Table can also be created using a concatamer 
approach, e.g. using an Excel program with MEGA4.1 soft-
ware. To create this Table, first all the sequences were sub-
jected to CLUSTAL W analysis using BioEdit software. 
Then, triplets of nucleotides in frame with the coding 
sequence were manually entered into an Excel table. In this 
manner, residue positions 155-428 of the hemagglutinin pro-
tein were analyzed, and the codons for residues of interest 
were included in the Table. For each residue position, at the 60 
bottom of the colunm, the codons used were retyped in lower 
case letters and the encoded amino acid was indicated using a 
single capital letter. The alternative codons that did not lead to 
change of amino acid (substitutive mutations, S/-) were also 
noted. For example, residue position 176 uses two codons (tct 65 
and tee, both encoding serine, S). The residues positions for 
which only the Ondersteport sequence differs from all other 
55 mization for new host adaptation being one of the fundamen-
tal reasons for evolution of emerging pathogens of animals 
and humans. 
Example 5 
Phylogenetic Analysis of Recent CDV Sequences, 
Reference CDV Sequences from Gen-Bank for Each 
CDV Genetic Lineage, and all Commercial CDV 
Vaccines 
FIG. 35 shows the phylogenetic analysis of several CDV 
hemagglutinin partial sequences from recent US CDV 
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samples compared to commercial CDV vaccines strains and 
GenBank reference sequences for all known CDV genetic 
lineages, including SouthAmerican sequences. Observations 
that can be made are as follows: 
American-I (AM-1) genetic lineage: reference 5 
sequence=AF3 78705, Ondersteport strain from 1950' s; none 
of the currently circulating CDV isolates from the US cases 
were of this CDV lineage. Most of the current commercial 
CDV vaccines (Continuum DAP, Intervet (n=l lot); Dura-
mune Max 5, Fort Dodge (n=l lot); Galaxy DA2PPv, Scher- 10 
ing Plough (n=3 lots); Merial (recombinant canary pox vec-
tored CDV-H gene vaccine (n=l lot) are all based on the 
AM-I lineage. 
American-2 (AM-2) genetic lineage: reference 
sequences=AF112189; Z47762; AF259552. Based on the 15 
phylogenetic analysis, the 3 reference sequences were dis-
persed in three locations on the CDV tree shown by the 
underlined sequences. All but one AM-2 CDV isolate clus-
tered with and around the AF 112189 reference sequence. A 
total of 8 AM-2 CDV isolates were isolated in this study. 20 
America-2 is the second largest cluster ofCDV circulating in 
the USA now. An isolate from this lineage should be included 
in the updated CDV vaccine and has thus been deposited with 
ATCC (Manassas, Va.). 
30 
CDV vaccine development. One of the current limitations of 
CDV vaccines is the availability of CDV isolates from cases 
of vaccine failure. The problem of CDV vaccine failure has 
not been fully appreciated and there is not much published 
data to support these observations. Moreover, current veteri-
nary diagnostic techniques have not been extensively applied 
to the problem of vaccine failure due to a lack of available 
methods and the cost of diagnostic testing of ante-mortem 
samples showing neurological symptoms. Thus, prior to the 
present invention, the data on current CDV isolates with 
respect to improving the quality of CDV vaccines was very 
limited, consisting mainly of isolated reports that were 
largely overlooked and reports of single dogs. This is 
undoubtedly because most owners of the deceased dogs do 
not wish to pay for further medical investigations and simply 
dispose of the animal carcasses. Therefore, no further scien-
tific information is obtained. 
The 34 CDV isolates described herein are compared using 
hyper-immune serum against the American-I CDV isolate 
utilized in the commercially available Onderstreport canine 
distemper vaccine. Hyper-immune serum is a useful reagent 
because it is prepared by administering multiple vaccines to 
adult dogs that are immunocompetent. Hyper-immune sera 
offer the best case scenario. However, in a field situation, 
most dogs will receive two CDV vaccines as puppies. Thus, 
although hyper-immune serum is a useful reagent, it has 
limitations for designing and selecting CDV isolates for vac-
cine preparation. Here, we propose a novel bio-informatics 
approach (RPCU, described above) for broad-spectrum CDV 
Arctic (AR) genetic lineage: Two reference sequences 25 
(AY964112 andAY964108) constituted this cluster. Weiden-
tified a few USA samples in this cluster. Both (07110098; 
08040383) the samples were from Missouri, USA. This is 
minor CDV genetic cluster. This CDV lineage will be suitable 
for some parts of the USA. 
Asia-I (AS-1) genetic Lineage: Three reference sequences 
(ABOl 677 6; AB 212963; AY3 78091) constituted this cluster. 
None of the USA CDV isolate is related to this lineage. This 
type of CDV lineage has been reported in Japan, China, and 
Korea. CDV vaccines for these Asian countries may include 35 
this lineage. 
30 vaccine development. All available genotypes of CDV cur-
rently circulating in the US are included in the analysis. 
Several ( e.g. at least 3-5 isolates of each CDV genotype) are 
selected (using phylogenetic analysis) for antigenic compari-
Asia-2 (AS-2) Genetic Lineage: Two reference sequences 
(AB0470767 and AB 252718) constitute this genetic cluster. 
None of the USA CDV isolate is related to this lineage. This 
type of CDV lineage has been reported in Japan, China, and 40 
Korea. CDV vaccines for these Asian countries should 
include this lineage. 
European-Wildlife (EW) Genetic Lineage: The reference 
sequence for this lineage was AY964110. Most of the EW 
CDV isolates (n=14) from the US clustered around the refer- 45 
ence strain ofCDV. However, two EW were branched sepa-
rately. This major cluster of CDV isolates should be included 
in the updated CDV vaccines for use in USA dogs. 
European (E) CDV Lineage: This lineage cluster contained 
only the two reference sequences (AF478550, DQ494318). 50 
Pfizer CDV vaccine branched close to this cluster. South 
American (SA) CDV Lineage: Four reference CDV 
sequences clustered in this lineage. These isolates separated 
son based on sequence alignment using Bio-Edit. This allows 
CDV isolates that have the maximum antigenic distance to be 
selected and compared to the current CDV vaccines. Any 
isolate that is at least 4-fold lower in SN test using either 
hyper-immune serum or a serum from a dog that has received 
only two vaccines is selected for further testing in vivo. 
Both sero-negative and low sero-positive puppies (at least 
5 puppies in each group) are injected with each of the selected 
(e.g. 3) lineages ofCDV isolates either as a single injection 
multivalent CDV vaccine or in separate, back-to-back injec-
tions of each of the 2-3 different genetic variants 3-4 weeks 
apart. This experiment identifies one or more broadly reacting 
CDV isolates that will elicit a higher level of titers against all 
the 34 CDV isolates. For example, isolates identified by 
RPCU analysis such as 09041474B are confirmed to be 
broadly reacting isolates due to shared codons of H protein. 
This translates into higher vaccine titers, better protection in 
challenge experiments, no clinical evidence of disease in 
vaccinated dogs (or alternatively, mild clinical symptoms), 
and longer duration of immunity. Moreover, CDV isolates 
selected using the RFCU will provide broad protection as a new branch from the tree indicating that they are unique 
from USA isolates and current vaccines. 
Measles virus Edmonton B sequence was used as an outlier 
sequence for comparison with US vaccines and current iso-
lates for phylogenetic analysis. 
55 against other genetic and antigenic variants that are present in 
other continents. 
A potential new lineage of CDV has been described in 
South Africa (Woma, supra). 
Example 6 
Vaccine Development 
Many limitations in the current art of CDV vaccine devel-
opment had to be overcome to select the isolates for improved 
Additional criteria are also used to select CDV isolates for 
use in a modified live virus vaccine, including the following: 
A). CDV isolates should grow to high titers (106 or more) 
60 on an approved non-recombinant cell line such as Vero and 
canine kidney cell line. It is expected that CDV isolates will 
grow to higher titer (2-3 log higher titers) in the recombinant 
Vero+SLAM (Signaling Lymphocyte Activation Molecule) 
cell line. Although recombinant Vero SLAM is suitable for 
65 primary isolation of morbilliviruses, it is expensive to propa-
gate CDV isolates therein due to the required addition of the 
selection antibiotic, gentamycin. CDV isolates that grow in 
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one or more non-recombinant Vero cell lines that are 
approved by the USDA for animal vaccine production are 
selected for further propagation. 
32 
viruria ( the presence of CDV virus or RNA in urine) may be 
an important parameter to include in vaccine-protection 
evaluation studies, and may be used non-invasively to detect 
the residual virus in CDV vaccinated dogs. Moreover, after B). The speed of growth of CDV isolates is another crite-
rion for evaluation. Most CDV isolates can grow to high titers 
in 3 days. However, the growth is slightly slower in conven-
tional Vero cell line or dog kidney cells. 
5 extensive in depth diagnostic investigation, it has been found 
that CDV can cause residual CDV infections that were not 
evaluated in past CDV vaccine approval processes. Highly 
sensitive PCR assays are used and safety data is provided on 
the improved broad-spectrum CDV vaccines. Viruria is used 
as one of the parameters of CDV vaccine efficacy. 
C). A few CDV isolates (n=5) from the major EW-branch 
are selected for further evaluation as vaccine antigens. A few 
isolates (n=5) from the second largest cluster (AM-2) are also 10 
selected as vaccine antigens. A few Arctic CDV isolates are 
also evaluated. 
An ideal candidate CDV vaccine should protect against all 
genetically diverse CDV isolates. CDV isolates from other 
continents should be included to check global coverage of a 
15 broad-spectrum CDV vaccine. American-I is not checked 
because this virus has not been found in the US in nature for 
Example 7 
Preparation of a Broad-Spectrum CDV Vaccine 
A broadly reactive and predominant CDV isolate ( e.g. a 
candidate identified by RPCU) is selected and confirmed by 
CDV-serum neutralization (CDV-SN) and/or plaque reduc- 20 
tion tests. In some embodiments, this is a wild-type CDV 
isolate that is obtained from a fully vaccinated adult dog 
(above 5-6 months of age) that died in spite of complete 
vaccination (specifically 2 CDV vaccines). 
the last 20 years, existing only in vaccines that have not been 
updated for 6 decades. 
Example 8 
Evaluation ofCDVVaccines in Ferret Models 
Prior to testing the vaccines in a large animal model such as 
dogs, they can be evaluated in a ferret model. Ferrets are 
known to be suitable models ofCDV infection and evaluation 
of CDV vaccines (Pillet et al., 2009: Ferrets as a model for 
morbillivirus pathogenesis, complications, and vaccines. 
Curr. Top. Micro biol. Immunol. 330:73-87). Ferrets are used 
to screen a large number of CDV vaccine candidates. The 
ferrets are vaccinated with attenuated modified live CDV, 
preferably a European-wildlife type (e.g. 09041474B). Euro-
pean-wildlife is preferred because a closely related cluster of 
these CDV viruses is causing vaccine failure in dogs in the 
US. Ferrets are checked for serum antibody titers against 
CDV after vaccination. The bleed dates are 0, 7, 14 and 21 
days after vaccination. Low passage CDV viruses ( e.g. Euro-
pean wildlife, or Arctic, or American-2) are then administered 
Dogs are vaccinated subcutaneously or intranasally with 25 
the vaccine. The antibody titer against the vaccine strain is 
checked by CDV-SN or plaque reduction assays using serum 
from the vaccinated dog. The selected CDV strain shows high 
cross-reactivity with a panel of recent CDV isolates from the 
US belonging to all the CDV lineages circulating in the USA. 30 
All isolates are checked for cross-reactivity with sera from the 
vaccinated dog or ferrets ( a laboratory model animal for 
CDV). A titer of ;;,;1:8, preferably ;;,;l:16, more 
preferably ;;el :32, and most preferably ;;el :64 after one vacci-
nation of a naive puppy 6-8 weeks of age is sufficient using a 35 
CDV-SN assay. In addition, the vaccine will not induce any 
cerebrospinal fluid (CSF) titers against CDV. Lack of CDV 
titers in the CSF indicates that the vaccine virus has not 
crossed the blood-brain barrier and is safe for use in puppies. 
40 to the ferrets as challenge viruses. A vaccine that is safe in puppies is very likely safe in dogs. In 
summary, all the guidelines of the Code of Federal Regula-
tions (CFR) will be followed to develop an effective broad 
spectrum and safe CDV vaccine that will be approved by the 
USDA for use in dogs and other species susceptible to CDV. 
Ferrets also have been documented to show CDV vaccine 
failure based on a recent case report (Zehnder et al., 2008: An 
unusual presentation of canine distemper virus infection in a 
domestic ferret (Mustela putorius furo) DOI: 10.1111/j). This 
Challenge studies are performed in which dogs are vacci-
nated with the broad spectrum CDV vaccine and then exposed 
to circulating, wild type CDV ( e.g. 08080696 EW; 08081112 
AM-2; 09011024 EW). These CDV viruses are genetically 
distinct and so are suitable as challenge viruses rather than as 
vaccine components. Dogs vaccinated with the vaccine 
preparation of the invention develop few or no symptoms of 
disease. Low-passage CDV isolates from the US as described 
herein can be used as the challenge virus. Unvaccinated con-
trols will develop symptoms of CDV. 
45 domestic ferret, from the US, was repeatedly vaccinated 
using chick-embryo modified live virus vaccine 18 months 
prior to the onset of clinical CDV problems and annually 
thereafter. This vaccinated ferret developed a systemic CDV 
infection manifesting in skin lesions, with a prolonged course 
50 of disease yet with complete absence of respiratory and neu-
rologic signs. Thus, CDV should be suspected in vaccinated 
ferrets with skin lesions (Zehnder, supra). 
With respect to evaluating the results of challenge studies, 55 
diagnostic laboratories typically use relatively insensitive 
tests that often may not detect weakly CDV positive cases, 
such as those involving the nervous system. CDV may be 
detected using immunohistochemistry of brain samples after 
as animal dies or is sacrificed or euthanized. However, CSF 60 
and brain biopsy are expensive and invasive procedures and 
are not used routinely. In a recent study, urine has been 
described as a sensitive sample for detection of CDV in live 
dogs (Amude, A. M., A. A. Alfieri, and A. F. Alfieri. 2006. 
Antemortem diagnosis ofCDV infection by RT-PCR in dis- 65 
temper dogs with neurological deficits without the typical 
clinical presentation. Vet. Res. Comm. 30:679-687). Thus, 
Example 9 
Critical H-Protein Residues Undergoing Positive 
Selection Among CDV Lineages: Application to 
Diagnostics 
Depending on the specific needs of diagnostic clients, dif-
ferential RT-PCR experiments and kits (including primers) 
are designed around critical H-residues (see Example 3) to 
differentially detect CDV wild types; to differentiate the 
Ondersteport-like vaccines from the Pfizer vaccine; and to 
differentiate CDV viruses down to the level of major CDV 
lineages using rapid assays with a 1 hour turnaround time. 
Ongoing monitoring of CDV viruses by complete H-gene 
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sequencing further refines these fast CDV differential assays 
by identifying new CDV variants that arise in the future. 
Example 10 
Comparative Growth Characteristics of Three 
Selected CDV Isolates in Cell Culture 
From a panel of current CDV isolates at OADDL, two 
CDV isolates (09041474B and 08021509) were selected for 
depositing at the American Type Culture Collection (ATCC). 
The isolate 09041474B has been selected for developing a 
broad-spectrum CDV vaccine against current CDV isolates. 
Three CDV isolates: 09041474B (European-Wildlife); 
08021509 (American-2); and 07110098 (Arctic), were 
propagated in cell culture and observed for their speed of 
growth based on cytopathology, and the flasks were frozen 
when most of the mono layer ( over 80%) was exhibiting cyto-
pathology. The results showed that the speed of growth of 
these selected isolates was as follows: EW>>>AM-2>AR. In 
other words, the EW 09041474B isolate grew significantly 
faster than AM-2 and AR. The individual plaques of 
09041474 were very large. At 23 hours, the entire flask of 
cells was covered with very large syncytia that touched each 
other (were fused) leaving almost no space between syncytia. 
Isolate 08021509 (AM-2) displayed medium size plaques 
and grew as isolated plaques (non-fused plaques) initially. 
The speedofAM-2 isolate growth was at leasthalfor less that 
of 090414748. This isolate was harvested at about 96 hours 
after inoculation. 
Arctic isolate 07110098 grew very slowly and the plaque 
size was small. Only a few isolated small plaques were 
detected. This isolate was not deposited atATCC. This isolate 
was harvested at 7 days post infection. Even at one week, the 
monolayer showed only about 25% cytopathology. Based on 




Full-Length Hemagglutinin Sequences of Two 
Exemplary/Selected CDV Isolates Deposited at 
ATCC,MD 
To derive the full-length sequences of the two CDV 
selected isolates, new primers were designed: 
5'-TCGAAATCCTATGTGAGATCACT-3' (forward primer, 
10 
CDVffl, SEQ IS NO: 40) and 5'-ATGCTGGAGATGGTT-
TAATTCAATCG-3' (reverse primer, CDVHS-2, SEQ IS NO: 
41). The RNA was extracted from the same batch of CDV 
isolates that were deposited at ATCC on Jan. 21, 2010. A 
QIAGEN viral RNA extraction kit was used according to the 
manufacturer's instructions. The primers for the full-length 
15 H-protein have been published (Lan N T, Yamaguchi R, 
Inomata A, Furuya Y, Uchida K, Sugano S, and S Tateyama. 
2006. Comparative analyses of canine distemper viral iso-
lates from clinical cases of canine distemper in vaccinated 
dogs. Vet. Microbial. 115:32-42) but the RT-PCR protocol 
20 was not described. Thus, a new protocol was developed based 
on the properties of the primers. 
A one step RT-PCR protocol was as follows: reverse tran-
scription at 45° C. for 1 hour, denature at 95° C. for 3 minutes, 
followed by 30 cycles of 94 ° C. for 30 seconds, anneal at 50° 
25 C. for 30 seconds, extend at 72° C. for 2 minutes, final exten-
sion at 72° C. for 7 minutes, and hold the reaction at 4 ° C. 
The reaction set up was as follows for each PCR reaction: 
12.5 ul of 2x reaction buffer (Invitrogen, Cat#10928-034), 
both primers 1.7ul eachat(15 uM), MgSO4 (50mM), dNTPs 30 (10 mM) 0.5 ul, and RT/platinum-Taq (0.5 ul). The PCR 
amplicons were purified by electrophoresis on 1.5% agarose 
gel. Correct full length amplicons about 2100 bp were 
observed. The amplicons were purified on a Promega Wizard 
column. Sequencing was performed at Noble Research Cen-
35 ter, Stillwater, Okla. The forward and reverse sequences of 
both CDV isolates were subjected to sequence analysis 
(FIGS. 37 and 38). The CDV isolate 09041474B had the 
highest match with European-Wildlife CDV isolates. The 
CDV isolate 08021509 had the highest match with Ameri-
40 can-2 CDV isolates. 
The type of active replication displayed by 09041474B is 
indicative of optimum (robust) growth that is expected from a 
CDV isolate that exhibits high "Relative Preferred Codon 
Usage (RPCU)". This isolate has been chosen for vaccine 
preparation because it will replicate to higher titers after 
inoculation and express relatively higher amounts ofhemag-
glutinin protein, the major CDV immunogen. The ATCC 45 
depositnumberfor09041474B is PTA-10596, deposited Jan. 
21, 2010. The ATCC deposit number for 08021509 is PTA-
10597, deposited Jan. 21, 2010. 
While the invention has been described in terms of its 
preferred embodiments, those skilled in the art will recognize 
that the invention can be practiced with modification within 
the spirit and scope of the appended claims. Accordingly, the 
present invention should not be limited to the embodiments as 
described above, but should further include all modifications 
and equivalents thereof within the spirit and scope of the 
description provided herein. 
<160> NUMBER OF SEQ ID NOS, 45 
<210> SEQ ID NO 1 
<211> LENGTH, 866 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM: canine distemper virus 
<400> SEQUENCE, 1 
aaggtgaatt ttactaacta ctgcgataca attgggatca gaaaatctat tgcatcggca 60 
gcaaatccca tcctcctgtc agcactctct gggggcagag gtgacatatt cccaccatac 120 
agatgcagtg gagctgctac ctcagtaggc agagttttcc ccctatcagt gtcattgtcc 180 
atgtctttga tctcaagaaa atcagagata atcaatatgc taaccgctat ctcaaacgga 240 
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gtgtatggta aaacttattt actagtgcct gattatattg aagaggagtt cgacacacaa 300 
aagattcgag tctttgagat agggttcatc aaacggtggc tgaatgacat gccattactc 360 
cagacaacca actatatggt cctcccagag aattccaaag ctaaggtatg tactatagca 420 
gtgggcgagt tgacactggc ttccttgtgt gtaggtgaga gcaccgtgtt gttatatcat 480 
gacagcaatg gttcgcaaga tagtatccta gcagtgacgc tgggaatatt tggggcaaca 540 
actatggatc aagttgaaga ggtgatacct gttgctcacc catcagtaga aaaaatacat 600 
ataacaaatc accgtgggtt cataaaagat tcaatagcaa cctggatggt gcctgcattg 660 
gtctctgaga aacaggaaga gcaaaaaaat tgtctggagt cggcttgtca aagaaaatcc 720 
taccctatgt gcaaccaaac gtcatgggaa cccttcggag gaggacagtt gccatcttat 780 
gggcggttga cattacctct agatccaagc actgaccttc aacttaacat atcgtttaca 840 
tacggtccgg ttatactgaa tggaga 866 
<210> SEQ ID NO 2 
<211> LENGTH, 1054 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 2 
ggtgaatttt actaactact gcgatacaat tgggatcaga aaatctattg catcggcagc 60 
aaatcccatc ctcctgtcag cactctctgg gggcagaggt gacatattcc caccatacag 120 
atgcagtgga gctgctacct cagtaggcag agttttcccc ctatcagtgt cattgtccat 180 
gtctttgatc tcaagaaaat cagagataat caatatgcta accgctatct caaacggagt 240 
gtatggtaaa acttatttac tagtgcctga ttatattgaa gaggagttcg acacacaaaa 300 
gattcgagtc tttgagatag ggttcatcaa acggtggctg aatgacatgc cattactcca 360 
gacaaccaac tatatggtcc tcccagagaa ttccaaagct aaggtatgta ctataggagt 420 
gggcgagttg acactggctt ccttgtgtgt aggtgagagc accgtgttgt tatatcatga 480 
cagcaatggt tcgcaagata gtatcctagc ggtgacggtg ggaatatttg gggcaacatc 540 
tatggatcaa gttgaagagg tgatacctgt tgctcaccca tcagtagaaa aaatacatat 600 
aacaaatcac cgtgggttca taaaagattc aatagcaacc tggatggtgc ctgcattggt 660 
ctctgagaaa caggaagagc aaaaaaattg tctggagtcg gcttgtcaaa gaaaatccta 720 
ccctatgtgc aaccaaacgt catgggaacc cttcggagga ggacagttgc catcttatgg 780 
gcggttgaca ttacctctag atccaagcac tgaccttcaa cttaacatat cgtttacata 840 
cggtccggtt atactgaatg gagacggtat ggattattat gaaagcccac tgtcggactc 900 
cggatggctt accattcctc ccaaaaacgg aacagtcctt ggattgataa acaaagcaag 960 
tagaggagac cagttcattg taatccccca tgtgttgaca tttgcgccca gggaatcaag 1020 
tgggaattgt tatttaccta ttcaaacatc ccag 1054 
<210> SEQ ID NO 3 
<211> LENGTH, 785 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 3 
ggtgaatttt actaactact gcgatacaat tgggatcaga aaatctattg catcggcagc 60 
aaatcccatc ctcctgtcag cactctctgg gggcagaggt gacatattcc caccatacag 120 
atgcagtgga gctgctacct cagtaggcag agttttcccc ctatcagtgt cattgtccat 180 
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gtctttgacc tcaagaaaat cagagataat caatatgcta accgctatct caaacggagt 240 
gtatggtaaa acttatttac tagtgcctga ttatattgaa gaggagttcg acacacaaaa 300 
gattcgagtc tttgagatag ggttcatcaa acggtggctg aatgacatgc cattactcca 360 
gacaactaac tatatggtcc tcccagagaa ttccaaagct aaggtatgta ctatagcagt 420 
gggcgagttg acactggctt ccttgtgtgt aggtgagagc accgtgttgt tatatcatga 480 
cagcaatggt tcgcaagata gtatcctagc agtgacgctg ggaatatttg gggcaacatc 540 
tatggatcaa gttgaagagg tgatacctgt tgctcaccca tcagtagaaa aaatacatat 600 
aacaaatcac cgtgggttca taaaagattc aatagcaacc tggatggtgc ctgcattggt 660 
ctctgagaaa caggaagagc aaaaaaattg tctggagtcg gcttgtcaaa gaaaatccta 720 
ccctatgtgc aacccaaacg tcatgggaac ccttcggagg aggacagttg ccatcttatg 780 
ggcgg 785 
<210> SEQ ID NO 4 
<211> LENGTH, 908 
<212> TYPE, DNA 
<213> ORGANISM: canine distemper virus 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (815) .. (815) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (880) .. (880) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 4 
ctagtaagat caggtgaatt ttactaatta ctgctataca attgggatca gaaaatctat 60 
tgcatcggca gcaaatccca tcctccagtc agcactctct gggggcagag gtgacatatt 120 
cccaccatac agatgcagtg gagctgctac ctcagtaggc agagttttcc ccctatcagt 180 
gtcattgtcc atgtctttga tctcaagaaa atcagagata atcaatatgc taaccgctat 240 
ctcaaacgga gtgtatggta aaacttattt actagtgcct gattatattg aagaggagtt 300 
cgacacacaa aagattcgag tctttgagat agggttcatc aaacggtggc tgaatgacat 360 
gccattactc cagacaacca actatatggt cctcccagag aattccaaag ctaaggtatg 420 
tactatagca gtgggcgagt tgacactggc ttccttgtgt gtaggtgaga gcaccgtgtt 480 
gttatatcat gacagcaatg gttcgcaaga taatatccta gtagtgacgc tgggaatatt 540 
tggggcaaca tctatggatc aagttgaaga ggtgatacct gttgctcacc catcagtaga 600 
aaaaatacat ataacaaatc accgtgggtt cataaaagat tcaatagcaa cctggatggt 660 
gcctgcattg gtctctgaga aacaggaaga gcaaaaaatt tgtctggagt cggcttgtca 720 
aagaaaatcc taccctatgt gcaaccaaac gtcatgggaa cccttcggag gaggacagtt 780 
gccatcttat gggcggttga cattacctct agatncaagc actgaccttc aacttaacat 840 
atcgtttaca tacggtccgg ttatactgaa tggagacggn atggattatt atgaaagccc 900 
actgtcgg 908 
<210> SEQ ID NO 5 
<211> LENGTH, 380 
<212> TYPE, DNA 
<213> ORGANISM: canine distemper virus 
<400> SEQUENCE, 5 
aacttgtatc cggctcttgg gttgcatgag ttttccgggg agttaacaac cattgaatcc 60 
38 
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cttatgatgc tatatcaaca gatgggtgaa acagcaccgt acatggttat tctggaaaat 120 
tctgtccaga acaaatttag tgcaggatcc tacccattgc tctggagtta tgctatggga 180 
gttggtgttg aacttgaaaa ctccatggga gggttaaatt tcggtagatc ctactttgac 240 
ccagcttatt tcaggctcgg gcaagaaatg gttagaagat cggccggtaa ggtaagctct 300 
gcacttgccg ccgagcttgg catcaccaag gaagaggctc agctagtgtc agaaatagca 360 
tccaagacaa cagaggacca 380 
<210> SEQ ID NO 6 
<211> LENGTH, 847 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 6 
aagtgaattt tactagttac tgtgatacaa ttgggatcag aaaatccatt gcattggcag 60 
caaatcccgt ccttttgtca gcactctccg gaggcagagg tgacatattc ccaccataca 120 
gatgcagtgg age tac tact tcagttggca aatctttccc cctatcagta tcattatcca 180 
tgtctttgat ctcaagaaca tcagagataa tcaatatgct gacctctatc tcagacggag 240 
tgtatggtaa aacttatttg ctagtgcctg attatattga aggggagttc gacacgcaaa 300 
agattcgagt ctttgagata gggttcatca aaaggtggct gaatgacatg ccattattcc 360 
agacaaccaa ctatatgatc ctcccggaga attctaaaac caaggtatgt actatagcag 420 
tgggcgagtt gacactggct tccttgtgtg tagatgagag cactgtatta ttatatcatg 480 
acagcaatgg ttcacaagat ggtattctag tagtgacgct gggaatcttt ggggcaacac 540 
ctatggatca agtcgaagag gtgatacctg tcgctcaccc atcagtcgaa aaaatacata 600 
taacaaatca ccgtggtttc ataaaagatt cagtagcaac ctggatggtg cctgcattgg 660 
tctctgagaa cctagaggaa caagaaaatt gtctggagtc ggcttgtcag agaaaatcct 720 
accctatgtg caatcaaaca tcatgggaac cctttggagg aggacagttg ccatcttatg 780 
ggcggttgac gttacatcta gatgcaagca ttgaccgtca acttaacata tcatttacat 840 
acggtcc 847 
<210> SEQ ID NO 7 
<211> LENGTH, 871 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 7 
tcaagaaaat cagagataat caatatgcta cccgctatct caaacggagt gtatggtaaa 60 
acttatttac tagtgcctga ttatatgaag aggagttcga cacacaaaag attcgagtct 120 
ttgagatagg gttcatcaaa cggtggctga atgacatgcc attactccag acaaccaact 180 
atatggtcct cccagagaat tccaaagcta aggtatgtac tatagcagtg ggcgagttga 240 
cactggcttc cttgtgtgta ggtgagagca ccgtgttgtt atatcatgac agcaatggtt 300 
cgcaagatag tatcctagca gtgacgctgg gaatatttgg ggcaacatct atggatcaag 360 
ttgaagaggt gatacctgtt gctcactcat cagtagaaaa aatacatata acaaatcacc 420 
gtgggttcat aaaagattca atagcaacct ggatggtgcc tgcattggtc tctgagaaac 480 
aggaagagca aaaaaattgt ctggagtcgg cttgtcaaag aaaatcctac cctatgtgca 540 
accaaacgtc atgggaaccc ttcggaggag gacagttgcc atcttatggg cggttgacat 600 
tacctctaga tccaagcact gaccttcaac ttaacatatc gtttacatac ggtccggtta 660 
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tactgaatgg agacggtatg gattattatg aaagcccact gtcggactcc ggatggctta 720 
ccattcctcc caaaaacgga acagtccttg gattgataaa taaagcaagt agaggagacc 780 
agttcattgt aatcccccat gtgttgacat ttgcgcccag ggaatcaagt gggaattgtt 840 
atttacctat tcaaacatcc cagattatag a 871 
<210> SEQ ID NO 8 
<211> LENGTH, 900 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 8 
gaattttact aattactgcg atacaattgg gatcagaaaa tctattgcat cggcagcaaa 60 
tcccatcctc ctgtcagcac tctctggggg cagaggtgac atattcccac catacagatg 120 
cagtggagct gctacctcag taggcagagt tttcccccta tcagtgtcat tgtccatgtc 180 
tttgatctca agaaaatcag agataatcaa tatgctaacc gctatctcaa acggagtgta 240 
tggtaaaact tatttactag tgcctgatta tattgaagag gagttcgaca cacaaaagat 300 
tcgagtcttt gagatagggt tcatcaaacg gtggctgaat gacatgccat tactccagac 360 
aaccaactat atggtcctcc cagagaattc caaagctaag gtatgtacta tagcagtggg 420 
cgagttgaca ctggcttcct tgtgtgtagg tgagagcacc gtgttgttat atcatgacag 480 
caatggttcg caagataata tcctagtagt gacgctggga atatttgggg caacatctat 540 
ggatcaagtt gaagaggtga tacctgttgc tcacccatca gtagaaaaaa tacatataac 600 
aaatcaccgt gggttcataa aagattcaat agcaacctgg atggtgcctg cattggtctc 660 
tgagaaacag gaagagcaaa aaaattgtct ggagtcggct tgtcaaagaa aatcctaccc 720 
tatgtgcaac caaacgtcat gggaaccctt cggaggagga cagttgccat cttatgggcg 780 
gttgacatta cctctagatc caagcactga ccttcaactt aacatatcgt ttacatacgg 840 
tccgggttat actgaatgga gacggtatgg attattatga aagcccactg tcggactccg 900 
<210> SEQ ID NO 9 
<211> LENGTH, 1133 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 9 
gccgggctgc atcaccccct agtaagacag gtgaatttta cttattactg cgatacaatt 60 
gggatcagaa aatctattgc atcggcagca aatcccatcc tcctgtcagc actctctggg 120 
ggcagaggtg acatattccc accatacaga tgcagtggag ctgctacctc agtaggcaga 180 
gttttccccc tatcagtgtc attgtccatg tctttgatct caagaaaatc agagataatc 240 
aatatgctaa ccgctatctc aaacggagtg tatggtaaaa cttatttact agtgcctgat 300 
tatattgaag aggagttcga cacacaaaag attcgagtct ttgagatagg gttcatcaaa 360 
cggtggctga atgacatgcc attactccag acaaccaact atatggtcct cccagagaat 420 
tccaaagcta aggtatgtac tatagcagtg ggcgagttga cactggcttc cttgtgtgta 480 
ggtgagagca ccgtgttgtt atatcatgac agcaatggtt cgcaagataa tatcctagta 540 
gtgacgctgg gaatatttgg ggcaacatct atggatcaag ttgaagaggt gatacctgtt 600 
gctcacccat cagtagaaaa aatacatata acaaatcacc gtgggttcat aaaagattca 660 
atagcaacct ggatggtgcc tgcattggtc tctgagaaac aggaagagca aaaaaattgt 720 
ctggagtcgg cttgtcaaag aaaatcctac cctatgtgca accaaacgtc atgggaaccc 780 
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ttcggaggag gacagttgcc atcttatggg cggttgacat tacctctaga tccaagcact 840 
gacccttcca acttaacata tcgtttacat accgtccggt tatacttgaa tggagacggt 900 
atggataatt atgaaagccc actgtcggac tcggatggct taccatttcc ttccaaaacg 960 
gaacagtcct tggattgata aacaaaccag taggggagac cagttcattg tatcccccat 1020 
gtgttgacca ttgccccagg gaatcaaggg gaatgtattt acctattcaa ccttcccaaa 1080 
taatgggata aaggatggcc ctcctgaatc caaattacgg tgttgcccta aac 1133 
<210> SEQ ID NO 10 
<211> LENGTH, 1120 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 10 
ttggttaagg ccatcctttt tccctaatct gggctgtttg aataggtaaa taacaattcc 60 
ccacttgatt ccctgggcgc aaatgtcaac acatggggga ttacaatgaa ctggtctccc 120 
ctacttgctt tgtttatcaa tccaaggact gttccgtttt tgggaggaat ggtaagccat 180 
ccggagtccg acagtgggct ttcataataa tccataccgt ctccattcag tataaccgga 240 
ccgtatgtaa acgatatgtt aagttgaagg tcagtgcttg gatctagagg taatgtcaac 300 
cgcccataag atggcaactg tcctcctccg aagggttccc atgacgtttg gttgcacata 360 
gggtaggatt ttctttgaca agccgactcc agacaatttt tttgctcttc ctgtttctca 420 
gagaccaatg caggcaccat ccaggttgct attgaatctt ttatgaaccc acggtgattt 480 
gttatatgta ttttttctac tgatgggtga gcaacaggta tcacctcttc aacttgatcc 540 
atagatgttg ccccaaatat tcccagcgtc actactagga tattatcttg cgaaccattg 600 
ctgtcatgat ataacaacac ggtgctctca cctacacaca aggaagccag tgtcaactcg 660 
cccactgcta tagtacatac cttagctttg gaattctctg ggaggaccat atagttggtt 720 
gtctggagta atggcatgtc attcagccac cgtttgatga accctatctc aaagactcga 780 
atctttttgt gtgtcgaact cctcttcaat ataaatcagg cacctagtaa ataaagttta 840 
ccatacacct ccgtttgaga tagccggtta gcatattgat tatctctgat cctcttgaga 900 
tcaaagacat ggacaatgac actgataggc gggaaaactc tgcctactga ggtagcagct 960 
ctactgcttt tgttgggtgg gaaatattta accctttgcc cccgaaagtg cttacaggag 1020 
gatgggattt gctgccgatc caataaattt tctgatccca attgtatcga agaactaata 1080 
aattacctgg accttacttg ggggggtgat gaaccagcgc 1120 
<210> SEQ ID NO 11 
<211> LENGTH, 797 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 11 
agatcaaggt gaattttact aattactgcg atacaattgg gatcagaaaa tctattgcat 60 
cggcagcaaa tcccatcctc ctgtcagcac tctctggggg cagaggtgac atattcccac 120 
catacagatg cagtggagct gctacctcag taggcagagt tttcccccta tcagtgtcat 180 
tgtccatgtc tttgatctca agaaaatcag agataatcaa tatgctaacc gctatctcaa 240 
acggagtgta tggtaaaact tatttactag tgcctgatta tattgaagag gagttcgaca 300 
cacaaaagat tcgagtcttt gagatagggt tcatcaaacg gtggctgaat gacatgccat 360 
tactccagac aaccaactat atggtcctcc cagagaattc caaagctaag gtatgtacta 420 
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tagcagtggg cgagttgaca ctggcttcct tgtgtgtagg tgagagcacc gtgttgttat 480 
atcatgacag caatggttcg caagataata tcctagtagt gacgctggga atatttgggg 540 
caacatctat ggatcaagtt gaagaggtga tacctgttgc tcacccatca gtagaaaaaa 600 
tacatataac aaatcaccgt gggttcataa aagattcaat agcaacctgg atggtgcctg 660 
cattggtctc tgagaaacag gaagagcaaa aaaattgtct ggagtcggct tgtcaaagaa 720 
aatcctaccc tatgtgcaac caaacgtcat gggaaccctt tcggaggagg acagttgcca 780 
tcttatgggc ggttgac 797 
<210> SEQ ID NO 12 
<211> LENGTH, 745 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 12 
ccccaattgg cattgaacca tgtatccggc tcttgggttg catgagtttt ccggggagtt 60 
aacaaccatt gaatccctta tgatgctata tcaacagatg ggtgaaacag caccgtacat 120 
ggttattctg gaaaattctg tccagaacaa atttagtgca ggctcctacc cattgctctg 180 
gagttatgct atgggagttg gtgttgaact tgaaaactcc atgggagggt taaatttcgg 240 
tagatcctac tttgacccag cttatttcag gctcgggcaa gaaatggtta gaagatctgc 300 
cggtaaggta agctctgcac ttgccgccga gctcggcatc accaaggaag aggctcagct 360 
agtgtcagaa atagcatcca agacaacaga ggacctccca tttggcattg aaactatgta 420 
tccggctctt gggttgcatg agttttccgg ggagttaaca acccttgaat cttaatgacc 480 
tttttccgca gggaacaaac ccacaatcgc tgaattctgt gaaatatggc tcaccacatt 540 
gtggcagctc gacaccgact ttaaccttac ctatggaatt tggcgttgaa actgtaaatc 600 
cctcttcggg ttaccacctc ttttgatcac tttaaccgtt atttacgccg gcagccacgt 660 
tagaacatat ccgccttcgc aagttttcct gcctcctcct tccacccaat tagagggccc 720 
ccctcctttg ttatgaaccc cctta 745 
<210> SEQ ID NO 13 
<211> LENGTH, 1167 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 13 
cctgggcgcc ttaccccccc ctagtaagct caggtgaatt ttactaacta ctgcgatacc 60 
cttgggatca gaaaatctat tgcatcggca gcaaatccca tcctcctgtc agcactctct 120 
gggggcagag gtgacatatt cccaccatac cgatgcagtg gagctgctac ctcagtaggc 180 
agagttttcc ccctgtcagt gtcattgtcc atgtctttga tctcaagaaa atcagagata 240 
atcaatatgc taaccgctat ctcaaacgga gtgtatggta aaacttattt actagtgcct 300 
gattatattg aagaggagtt cgacacacaa aagattcgag tctttgagat agggttcatc 360 
aaacggtggc tgaatgacat gccattactc cagacaacca actatatggt cctcccagag 420 
aattccaaag ctaaggtatg tactatagca gtgggcgagt tgacactggc ttccttgtgt 480 
gtaggtgaga gcaccgtgtc gttatatcat gacagcaatg gttcgcaaga tagtatccta 540 
gcagtgacgc tgggaatatt tggggcaaca tctatggatc aagttgaaga ggcgatacct 600 
gttgctcacc catcagtaga aaaaatacat ataacaaatc accgtgggtt cataaaagat 660 
tcaatagcaa cctggatggt gcctgcattg gtctctgaga aacaggaaga gcaaaacaat 720 
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tgtctggagt cggcttgtca aagaaaatcc taccctatgt gcaaccaaac gtcatgggaa 
cccttcggag gaggacagtt gccatcttat gggcggttga cattacctta gatccaagca 
ctgaccttca actcaacata tcgcttacat accgtccggc tatactgaat gggagacggt 
atggatttta tgacaagccc ccctgtcgga ctcccggatg gcttaccacc ccctcccaaa 
accggaacag ctccttcgat tgataaacca aaccagtacg aggagactca gtttcattgt 
tattccccta cgtgttgaca tttccgcccc aggccatcca tgtcggattg ctctttaccc 
aataacccac cccacatcat ggatacagct ctccttactg actccacact accgctgttg 
cctaccctcc cgctctccct tccccta 
<210> SEQ ID NO 14 
<211> LENGTH, 245 
<212> TYPE, DNA 
<213> ORGANISM: canine distemper virus 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (161) .. (161) 
<223> OTHER INFORMATION, n is a, c, g, or t 









gtgaatttta ctaattactg cgatactatg gggatcagaa aatctattgc atcggcagca 60 
aatcccatcc ttttatcagc actctccgga ggtagaggtg acatattccc accatacaga 120 
tgcaatggag ctactatttc agtaggcaag attttccccc natcagtatc attatctatg 180 
tctttgatct caagaacatc agagataatc aatatgctaa ccgctatctc agacggagtg 240 
tatgg 245 
<210> SEQ ID NO 15 
<211> LENGTH, 835 
<212> TYPE, DNA 
<213> ORGANISM: canine distemper virus 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (764) .. (764) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 15 
caaggtgaat tttactaatt actgcgatac aattgggatc agaaaatcta ttgcatcggc 60 
agcaaatccc atcctcctgt cagcactctc tgggggcaga ggtgacatat tcccaccata 120 
cagatgcagt ggagctgcta cctcagtagg cagagttttc cccctatcag tgacattgtc 180 
catgtctttg atctcaagaa aatcagagat aatcaatatg ctaaccgcta tctcaaacgg 240 
agtgtatggt aagacttatt tactagtgcc tgattatatt gaagaggagt tcgacacaca 300 
aaagattcga gtctttgaga tagggttcat caaacggtgg ctgaatgaca tgccattact 360 
ccagacaacc aactatatgg tcctcccaga gaattccaaa gctaaggtat gtactatagc 420 
agtgggcgag ttgacactgg cttccttgtg tgtaggtgag agcaccgtgt tgttatatca 480 
tgacagcaat ggttcgcaag ataatatcct agtagtgacg ctgggaatat ttggggcaac 540 
atctatggat caagttgaag aggtgatacc tgttgctcac ccatcagtag aaaaaataca 600 
tataacaaat caccgtgggt tcataaaaga ttcaatagca acctggatgg tgcctgcatt 660 
ggtctctgag aaacaggaag agcaaaaaaa ttgtctggag tcggcttgtc aaagaaaatc 720 
ctaccctatg tgcaaccaaa cgtcatggga acccttcgga gganggacag ttgccatctt 780 
atgggcggtt gacattacct ctagatccaa gcactgacct tcaacttaac atatc 835 
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<210> SEQ ID NO 16 
<211> LENGTH, 1119 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 16 
tcctgtttgc ctttcccccc cctagtaaga tcaggtgaat tttactaaca actgcgatac 60 
aattgggatc agaaaatcta ttgcatcggc agcaaatccc atcctcctgt cagcactctc 120 
tgggggcaga ggtgacatat tcccaccata cagatgcagt ggagctgcta cctcagtagg 180 
cagagttttc cccctatcag tgtcattgtc catgtctttg atctcaagaa aatcagagat 240 
aatcaatatg ctaaccgcta tctcaaacgg agtgtatggt aaaacttatt tactagtgcc 300 
tgattatatt gaagaggagt tcgacacaca aaagattcga gtctttgaga tagggttcat 360 
caaacggtgg ctgaatgaca tgccattact ccagacaacc aactatatgg tcctcccaga 420 
gaattccaaa gctaaggtat gtactatagc agtgggcgag ttgacactgg cttccttgtg 480 
tgtaggtgag agcaccgtgt tgttatatca tgacagcaat ggttcgcaag atagtatcct 540 
agcagtgacg ctgggaatat ttggggcaac aactatggat caagttgaag aggtgatacc 600 
tgttgctcac ccatcagtag aaaaaataca tataacaaat caccgtgggt tcataaaaga 660 
ttcaatagca acctggatgg tgcctgcatt ggtctctgag aaacaggaag agcaaaaaaa 720 
ttgtctggag tcggcttgtc aaagaaaatc ctaccctatg tgcaaccaaa cgttatggga 780 
acccttcgga ggaggacagt tgccatctta tgggcggttg acattacctc tagatccaag 840 
cactgacctt caacttaaca tatcgtttac atacggtccg gttatcctga atggagacgg 900 
tatggattat tatgaaagcc cactgtcgga ctcccgatgg cttaccattc ctccaaaacg 960 
gaacagtcct tggattgata aacaaacaag tagaggagac cagttcattg aatccccatg 1020 
tgttgacttt tcgcccaggg aatcaagtgg aattgtattt actatcaact tccagattat 1080 
ggataagatg tccttctgat tccaatacgg tgtgcctta 1119 
<210> SEQ ID NO 17 
<211> LENGTH, 1126 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 17 
tcgtggtgct taaccccccc tagtaagatc aggtgaattt tactaattac tgcgatacta 60 
ttgggatcag aaaatctatt gcatcggcag caaatcccat ccttttatca gcactctccg 120 
gaggtagagg tgacatattc ccaccataca gatgcaatgg agctactatt tcagtaggca 180 
agattttccc cctatcagta tcattatcta tgtctttgat ctcaagaaca tcagagataa 240 
tcaatatgct aaccgctatc tcagacggag tgtatggtaa aacttattta ctaatgcctg 300 
attatattga aggggagttc gacacgcaaa agattcgagt ctttgagata gggttcatca 360 
aacggtggct gaatgacatg ccattactcc agacaaccaa ctatatggtc ctcccagaga 420 
attccaaagc caaggtatgt actatagcag tgggcgagtt gacactggct tctttgtgtg 480 
tagatgagag caccgtattg ttatatcatg acagcaatgg ttcacaagat ggtgttctag 540 
tagtgacgct gggaatattc ggggcaacat ctatggatca agttgaagag gtgatacctg 600 
tcgctgaccc attagcagaa aaaatacata taacaaatca ccgtgggatc ataaaagact 660 
caatagcaac ctggatggtg cctgcattag tttctgagaa acaagaggaa caaacaaatt 720 
gtctggagtc agcttgtcaa agaaaatcct accctatgtg caatcaaacg tcatgggaac 780 
cctttggagg aggacagttg ccatcttatg ggcggctgac attacctcta catccaagca 840 
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ttgacctcca cttaacatat catttacata cggtccgact atactgaatg gagacggatg 900 
gctattatga gagccccctg cggactccgg atggcttacc tttccctcca gcacggcaca 960 
gcctggattg ataaacaaag agtagaggac gaccagttat tgtcattccc ctgtgttgac 1020 
atttcgcccc cggcatccac ccgaaattgc tattacccta tcccacattc cccttcgcgc 1080 
tcaagatccc cctcctgctc cccaccacgg cgcgctccct atctcc 1126 
<210> SEQ ID NO 18 
<211> LENGTH, 623 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 18 
cctagtagat caaggtgaat tttactaatt actgcgatac aattgggatc agaaaatcta 60 
ttgcatcggc agcaaatcca atcctcctgt cagcactctc tgggggcaga ggtgacatat 120 
tcccaccata cagatgcagt ggagctgcta cctcagtagg cagagttttc cccctatcag 180 
tgtcattgtc catgtctttg atctcaagaa aatcagagat aatcaatatg ctaaccgcta 240 
tctcaaacgg agtgtatggt aaaacttatt tactagtgcc tgattatatt gaagaggagt 300 
tcgacacaca aaagattcga gtctttgaga tagggttcat caaacggtgg ctgaatgaca 360 
tgccattact ccagacaacc aactatatgg tcctcccaga gaattccaaa gctaaggtat 420 
gtactatagc agtgggcgag ttgacactgg cttccttgtg tgtaggtgag agcaccgtgt 480 
tgttatatca tgacagcaat ggttcgcaag atagtatcct agcagtgacg ctgggaatat 540 
ttggggcaac atctatggat caagttgaag aggtgatacc tgttgctcac ccatcagtag 600 
aaaaaataca tataacaaat cac 623 
<210> SEQ ID NO 19 
<211> LENGTH, 866 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 19 
gtttgatagg taaataacag tttccacttg attccctggg tgcaaatgac aacacatgag 60 
ggaccacagt gaactggtct cctctacttg ctttgtttat caatccaaga attgttccat 120 
tcttaggagg aatggtaagc catccggatt ccaaaagtgg gctttcataa taatccatac 180 
catctccatt cagtataacc ggaccgtatg taaatgatat gttaagttta cggtcaatgc 240 
ttgcatctag atgtaacgtc aaccgcccat aagatggcaa ctgtcctcct ccaaagggtt 300 
cccatgatgt ttgattgcac atggggtagg attttctctg acaagccgac tccagacaat 360 
tttcttgttc ctctaggttc tcagagacca atgcaggcac catccaggtt gctactgaat 420 
cttttatgaa accacggtga tttgttatat gtattttttc gactgatggg tgagcgacag 480 
gtatcacctc ttcgacttga tccataggtg ttgccccaaa gattcccagc gtcactacta 540 
gaataccatc ttgtgaacca ttgctgtcat gatataataa tacagtgctc tcatctacac 600 
acaaggaagc cagtgtcaac tcgcccactg ctatagtaca taccttggtt ttagaattct 660 
ccgggaggat catatagttg gttgtctgga ataatggcat gtcattcagc caccttttga 720 
tgaaccctat ctcaaagact cgaatctttt gcgtgtcgaa ctccccttca atataatcag 780 
gcactagcaa ataagtttta ccatacactc cgtctgagat agaggtcagc atattgatta 840 
tctctgatgt tcttgagatc aaagac 866 
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<210> SEQ ID NO 20 
<211> LENGTH, 1134 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 20 
aatgcttcct ttacccaccc tagtaagatc aagtaaattt tacggtaaat aaatagcgat 60 
acaattggga tcagaaaatc tattgcatcg gcagcaaatc ctatcctttt atcagcactc 120 
tccggaggta gaggtgacat attcccacca tacaggtgca gtggagctac tacttcagta 180 
ggcagagtct tccccctatc agtatcattg tccatgtctt tggtctcaag aacatctgaa 240 
ataatcaata tgctaaccgc tatctcagac ggtgtgtatg gtaaaactta tttgctagtt 300 
cctgattatc ttgaagggga gttcgacacg caaaagattc gagtctttga gatagggttc 360 
atcaaacggt ggctgaacaa catgccatta ctccagacaa ccaactatat ggtcctcccg 420 
gaggattcca aagccaaggt atgtactata gcggtgggcg agttgacact ggcttccttg 480 
tgtgtagatg agagcaccgt attgttatat catgacagca gtggttcaca agatggtatt 540 
ctagtggtga cgctgggaat atttggggca acacctatgg atcaagttga agaggtgata 600 
cctgttgctc acccatcagt agaaaaaata catatagcaa accaccgtgg gttcatcaaa 660 
gattcaatag caacctggat ggtgcctgca ttggtctctg agaaacaaga ggaacaaaaa 720 
aattgtctgg agtcggcttg tcaaagaaaa tcctacccta tgtgcaacca aacgtcatgg 780 
gaaccctttg gaggaggaca gttgccatct tatgggcggt tgacattacc tctagatcaa 840 
agcattgacc tccagcttaa catctcattt acatatggtc cggttatact gaatggagac 900 
ggtatggatt attatgaaag tccgcttttg aactccggat ggcttaccat tcctcccaag 960 
aacggaacag tccttggatt gataaacaaa gcaagtagag gagaccagtt cactgtatcc 1020 
ccatgtgtga catttgcgcc cagggaatca agtggaattg tatttaccta ttcaaacatc 1080 
ccagatatgg ataaagatgt ccttactgaa tccaaattag tggtgttgcc taac 1134 
<210> SEQ ID NO 21 
<211> LENGTH, 1124 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 21 
accggggtgc ttaccccccc tagtaagatc aagtgaattt tacgaaaaac tgcgatccaa 60 
ttgggatcag gaaatctatt gcaacggcag caaatcctat ccttttatca gcaccctccg 120 
gaggtagagg tgacatattc ccatcataca gatgcagtgg age tact act tcagtaggca 180 
gagtcttccc cctatcagta tcattgtcca tgtctttgat ctcaagaaca tctgaaataa 240 
tcaatatgct aaccgctatc tcagacggag tgtatggtaa aacttatctg ctagttcctg 300 
attatcttga aggggagttc gacacgcaaa agattcgagt ctttgagata gggttcatca 360 
aacggtggct gaacaacatg ccattactcc agacaaccaa ctatatggtc ctcccagagg 420 
attccaaagc caaggtatgt actatagcag tgggcgagtt gacactggct tccttgtgtg 480 
tagatgagag caccatattg ttatatcatg acagcaatgg ttcacaagat ggtattctag 540 
tggtgacgct gggaatattt ggggcaacac ctatggatca agttgaagag gtgatacctg 600 
ttgctcaccc atcagtagaa aaaatacata tagcaaacca tcgtgggttt atcaaagatt 660 
caatagcaac ctggatggtg cctgcattgg tctctgagaa acaagaggaa caaaaaaatt 720 
gtctggagtc ggcttgtcaa agaaaatcct accctatgtg caaccaaacg tcatgggaac 780 
cctttggagg aggacagttg ccatcttatg ggcggttgac attacctcta gatccaagca 840 
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ttgaccttca gcttacatct catttacata cggcccgtta tactgaatgg agacggtatg 900 
gatactatga aagcccactt ttagactccg gatggcttac cattcctcca agaacggaac 960 
agtccttgga ttgataaaca aagcaagtag aggagaccag ttcactgtat ccccatgtgt 1020 
tgacatttgc gccaggaatc agtggaaatt gttatttacc tattcaaact tcccaattat 1080 
ggataagagt cctactggat ccaaattatg gtgtttccct aacc 1124 
<210> SEQ ID NO 22 
<211> LENGTH, 1145 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 22 
cattggtgca ttaacccacc tagtaagaca agtgaatttt actaatatac tgcgatacaa 60 
ttgggatcag gaaatctatt gcatcggcag caaatcctat ccttttatca gcaccctccg 120 
gaggtagagg tgacatattc ccatcataca gatgcagtgg age tact act tcagtaggca 180 
gagtcttccc cctatcagta tcattgtcca tgtctttgat ctcaagaaca tctgaaataa 240 
tcaatatgct aaccgctatc tcagacggag tgtatggtaa aacttatctg ctagttcctg 300 
attatcttga aggggagttc gacacgcaaa agattcgagt ctttgagata gggttcatca 360 
aacggtggct gaacaacatg ccattactcc agacaaccaa ctatatggtc ctcccagagg 420 
attccaaagc caaggtatgt actatagcag tgggcgagtt gacactggct tccttgtgtg 480 
tagatgagag caccatattg ttatatcatg acagcaatgg ttcacaagat ggtattctag 540 
tggtgacgct gggaatattt ggggcaacac ctatggatca agttgaagag gtgatacctg 600 
ttgctcaccc atcagtagaa aaaatacata tagcaaacca tcgtgggttt atcaaagatt 660 
caatagcaac ctggatggtg cctgcattgg tctctgagaa acaagaggaa caaaaaaatt 720 
gtctggagtc ggcttgtcaa agaaaatcct accctatgtg caaccaaacg tcatgggaac 780 
cctttggagg aggacagttg ccatcttatg ggcggttgac attacctcta gatccaagca 840 
ttgaccttca gcttaacatc tcatttacat acggtccggt tatactgaat ggagacggta 900 
tggattacta tgaaagccca cttttagact ccggatggct taccattcct cccaagaacg 960 
gaacagtcct tggattgata aacaaagcaa gtagaggaga ccagttcact gtaatccccc 1020 
atgtgttgac atttgcgccc agggaatcaa gtggaaattg ttatttacct attccaaaca 1080 
tcccagatta tggataaagg atgtccttac tgaagttcta aattagtggg ggtttgccct 1140 
aagac 1145 
<210> SEQ ID NO 23 
<211> LENGTH, 321 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 23 
gcctcccagg ggcaccttcc ccccccagta gctcaggtga atctcactta aaactgcgcc 60 
ccccttggga tcttacaatc tattgcatcg gcagcaaatc ccctcctttt atcagcactc 120 
tcccgaggta gaggtgacat attcccacca taccgatgca atggagctac tatttcacta 180 
ggcaagattt cccccctatc agtatcatta tctatgtctt tgatctcacg aacatcagag 240 
ataatcaata tgctaaccgc tatctcatac ggagtgtatg gtaaaactta tttactaatg 300 
cccgactata ttgaagggga g 321 
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<210> SEQ ID NO 24 
<211> LENGTH, 1135 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 24 
ttgatttcga ctccccgatt ttccactgtg cattaaccac ctagtaagat caaggtgaat 60 
tttactgact ctggaacaaa tgggatcaag aaatttattg catggcagca aatcccatct 120 
cctgtcagca ctctatgggg gcagaggtga catattccca ccatacaaga tgcagtggag 180 
ctgctacctc agtaggcaga gttttccccc tatcagtgtc attggccatg tctttgacct 240 
caagaaaatc agaggataat caatatgcta accgctatct caaaacggag tgtatggtaa 300 
aacttattta ctagtgcctg attatattga agaggagttc gacacacaaa aagattcgag 360 
tctttgagat agggttcatc aaacggtggc tgaataacat gccattactc cagacaacta 420 
actatatggt cctcccagag aattccaaag ctaaggtatg tactatagca gtgggcgagt 480 
tgacactggc ttccttgtgt gtaggtgaga gcaccgtgtt gttatatcat gacagcaatg 540 
gttcgcaaga tagtatccta gcagtgacgc tgggaatatt tggggcaaca tctatggatc 600 
aagttgaaga ggtgatacct gttgctcacc catcagtaga aaaaatacat ataacaaatc 660 
accgtgggtt cataaaagat tcaatagcaa cctggatggt gcctgcattg gtctctgaga 720 
aacaggaaga gcaaaaaaat tgtctggagt cggcttgtca aagaaaatcc taccctatgt 780 
gcaaccaaac gtcatgggaa cccttcggag gaggacagtt gccatcttat gggcggttga 840 
cattacctct agatccaagc actgaccttc aacttaacat atcgtttacg tacggtccgg 900 
ttatactgaa tggagacggt atggattatt atgaaagccc actgtcggac tccggatggc 960 
ttaccattcc tcccaaaaac ggaacagtcc ttggattgat aaacaaagca agtagaggag 1020 
atcagttcat tgtaatcccc catgtgttga catttgcgcc cagagaatca agtgggaatt 1080 
gttatttacc tattcaaaca tcccatatta ggaaaaaggg aggcctaccc gggga 1135 
<210> SEQ ID NO 25 
<211> LENGTH, 796 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 25 
tatggttcat taccccccgg cgtaagtgaa tttgaatcgt agtaattgct gtgataaaat 60 
tgggattgga aatgtattgc attgttatga aattctacct tttcagcact tgcctccgtt 120 
ggttgagggg acttattccc atcatacata tgcagtggag ctactacctc atccggcaga 180 
gttatatttg atcatcatta ttgcacatgt ttgtgaccta aaaaacatct ggcatatgca 240 
atctgctaac cgcgatctca tgtggagtgt atggcaaaac ttatctgcta cttcctgatt 300 
ttcttgaagg ggagtccgac actctgccga tgtccgacaa gctgatcggg ttcatcaaac 360 
tctggctgaa caacatgttg cgcgtctgac aacctccgat ttggcctgcc cagaggattt 420 
tacagccaag gtatgtacca tatcccaggg gaacttcaca ctgccttcct tgtgtgttag 480 
ccagagcccc atattgtccc ataatgatat gaatgtccta caagaggtca ttttccatgt 540 
gaccccgcgt tcatttgtgg caatggcggt ggttcaattg gaacagggta tatctgaccc 600 
tatctttcac tagagaaatt acatatgaca aaccatcatg gcttgatcaa agaataactt 660 
cctttctggc tgacgcttga cttgccctta tatataccat attttcttaa taaatcgcgg 720 
tcaattgcct gtggagccaa attttaccac tcttccaacc ttatgttacg ggctttcctt 780 
gccggaggac cgttgc 796 
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<210> SEQ ID NO 26 
<211> LENGTH, 1122 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 26 
gcgattttgc cctgtgcatt aacccaccta gtaagatcaa ggtaaatttt actaaattct 60 
gcgaaacatg tggatcagaa aatctatggc atcggcagca atcccatcct cctgcagccc 120 
tcttggggca gaggtgacat attcccacca tacagatgca gtgaggctgc tacctcagta 180 
ggccagagtt ttcccctatc agggtcattg tgcatgtctt tgacctcaag aaagtcagag 240 
ataatcaaat atgctaaccc gctatctcaa acggagtgta tgggaaaaac ttatttacta 300 
gtgcctggat tatattgaag aggagttcga cacacaaaag attcgagtct ttgagatagg 360 
gttcatcaaa cggtggctga ataacatgcc attactccag acaactaact atatggtcct 420 
cccagagaat tccaaagcta aggtatgtac tatagcagtg ggcgagttga cactggcttc 480 
cttgtgtgta ggtgagagca ccgtgttgtt atatcatgac agcaatggtt cgcaagatag 540 
tatcctagca gtgacgctgg gaatatttgg ggcaacatct atggatcaag ttgaagaggt 600 
gatacctgtt gctcacccat cagtagaaaa aatacatata acaaatcacc gtgggttcat 660 
aaaagattca atagcaacct ggatggtgcc tgcattggtc tctgagaaac aggaagagca 720 
aaaaaattgt ctggagtcgg cttgtcaaag aaaatcctac cctatgtgca accaaacgtc 780 
atgggaaccc ttcggaggag gacagttgcc atcttatggg cggttgacat tacctctaga 840 
tccaagcact gaccttcaac ttaacatatc gtttacatac ggtccggtta tactgaatgg 900 
agacggtatg gattattatg aaagcccact gtcggactcc ggatggctta ccattcctcc 960 
caaaaacgga acagtccttg gattgataaa caaagcaagt agaggagatc agttcattgt 1020 
aatcccccat gtgttaacat ttgcgcccag agaatcaagt gggggattgt tattttccta 1080 
ttcaaacatg cccatattat gataaaggat ggccttaacc cg 1122 
<210> SEQ ID NO 27 
<211> LENGTH, 798 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 27 
agttcgacgc acaaaagatt cgagtgttga gatagggttg atcggacgag gaggtgaagg 60 
acatgccatt actccagaca gctaactata tggtccgccc agagaattcc aaagctaagg 120 
tatgtactat agcagtgggc gaggtggcac tggcttcctt gtgtgtaggg gagagcgccg 180 
tgttgttata tcatggcagc aatggttcgc aagatagtat cgtagcagtg acgctgggaa 240 
tatttggggc aacatctatg gatcaagttg aagaggtgat acctgttgct cacccatcag 300 
tagagaaaat acatatagca aatcaccgtg ggttcataaa agattcaata gcaacctgga 360 
tggtgcctgc attggtctct gagaaacagg aagagcaaaa aaattgtctg gagtcggctt 420 
gtcaaagaaa atcctaccgt atgtgcagcc aaacggcatg ggaacccttc ggaggaggac 480 
agttgccatc ttatgggcgg ttgacattac ctctagatcc aagcgctgcc ttcaacttaa 540 
catatcgttt acatacggtc cggttatact gaatggagac ggtatggatt attatgaaag 600 
cccactgtcg ggctccggat ggcttgccat tcctcccaaa aacggaacag tccttggatt 660 
gataaacaaa gcaagtagag gagatcagtt cattgtaatc ccccatgtgt ggacatttgc 720 
gcccagagaa tcaagtgggg gattgttttt taaactatgc aaacggcgca tatgaggggg 780 
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gagggggggc gggaggct 798 
<210> SEQ ID NO 28 
<211> LENGTH, 1035 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 28 
cagtgagagc aaaaatgtag gaaagggcag gaattccatg ctcaaggagc ggatgtgggg 60 
agaggttgcg agtcccgcca gcagtgcagg aaggggtact cagtagcggg gtttccccct 120 
aggaggggga ttgtccagtc tttgatatca gaaaagaagg atatcaatat gctaaccgct 180 
atcgccaaag gagggtatgg taagagctta ttgggagtgc ctgattagag ggagggaagt 240 
tctacaggag agagattgga gtggtgagat gggggttcgt caagcggtgg atgaatgaca 300 
taccattact ccagacaacc aagtataggg gcctcccaga gaatgccaaa gctaaggtat 360 
gtactatagc agtgggcgag ttacgctggc ttccttgtgt gtaggtgaga gcgccgtgtt 420 
gt ta ta teat gacagcaatg gttcgcaaga tagtatccta gctgtgacgc tgggaatatt 480 
tggggcagca tctatggatc aagttgaaga ggtgatgcct gttgctcacc catcagtaga 540 
aaaaatacat ataacaaatc gccgtgggtt cataaaagat tcaatagcag catggatggt 600 
gcctgcattg gtctctgaga agcaggaaga gcaaaaaaat tgtcaggagt cgggttgtca 660 
aagaaaatcc tacccgatgt gcaaccaaac gtcatgggaa cccttcggag gaggacaggt 720 
gccatcttat gggcggttgg cattacctct agagccaagc actggccttc aacttgacat 780 
atcgtttaca tacgggccgg ttatactgaa tggagacggt atggattatt atgaaagccc 840 
actgtcggac gccggatggc ttaccattcc tcccaaaaac ggaacagtcc gtggattgat 900 
aaacaaagca agtagaggag gccagttcat tgtaatcccc catgtgttga catttgcgcc 960 
cagggaatca agtgggaatt gctattttcc tattcagaac accccagatt aggatagaag 1020 
gaggggcctg ggccg 1035 
<210> SEQ ID NO 29 
<211> LENGTH, 1131 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 29 
cttgtgggct taaaccacct agtaatacaa agtgaatttt actaattact gcgatacaat 60 
tgggatcaaa aaatctattg catcggcagc aaatcctatc cttttatcag cactctccgg 120 
aggcagaggt gacatattcc caccatacag atgcagtgga gctactactt cagtaggcag 180 
agtcttcccc ttatcagtat cattgtccat gtctttgatc tcaagaacat ctgaaataat 240 
caatatgcta accgctatct cagacggagt gtatggtaaa acttatttgc tagttcctga 300 
ttatcttgaa ggggagttcg acacgccgaa gattcgagtc tttgagatag ggttcatcaa 360 
acggtggctg aacaacatgc cattaatcca gacaaccaac tatatggtcc tcccggagga 420 
ttccaaagct aaggtatgta ctatagcagt gggcgagttg acactggctt ccttatgtgt 480 
agatgagagc accgtattgt tatatcatga cagcaatggt tcacaagatg gtattctagt 540 
ggtgacgctg ggaatatttg gggcaacacc tatggatcga gttgaagagg tgatacctgt 600 
tgctcacccg tcagtagaaa aaatacatat ggcaaaccac cgtgggttca tcaaagattc 660 
aatagcaacc tggatggtgc ctgcattggt ctctgagaaa caagaggaac aaaaaaattg 720 
tctggagtcg gcttgtcaaa gaaaatccct accctatgtg caaccaaacg tcatgggaaa 780 
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ccctttggag gaggacagtt gccatcttat gggcggttga cattacctct agatccaagc 840 
attgaccttc accttaacat ctcatttaca tacggcccag ttatactgaa tggggacggt 900 
atggattatt atgaaagccc acttttggac tccggatggc ttaccattcc tcccaagaac 960 
ggaacagtcc ttggattgat aaacagagca gtagaggaga acagttcact gtaatcccca 1020 
tgtgttgact tgcgcaaggg gatcaagtgg aaattgtatt tacctattca aacatcttaa 1080 
attatggata aagatgccct caccgagccc aaattagtgg tgttgcctca t 1131 
<210> SEQ ID NO 30 
<211> LENGTH, 759 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 30 
ctccctttcg gcttgaacat gtatccggct cttgggttgc atgagttttc cggggagtta 60 
acaaccattg aatcccttat gatgctatat caacagatgg gtgaaacagc accgtacatg 120 
gttattctgg aaaattctgt ccagaacaaa tttagtgcag gatcctaccc attgctctgg 180 
agttatgcta tgggagttgg tgttgaactt gaaaactcta tgggagggtt aaatttcggt 240 
agatcctact ttgacccagc ttatttcagg ctcgggcaag aaatggttag aagatcggcc 300 
ggtaaggtaa gctctgcact tgccgccgag cttggcatca ccaaggaaga ggctcagcta 360 
gtgtcagaaa tagcatccaa gacaacagag gacccgcatt tggcattgaa actatgtatc 420 
cggctcttgg gttgcatgag ttttccgggg agttaacaac cattgaatcc cttgtgatgc 480 
tttaccacca aatgggtgaa ggacccccca tggttattct tggaaaattt gtccgacaaa 540 
attagtgcag gatctaccat tgctctggag ttatgctatg ggagttggtg gtgaacttga 600 
aaaccccatg ggggggttaa atttcggcag attcttcttt gacagttaat tttaggctcg 660 
gccagaaaat ggttagaaaa ctcggccggt taggggaaag ctttgtcttt gcccgcttgg 720 
gttccccccc cgaaaggttt cccccctttt ctatatatt 759 
<210> SEQ ID NO 31 
<211> LENGTH, 1132 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 31 
tgtgaatgtg aacttccgcg atctccactg gtgcattaac ccactagtaa gatcaaggtg 60 
aatttactaa ctacgcgata caattgggat cagaaaatct attgcatcgg cagcaaatcc 120 
catcctcctg tcagcactct ctgggggcag aggtgacata ttcccaccat accgatgcag 180 
tggagctgct acctcagtag gcagagtttt ccccctgtca gtgtcattgt ccatgtcttt 240 
gatctcaaga aaatcagaga taatcaatat gctaaccgct atctcaaacg gagtgtatgg 300 
taaaacttat ttactagtgc ctgattatat tgaagaggag ttcgacacac aaaagattcg 360 
agtctttgag atagggttca tcaaacggtg gctgaatgac atgccattac tccagacaac 420 
caactatatg gtcctcccag agaattccaa agctaaggta tgtactatag cagtgggcga 480 
gttgacactg gcttccttgt gtgtaggtga gagcaccgtg tcattatatc atgacagcaa 540 
tggttcgcaa gatagtatcc tagcagtgac gctgggaata tttggggcaa catctatgga 600 
tcaagttgaa gaggtgatac ctgttgctca cccatcagta gaaaaaatac atataacaaa 660 
tcaccgtggg ttcataaaag attcaatagc aacctggatg gtgcctgcat tggtctctga 720 
gaaacaggaa gagcaaaaaa attgtctgga gtcggcttgt caaagaaaat cctaccctat 780 
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gtgcaaccaa acgtcatggg aacccttcgg aggaggacag ttgccatctt atgggcggtt 840 
gacattacct ctagatccaa gcactgacct tcaacttaac atatcgttta catacggtcc 900 
ggttatactg aatggagacg gtatggatta ttatgaaagc ccactgtcgg actccggatg 960 
gcttaccatt cctcccaaaa acggaacagt ccttggattg ataaacaaag caagtagagg 1020 
agaccagttc attgtaatcc cccatgtgtt gacatttgcg cccagggaat caagtgggaa 1080 
ttgttattta cctattcaaa catcccagat tatgaaaaga tgccttaacc cg 1132 
<210> SEQ ID NO 32 
<211> LENGTH, 1127 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 32 
tctgctgctt aaccacctag taagatcagg tgaattttac taactactgc gatacaattg 60 
ggatcagaaa atctattgca tcggcagcaa atcccatcct cctgtcagca ctctctgggg 120 
gcagaggtga catattccca ccataccgat gcagtggagc tgctacctca gtaggcagag 180 
ttttccccct gtcagtgtca ttgtccatgt ctttgatctc aagaaaatca gagataatca 240 
atatgctaac cgctatctca aacggagtgt atggtaaaac ttatttacta gtgcctgatt 300 
atattgaaga ggagttcgac acacaaaaga ttcgagtctt tgagataggg ttcatcaaac 360 
ggtggctgaa tgacatgcca ttactccaga caaccaacta tatggtcctc ccagagaatt 420 
ccaaagctaa ggtatgtact atagcagtgg gcgagttgac actggcttcc ttgtgtgtag 480 
gtgagagcac cgtgtcatta tatcatgaca gcaatggttc gcaagatagt atcctagcag 540 
tgacgctggg aatatttggg gcaacatcta tggatcaagt tgaagaggtg aacctgttgc 600 
tcacccatca gtagaaaaaa tacatataac aaatcaccgt gggttcataa aagattcaat 660 
agcaactgga tggtgcctgc attggtctct gagaaacagg aagagcaaaa aaattgtctg 720 
gagtcggctt gtcaaagaaa atcctaccct atgtgcaacc aaacgtcatg ggaacccttc 780 
ggaggaggac agttgccatc ttatgggcgg ttgacattac ctctagatcc aagcactgac 840 
cttcaactta acatatcgtt tacatacggt ccggttatac tgaatggaga cggtatggat 900 
tattatgaaa gcccactgtc ggactccgga tggcttacca ttcctcccaa aaacggaaca 960 
gtccttggat tgataaacaa agcagtagag gagaccagtt cattgtaatc ccccatgtgt 1020 
tgacatttgc gcccagggaa tcaagtggga attgttattt acctattcaa acatccagat 1080 
tatggataaa gatgtcctta ctgagtccaa attagtgtgt gtgccta 1127 
<210> SEQ ID NO 33 
<211> LENGTH, 1128 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 33 
attggttgcc cttaacccac ctagtaagat caggtgaatt ttactaacta ctgcgataca 60 
attgggatca gaaaatctat tgcatcggca gcaaatccca tcctcctgtc agcactctct 120 
gggggcagag gtgacatatt cccaccatac cgatgcagtg gagctgctac ctcagtaggc 180 
agagttttcc ccctgtcagt gtcattgtcc atgtctttga tctcaagaaa atcagagata 240 
atcaatatgc taaccgctat ctcaaacgga gtgtatggta aaacttattt actagtgcct 300 
gattatattg aagaggagtt cgacacacaa aagattcgag tctttgagat agggttcatc 360 













<210> SEQ ID NO 34 
<211> LENGTH, 18 














<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 














<223> OTHER INFORMATION, Synthetic oligonucleotide primer 
<400> SEQUENCE, 34 
atttgggatt gcttagga 
<210> SEQ ID NO 35 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide primer 
<400> SEQUENCE, 35 
ggcgctcatc ttggacat 
<210> SEQ ID NO 36 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide primer 
<400> SEQUENCE, 36 
gttagctagt ttcatcct 
<210> SEQ ID NO 37 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide primer 
<400> SEQUENCE, 37 
ggtcctctgt tgtcttgg 
<210> SEQ ID NO 38 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 


















<400> SEQUENCE, 38 
gaattcgact tccgcgatct cc 
<210> SEQ ID NO 39 
<211> LENGTH, 25 
<212> TYPE, DNA 
69 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Synthetic oligonucleotide primer 
<400> SEQUENCE, 39 
taggcaacac cactaatttr gactc 
<210> SEQ ID NO 40 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide primer 
<400> SEQUENCE, 40 
tcgaaatcct atgtgagatc act 
<210> SEQ ID NO 41 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide primer 
<400> SEQUENCE, 41 
atgctggaga tggtttaatt caatcg 
<210> SEQ ID NO 42 
<211> LENGTH, 1824 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 42 
atgctctcct accaagacaa ggtgggtgcc ttctataagg ataatgcaag agctaattca 
tccaagctgt ccctagtgac agaagagcaa gggggcagga gaccacccta tttgctgttt 
gtccttctca tcctactggt tggaatcctg gccttgcttg ctatcactgg agttcgattt 
caccaagtat caactagcaa cgtggaattt agcagattgc taaaagagga tatggagaaa 
tcagaggctg tacatcacca agtcatagat gttttgacgc cgctcttcaa aattattgga 
gatgagattg ggttacggct gccacaaaaa ctaaacgaga tcaaacaatt catccttcaa 
aagacaaact tcttcaatcc taacagggaa ttcgacttcc gtgatctcca ctggtgcatt 
aacccaccta gtaagatcaa ggtgaatttt actaactact gcgatacaat tgggatcaga 
aaatctattg catcggcagc aaatcccatc ctcctgtcag cactctctgg gggcagaggt 
gacatattcc caccataccg atgcagtgga gctgctacct cagtaggcag agttttcccc 
ctgtcagtgt cattgtccat gtctttgatc tcaagaaaat cagagataat caatatgcta 
accgctatct caaacggagt gtatggtaaa acttatttac tagtgcctga ttatattgaa 
gaggagttcg acacacaaaa gattcgagtc tttgagatag ggttcatcaa acggtggctg 
aatgacatgc cattactcca gacaaccaac tatatggtcc tcccagagaa ttccaaagct 
aaagtatgta ctatagcagt gggcgagttg acactggctt ccttgtgtgt aggtgagagc 
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ggaatatttg gggcaacatc tatggatcaa gttgaagagg tgatacctgt tgctcaccca 1020 
tcagtagaaa aaatacatat aacaaatcac cgtgggttca taaaagattc aatagcaacc 1080 
tggatggtgc ctgcattggt ctctgagaaa caggaagagc aaaaaaattg tctggagtcg 1140 
gcttgtcaaa gaaaatccta ccctatgtgc aaccaaacgt catgggaacc cttcggagga 1200 
ggacagttgc catcttatgg gcggttgaca ttacctctag atccaagcac tgaccttcaa 1260 
cttaacatat cgtttacata cggtccggtt atactgaatg gagacggtat ggattattat 1320 
gaaagcccac tgtcggactc cggatggctt accattcctc ccaaaaacgg aacagtcctt 1380 
ggattgataa acaaagcaag tagaggagac cagttcattg taatccccca tgtgttgaca 1440 
tttgcgccca gggaatcaag tgggaattgt tatttaccta ttcaaacatc ccagattatg 1500 
gataaagatg tccttactga gtccaattta gtggtgttgc ctacacagaa ttttagatat 1560 
gtcatagcaa catatgatat atcccgggac aatcatgcga tcgtttacta tgtctatgac 1620 
ccaattcgga cgatttctta tacgtaccca tttagactaa ctaccaaagg tagacctgat 1680 
ttcctaagga ttgaatgttt tgtttgggat gatgatttgt ggtgtcacca gttctaccga 1740 
ttcgaggctg acatcactaa ctctaccacc agtgttgaga atttagtccg tataagattc 1800 
tcatgtaacc gttcaagacc ttga 1824 
<210> SEQ ID NO 43 
<211> LENGTH, 1824 
<212> TYPE, DNA 
<213> ORGANISM, canine distemper virus 
<400> SEQUENCE, 43 
atgctctcct accgagacaa ggtgggtgcc ttctataagg acaatgctag agctaattca 60 
tccaagctgt ccttagtgac agaagagcaa gggggcagga gaccacccta tttgctgttt 120 
gtccttctca tcctactggt tggaatcatg gccttgcttg ctatcactgg agttcgattt 180 
caccaagtat caactagcaa tatggagttt agcagattgc tgaaagagga tctggagaaa 240 
tcagaggccg tacatcacca agtcatagat gtcttgacgc cgctcttcaa aattattgga 300 
gatgagattg ggttacggtt gccacaaaaa ctaaacgaga tcaaacaatt tatccttcaa 360 
aagacaaact tcttcaatcc gaacagggaa ttcgacttcc gcgatctcca ctggtgcatt 420 
aacccaccta gtaagatcaa ggtgaatttt actaattact gcgatactat ggggatcaga 480 
aaatctattg catcggcagc aaatcccatc cttttatcag cactctccgg aggtagaggt 540 
gacatattcc caccatacag atgcaatgga gctactattt cagtaggcaa gattttcccc 600 
ctatcagtat cattatctat gtctttgatc tcaagaacat cagagataat caatatgcta 660 
accgctatct cagacggagt gtatggtaaa acttatttac taatgcctga ttatattgaa 720 
ggggagttcg acacgcaaaa gattcgagtc tttgagatag ggttcatcaa acggtggctg 780 
aatgacatgc cattactcca gacaaccaac tatatggtcc tcccagagaa ttccaaagct 840 
aaggtatgta ctatagcagt gggcgagttg acactggctt ctttgtgtgt aggtgagagc 900 
accgtattgt tatatcatga cagcaatggt tcacaagatg gtattctagt agtgacgctg 960 
ggaatattcg gggcaacatc tatggatcaa gttgaagagg tgatacctgt cgctgaccca 1020 
ttagtagaaa aaatacatat aacaaatcac cgcgggatca taaaagattc aatagcaacc 1080 
tggatggtgc ctgcattagt ttctgagaaa caagaggaac aaaaaaattg tctggagtca 1140 
gcttgtcaaa gaaaatccta ccctatgtgc aatcaaacgt catgggaacc ctttggagga 1200 











<210> SEQ ID NO 44 
<211> LENGTH, 607 
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atactgaatg gggacggtat ggattattat 
accattcctc ccaagaacgg aacagtcctt 
cagttcactg taatccccca tgtgttgaca 
tatttaccta ttcaaacatc ccagattatg 
gtggtgttgc ctacacagaa ttttagatat 
gatcatgcga ttgtttatta tgtttatgac 
tttagactaa ctactaaggg tagacctgat 
gacgatttgt ggtgtcacca gttttaccga 
agtgtcgaga atttagtccg tatgagattc 
<213> ORGANISM: canine distemper virus 
<400> SEQUENCE, 44 
Met Leu Ser Tyr Gln Asp Lys Val Gly Ala Phe Tyr Lys Asp Asn Ala 
1 5 10 15 
Arg Ala Asn Ser Ser Lys Leu Ser Leu Val Thr Glu Glu Gln Gly Gly 
20 25 30 
Arg Arg Pro Pro Tyr Leu Leu Phe Val Leu Leu Ile Leu Leu Val Gly 
35 40 45 
Ile Leu Ala Leu Leu Ala Ile Thr Gly Val Arg Phe His Gln Val Ser 
50 55 60 
Thr Ser Asn Val Glu Phe Ser Arg Leu Leu Lys Glu Asp Met Glu Lys 
65 70 75 80 
Ser Glu Ala Val His His Gln Val Ile Asp Val Leu Thr Pro Leu Phe 
85 90 95 
Lys Ile Ile Gly Asp Glu Ile Gly Leu Arg Leu Pro Gln Lys Leu Asn 
100 105 110 
Glu Ile Lys Gln Phe Ile Leu Gln Lys Thr Asn Phe Phe Asn Pro Asn 
115 120 125 
Arg Glu Phe Asp Phe Arg Asp Leu His Trp Cys Ile Asn Pro Pro Ser 
130 135 140 
Lys Ile Lys Val Asn Phe Thr Asn Tyr Cys Asp Thr Ile Gly Ile Arg 
145 150 155 160 
Lys Ser Ile Ala Ser Ala Ala Asn Pro Ile Leu Leu Ser Ala Leu Ser 
165 170 175 
Gly Gly Arg Gly Asp Ile Phe Pro Pro Tyr Arg Cys Ser Gly Ala Ala 
180 185 190 
Thr Ser Val Gly Arg Val Phe Pro Leu Ser Val Ser Leu Ser Met Ser 
195 200 205 
Leu Ile Ser Arg Lys Ser Glu Ile Ile Asn Met Leu Thr Ala Ile Ser 
210 215 220 
Asn Gly Val Tyr Gly Lys Thr Tyr Leu Leu Val Pro Asp Tyr Ile Glu 
225 230 235 240 
Glu Glu Phe Asp Thr Gln Lys Ile Arg Val Phe Glu Ile Gly Phe Ile 
245 250 255 
Lys Arg Trp Leu Asn Asp Met Pro Leu Leu Gln Thr Thr Asn Tyr Met 
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Val Leu Pro Glu Asn Ser Lys Ala Lys Val Cys Thr Ile Ala Val Gly 
275 280 285 
Glu Leu Thr Leu Ala Ser Leu Cys Val Gly Glu Ser Thr Val Ser Leu 
290 295 300 
Tyr His Asp Ser Asn Gly Ser Gln Asp Ser Ile Leu Ala Val Thr Leu 
305 310 315 320 
Gly Ile Phe Gly Ala Thr Ser Met Asp Gln Val Glu Glu Val Ile Pro 
325 330 335 
Val Ala His Pro Ser Val Glu Lys Ile His Ile Thr Asn His Arg Gly 
340 345 350 
Phe Ile Lys Asp Ser Ile Ala Thr Trp Met Val Pro Ala Leu Val Ser 
355 360 365 
Glu Lys Gln Glu Glu Gln Lys Asn Cys Leu Glu Ser Ala Cys Gln Arg 
370 375 380 
Lys Ser Tyr Pro Met Cys Asn Gln Thr Ser Trp Glu Pro Phe Gly Gly 
385 390 395 400 
Gly Gln Leu Pro Ser Tyr Gly Arg Leu Thr Leu Pro Leu Asp Pro Ser 
405 410 415 
Thr Asp Leu Gln Leu Asn Ile Ser Phe Thr Tyr Gly Pro Val Ile Leu 
420 425 430 
Asn Gly Asp Gly Met Asp Tyr Tyr Glu Ser Pro Leu Ser Asp Ser Gly 
435 440 445 
Trp Leu Thr Ile Pro Pro Lys Asn Gly Thr Val Leu Gly Leu Ile Asn 
450 455 460 
Lys Ala Ser Arg Gly Asp Gln Phe Ile Val Ile Pro His Val Leu Thr 
465 470 475 480 
Phe Ala Pro Arg Glu Ser Ser Gly Asn Cys Tyr Leu Pro Ile Gln Thr 
485 490 495 
Ser Gln Ile Met Asp Lys Asp Val Leu Thr Glu Ser Asn Leu Val Val 
500 505 510 
Leu Pro Thr Gln Asn Phe Arg Tyr Val Ile Ala Thr Tyr Asp Ile Ser 
515 520 525 
Arg Asp Asn His Ala Ile Val Tyr Tyr Val Tyr Asp Pro Ile Arg Thr 
530 535 540 
Ile Ser Tyr Thr Tyr Pro Phe Arg Leu Thr Thr Lys Gly Arg Pro 
545 550 555 
Phe Leu Arg Ile Glu Cys Phe Val Trp Asp Asp Asp Leu Trp Cys 
565 570 575 
Gln Phe Tyr Arg Phe Glu Ala Asp Ile Thr Asn Ser Thr Thr Ser 
580 585 590 
Glu Asn Leu Val Arg Ile Arg Phe Ser Cys Asn Arg Ser Arg Pro 
595 600 605 
<210> SEQ ID NO 45 
<211> LENGTH, 607 
<212> TYPE, PRT 
<213> ORGANISM: canine distemper virus 





Met Leu Ser Tyr Arg Asp Lys Val Gly Ala Phe Tyr Lys Asp Asn Ala 
1 5 10 15 
Arg Ala Asn Ser Ser Lys Leu Ser Leu Val Thr Glu Glu Gln Gly Gly 
20 25 30 
Arg Arg Pro Pro Tyr Leu Leu Phe Val Leu Leu Ile Leu Leu Val Gly 
35 40 45 
76 
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Ile Met Ala Leu Leu Ala Ile Thr Gly Val Arg Phe His Gln Val Ser 
50 55 60 
Thr Ser Asn Met Glu Phe Ser Arg Leu Leu Lys Glu Asp Leu Glu Lys 
65 70 75 80 
Ser Glu Ala Val His His Gln Val Ile Asp Val Leu Thr Pro Leu Phe 
85 90 95 
Lys Ile Ile Gly Asp Glu Ile Gly Leu Arg Leu Pro Gln Lys Leu Asn 
100 105 110 
Glu Ile Lys Gln Phe Ile Leu Gln Lys Thr Asn Phe Phe Asn Pro Asn 
115 120 125 
Arg Glu Phe Asp Phe Arg Asp Leu His Trp Cys Ile Asn Pro Pro Ser 
130 135 140 
Lys Ile Lys Val Asn Phe Thr Asn Tyr Cys Asp Thr Met Gly Ile Arg 
145 150 155 160 
Lys Ser Ile Ala Ser Ala Ala Asn Pro Ile Leu Leu Ser Ala Leu Ser 
165 170 175 
Gly Gly Arg Gly Asp Ile Phe Pro Pro Tyr Arg Cys Asn Gly Ala Thr 
180 185 190 
Ile Ser Val Gly Lys Ile Phe Pro Leu Ser Val Ser Leu Ser Met Ser 
195 200 205 
Leu Ile Ser Arg Thr Ser Glu Ile Ile Asn Met Leu Thr Ala Ile Ser 
210 215 220 
Asp Gly Val Tyr Gly Lys Thr Tyr Leu Leu Met Pro Asp Tyr Ile Glu 
225 230 235 240 
Gly Glu Phe Asp Thr Gln Lys Ile Arg Val Phe Glu Ile Gly Phe Ile 
245 250 255 
Lys Arg Trp Leu Asn Asp Met Pro Leu Leu Gln Thr Thr Asn Tyr Met 
260 265 270 
Val Leu Pro Glu Asn Ser Lys Ala Lys Val Cys Thr Ile Ala Val Gly 
275 280 285 
Glu Leu Thr Leu Ala Ser Leu Cys Val Gly Glu Ser Thr Val Leu Leu 
290 295 300 
Tyr His Asp Ser Asn Gly Ser Gln Asp Gly Ile Leu Val Val Thr Leu 
305 310 315 320 
Gly Ile Phe Gly Ala Thr Ser Met Asp Gln Val Glu Glu Val Ile Pro 
325 330 335 
Val Ala Asp Pro Leu Val Glu Lys Ile His Ile Thr Asn His Arg Gly 
340 345 350 
Ile Ile Lys Asp Ser Ile Ala Thr Trp Met Val Pro Ala Leu Val Ser 
355 360 365 
Glu Lys Gln Glu Glu Gln Lys Asn Cys Leu Glu Ser Ala Cys Gln Arg 
370 375 380 
Lys Ser Tyr Pro Met Cys Asn Gln Thr Ser Trp Glu Pro Phe Gly Gly 
385 390 395 400 
Gly Gln Leu Pro Ser Tyr Gly Arg Leu Thr Leu Pro Leu Asp Pro Ser 
405 410 415 
Ile Asp Leu Gln Leu Asn Ile Ser Phe Thr Tyr Gly Pro Ile Ile Leu 
420 425 430 
Asn Gly Asp Gly Met Asp Tyr Tyr Glu Ser Pro Leu Leu Asp Ser Gly 
435 440 445 
Trp Leu Thr Ile Pro Pro Lys Asn Gly Thr Val Leu Gly Leu Ile Asn 
450 455 460 
Lys Ala Ser Arg Gly Asp Gln Phe Thr Val Ile Pro His Val Leu Thr 
465 470 475 480 
78 
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Phe Ala Pro Arg Glu Ser Ser Gly Asn Cys Tyr Leu Pro Ile Gln Thr 
485 490 495 
Ser Gln Ile Met Asp Lys Asp Val Leu Thr Glu Ser Asn Leu Val Val 
500 505 510 
Leu Pro Thr Gln Asn Phe Arg Tyr Val Val Ala Thr Tyr Asp Ile Ser 
515 520 525 
Arg Asp Asp His Ala Ile Val Tyr Tyr Val Tyr Asp Pro Ile Arg Thr 
530 535 540 
Ile Ser Tyr Thr Tyr Pro Phe Arg Leu Thr Thr Lys Gly Arg Pro Asp 
545 550 555 560 
Phe Leu Arg Ile Glu Cys Phe Val Trp Asp Asp Asp Leu Trp Cys His 
565 570 575 
Gln Phe Tyr Arg Phe Glu Ala Asp Ile Thr Asn Ser Thr Thr Ser Val 
580 585 590 
Glu Asn Leu Val Arg Met Arg Phe Ser Cys Asn Arg Ser Arg Pro 
595 600 605 
The invention claimed is: 
1. An isolated canine distemper virus (CDV) of European 25 
wildlife (EW) lineage comprising the characteristics ofCDV 
9041474B CDV-EW (ATCC Deposit No. PTA-10596). 
9. An isolated canine distemper virus (CDV) of Ameri-
can-2 (AM-2) lineage having the characteristics of CDV 
08021509 CDV-AM-2 (ATCC Deposit No. PTA-10597). 
10. An attenuated strain ofCDV isolated in cell culture in 
which the CDV strain of claim 9 or a progeny strain thereof 
has been propagated. 
2. An attenuated strain of CDV isolated in cell culture in 
which the CDV strain of claim 1 or a progeny strain thereof 
has been propagated. 
30 11. An immunogenic composition, comprising 
the isolated CDV of claim 9, or progeny thereof. 3. An immunogenic composition, comprising 
the isolated CDV of claim 1, or progeny thereof. 12. A method of eliciting an immune response to canine 
distemper virus in a subject in need thereof, comprising the 
step of 
4. A method of eliciting an immune response to canine 
distemper virus in a subject in need thereof, comprising the 
step of 
35 administering to said subject the immunogenic composi-
tion of claim 11. 
administering to said subject the immunogenic composi-
tion of claim 3. 
5. An isolated nucleic acid molecule encoding the amino 
acid sequence of SEQ ID NO: 44, or the complement thereof. 
6. The isolated nucleic acid molecule of claim 5 that com-
prises the nucleotide sequence of SEQ ID NO: 42, or the 
complement thereof. 
7. An isolated polypeptide comprising the amino acid 
sequence of SEQ ID NO: 44. 
8. An isolated canine distemper virus (CDV) of European 
wildlife (EW) lineage encoding a polypeptide comprising the 
amino acid sequence of SEQ ID NO: 44. 
13. An isolated nucleic acid molecule encoding the amino 
acid sequence of SEQ ID NO: 45, or the complement thereof. 
14. The isolated nucleic acid molecule of claim 13 that 
40 comprises the nucleotide sequence of SEQ ID NO: 43, or the 
complement thereof. 
15. An isolated polypeptide comprising the amino acid 
sequence of SEQ ID NO: 45. 
16. An isolated canine distemper virus ( CDV) of European 
45 wildlife (EW) lineage encoding a polypeptide comprising the 
amino acid sequence of SEQ ID NO: 45. 
* * * * * 
